chr1	1244380	1244386	Q5T7M4	0	-	1244380	1244386	102,0,51	1	6	0	.	Cleavage; by FURIN.
chr1	1354480	1354486	Q9BRK3	0	-	1354480	1354486	102,0,51	1	6	0	.	Cleavage.
chr1	1632857	1632863	O75900	0	+	1632857	1632863	102,0,51	1	6	0	.	Cleavage; by furin-like protease.
chr1	2612136	2612142	Q495T6	0	-	2612136	2612142	102,0,51	1	6	0	.	Cleavage.
chr1	9731761	9731767	O94985	0	-	9731761	9731767	102,0,51	1	6	0	.	Cleavage.
chr1	9731848	9731854	O94985	0	-	9731848	9731854	102,0,51	1	6	0	.	Cleavage.
chr1	10095573	10095579	O95155	0	+	10095573	10095579	102,0,51	1	6	0	.	Cleavage; by caspase-3 and caspase-7.
chr1	10101126	10101132	O95155	0	+	10101126	10101132	102,0,51	1	6	0	.	Cleavage; by caspase-6 and granzyme B.
chr1	10463165	10463171	O00273	0	-	10463165	10463171	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr1	10467276	10467282	O00273	0	-	10467276	10467282	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr1	11027610	11027616	O00187	0	-	11027610	11027616	102,0,51	1	6	0	.	Cleavage.
chr1	11649946	11649949	Q9UK22	0	-	11649946	11649949	102,0,51	1	3	0	.	Important for carbohydrate binding.
chr1	11824502	11824505	P51797	0	+	11824502	11824505	102,0,51	1	3	0	.	Mediates proton transfer from the outer aqueous phase to the interior of the protein; involved in linking H(+) and Cl(-) transport.
chr1	11827179	11827182	P51797	0	+	11827179	11827182	102,0,51	1	3	0	.	Mediates proton transfer from the protein to the inner aqueous phase.
chr1	11858286	11858292	P16860	0	-	11858286	11858292	102,0,51	1	6	0	.	Cleavage; by FAP. Pubmed:21314817
chr1	18883168	18883171	P30038	0	-	18883168	18883171	102,0,51	1	3	0	.	Transition state stabilizer.
chr1	19286355	19286358	O95154	0	-	19286355	19286358	102,0,51	1	3	0	.	Lowers pKa of active site Tyr.
chr1	19308625	19308628	O43488	0	-	19308625	19308628	102,0,51	1	3	0	.	Lowers pKa of active site Tyr.
chr1	19975775	19975778	P14555	0	-	19975775	19975778	102,0,51	1	3	0	.	Important for integrin binding. Pubmed:18635536
chr1	19978024	19978027	P14555	0	-	19978024	19978027	102,0,51	1	3	0	.	Important for integrin binding. Pubmed:18635536
chr1	20886353	20886359	O43432	0	-	20886353	20886359	102,0,51	1	6	0	.	Cleavage; by foot-and-mouth disease virus leader protease.
chr1	20886356	20886362	O43432	0	-	20886356	20886362	102,0,51	1	6	0	.	Cleavage; by enterovirus/rhinovirus protease 2A.
chr1	21824777	21827866	P98160	0	-	21824777	21827866	102,0,51	1	3089	0	.	Cleavage; by BMP1.
chr1	23854440	23854443	P04066	0	-	23854440	23854443	102,0,51	1	3	0	.	May be important for catalysis.
chr1	26863377	26863380	P31947	0	+	26863377	26863380	102,0,51	1	3	0	.	Interaction with phosphoserine on interacting protein.
chr1	26863596	26863599	P31947	0	+	26863596	26863599	102,0,51	1	3	0	.	Interaction with phosphoserine on interacting protein.
chr1	26889862	26889865	Q9H9Y4	0	-	26889862	26889865	102,0,51	1	3	0	.	Stabilizes the phosphate intermediate; shared with dimeric partner.
chr1	27107819	27107822	P19634	0	-	27107819	27107822	102,0,51	1	3	0	.	Not glycosylated.
chr1	27114155	27114158	P19634	0	-	27114155	27114158	102,0,51	1	3	0	.	Channel pore-lining.
chr1	27967074	27967080	Q9H6D3	0	+	27967074	27967080	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr1	30874306	30874312	O75056	0	-	30874306	30874312	102,0,51	1	6	0	.	Cleavage of ectodomain.
chr1	31619297	31619300	O43613	0	+	31619297	31619300	102,0,51	1	3	0	.	Important for responses to orexin. Pubmed:26950369
chr1	31744678	31744684	O60241	0	-	31744678	31744684	102,0,51	1	6	0	.	Cleavage; by furin. Pubmed:20367554
chr1	33084055	33084058	Q96A70	0	+	33084055	33084058	102,0,51	1	3	0	.	Not modified.
chr1	35184590	35187003	P23246	0	-	35184590	35187003	102,0,51	1	2413	0	.	Breakpoint for translocation to form SFPQ-TFE3.
chr1	39850203	39850206	Q9H3H1	0	-	39850203	39850206	102,0,51	1	3	0	.	Interaction with substrate tRNA.
chr1	39854017	39854020	Q9H3H1	0	-	39854017	39854020	102,0,51	1	3	0	.	Interaction with substrate tRNA.
chr1	41484057	41484063	P20800	0	-	41484057	41484063	102,0,51	1	6	0	.	Cleavage; by KEL.
chr1	42696941	42697182	P67809	0	+	42696941	42697182	102,0,51	1	241	0	.	Cleavage; by 20S proteasomal protease.
chr1	42927649	42927652	P11166	0	-	42927649	42927652	102,0,51	1	3	0	.	Not glycosylated.
chr1	43976602	43976605	Q99437	0	+	43976602	43976605	102,0,51	1	3	0	.	Essential for proton translocation.
chr1	45013333	45013336	P06132	0	+	45013333	45013336	102,0,51	1	3	0	.	Transition state stabilizer.
chr1	45332470	45332473	Q9UIF7	0	-	45332470	45332473	102,0,51	1	3	0	.	Transition state stabilizer.
chr1	45566901	45566904	P14550	0	+	45566901	45566904	102,0,51	1	3	0	.	Lowers pKa of active site Tyr. Pubmed:7669785
chr1	45566901	45566904	V9HWI0	0	+	45566901	45566904	102,0,51	1	3	0	.	Lowers pKa of active site Tyr.
chr1	52905061	52905064	Q86YB7	0	-	52905061	52905064	102,0,51	1	3	0	.	Important for catalytic activity.
chr1	52906549	52906552	Q86YB7	0	-	52906549	52906552	102,0,51	1	3	0	.	Important for catalytic activity.
chr1	54854102	54854108	Q15392	0	-	54854102	54854108	102,0,51	1	6	0	.	Cleavage; by caspase.
chr1	54883635	54883641	Q15392	0	-	54883635	54883641	102,0,51	1	6	0	.	Cleavage; by caspase.
chr1	55046576	55046582	Q8NBP7	0	+	55046576	55046582	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr1	55052405	55052411	Q8NBP7	0	+	55052405	55052411	102,0,51	1	6	0	.	Cleavage; by furin and PCSK5.
chr1	56867657	56867660	P07357	0	+	56867657	56867660	102,0,51	1	3	0	.	Not glycosylated.
chr1	58782254	58782257	P05412	0	-	58782254	58782257	102,0,51	1	3	0	.	Necessary for synergistic transcriptional activity with SMAD3.
chr1	62450633	62450639	O94782	0	+	62450633	62450639	102,0,51	1	6	0	.	Cleavage; by autolysis. Pubmed:16531995
chr1	66368822	66368825	Q07343	0	+	66368822	66368825	102,0,51	1	3	0	.	Binds AMP, but not cAMP.
chr1	78921648	78921654	Q9HBW9	0	-	78921648	78921654	102,0,51	1	6	0	.	Cleavage.
chr1	81968157	81968163	O95490	0	+	81968157	81968163	102,0,51	1	6	0	.	Cleavage.
chr1	83929221	83929224	Q6ZT98	0	-	83929221	83929224	102,0,51	1	3	0	.	Binds negatively charged residues of beta-tubulin C-terminal tails. Pubmed:25959773
chr1	83948656	83948659	Q6ZT98	0	-	83948656	83948659	102,0,51	1	3	0	.	Binds negatively charged residues of beta-tubulin C-terminal tails. Pubmed:25959773
chr1	86450699	86450705	Q9UQC9	0	+	86450699	86450705	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr1	86495641	86495647	A8K7I4	0	+	86495641	86495647	102,0,51	1	6	0	.	Cleavage; by autolysis. Pubmed:23112050
chr1	86578038	86578044	Q14CN2	0	+	86578038	86578044	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr1	88760220	88760226	Q16513	0	+	88760220	88760226	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr1	88807770	88807776	Q16513	0	+	88807770	88807776	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr1	92607724	92607727	O60447	0	-	92607724	92607727	102,0,51	1	3	0	.	Breakpoint for translocation to form EVI5-TRNG10 fusion protein.
chr1	93529738	93529741	Q5T0N5	0	+	93529738	93529741	102,0,51	1	3	0	.	Mediates end-to-end attachment of dimers.
chr1	100877746	100877752	Q9UBQ6	0	-	100877746	100877752	102,0,51	1	6	0	.	Cleavage.
chr1	103575286	103575289	P19961	0	+	103575286	103575289	102,0,51	1	3	0	.	Transition state stabilizer.
chr1	103621640	103621643	P04746	0	+	103621640	103621643	102,0,51	1	3	0	.	Transition state stabilizer. Pubmed:10091666, Pubmed:10769135, Pubmed:11914097
chr1	103660423	103660426	P04745	0	+	103660423	103660426	102,0,51	1	3	0	.	Transition state stabilizer.
chr1	103691543	103691546	P04745	0	-	103691543	103691546	102,0,51	1	3	0	.	Transition state stabilizer.
chr1	103754562	103754565	P04745	0	+	103754562	103754565	102,0,51	1	3	0	.	Transition state stabilizer.
chr1	109674806	109674809	P28161	0	+	109674806	109674809	102,0,51	1	3	0	.	Important for substrate specificity.
chr1	110342264	110345540	Q96T37	0	+	110342264	110345540	102,0,51	1	3276	0	.	Breakpoint for translocation to form RBM15-MKL1.
chr1	110603639	110603642	P16389	0	-	110603639	110603642	102,0,51	1	3	0	.	Important for binding with the scorpion mesomartoxin; when the scorpion mesomartoxin-rKv1.2/KCNA2 interaction is modeled, this residue is close to the 'Y-57' residue of the toxin.
chr1	110604026	110604029	P16389	0	-	110604026	110604029	102,0,51	1	3	0	.	Important for normal, slow channel gating.
chr1	114401460	114402762	Q9UPN9	0	-	114401460	114402762	102,0,51	1	1302	0	.	Breakpoint for translocation to form TRIM33-RET oncogene.
chr1	119963646	119963649	Q04721	0	-	119963646	119963649	102,0,51	1	3	0	.	Essential for O-xylosylation.
chr1	146019312	146019318	Q6ZVN8	0	-	146019312	146019318	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr1	149965789	149965792	Q6GQQ9	0	-	149965789	149965792	102,0,51	1	3	0	.	Stabilizes the conformation of the regulatory loop. Pubmed:27732584
chr1	150159220	150159226	Q53GL0	0	+	150159220	150159226	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr1	150159325	150159331	Q53GL0	0	+	150159325	150159331	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr1	150579056	150579062	Q07820	0	-	150579056	150579062	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr1	150579146	150579152	Q07820	0	-	150579146	150579152	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr1	153948303	153948306	Q53ET0	0	-	153948303	153948306	102,0,51	1	3	0	.	Required for ubiquitination and degradation.
chr1	153973888	153973894	Q8TEY5	0	+	153973888	153973894	102,0,51	1	6	0	.	Cleavage; by PS1.
chr1	154273835	154273841	O00165	0	+	154273835	154273841	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr1	154435081	154435084	P08887	0	+	154435081	154435084	102,0,51	1	3	0	.	Not glycosylated.
chr1	154569830	154569833	P17787	0	+	154569830	154569833	102,0,51	1	3	0	.	Key residue that may interfere with effective access of the conotoxin BuIA to the channel binding site.
chr1	154571228	154571231	P17787	0	+	154571228	154571231	102,0,51	1	3	0	.	Key residue for a rapid dissociation (K(off)) from the conotoxin BuIA.
chr1	154571252	154571255	P17787	0	+	154571252	154571255	102,0,51	1	3	0	.	Key residue for a rapid dissociation (K(off)) from the conotoxin BuIA.
chr1	155294507	155294510	P30613	0	-	155294507	155294510	102,0,51	1	3	0	.	Transition state stabilizer.
chr1	155309911	155309914	P30613	0	-	155309911	155309914	102,0,51	1	3	0	.	Transition state stabilizer.
chr1	155317949	155317952	P14324	0	+	155317949	155317952	102,0,51	1	3	0	.	Important for determining product chain length.
chr1	155317952	155317955	P14324	0	+	155317952	155317955	102,0,51	1	3	0	.	Important for determining product chain length.
chr1	156134960	156134963	P02545	0	+	156134960	156134963	102,0,51	1	3	0	.	Heptad change of phase.
chr1	156135936	156135939	P02545	0	+	156135936	156135939	102,0,51	1	3	0	.	Stutter.
chr1	156135951	156135954	P02545	0	+	156135951	156135954	102,0,51	1	3	0	.	Heptad change of phase.
chr1	156138724	156138730	P02545	0	+	156138724	156138730	102,0,51	1	6	0	.	Cleavage; by endoprotease.
chr1	156243036	156243039	P02818	0	+	156243036	156243039	102,0,51	1	3	0	.	Not hydroxylated.
chr1	156476502	156476508	Q14814	0	-	156476502	156476508	102,0,51	1	6	0	.	Cleavage.
chr1	156874396	156874572	P04629	0	+	156874396	156874572	102,0,51	1	176	0	.	Breakpoint for translocation to form TRK and TRK-T3.
chr1	156875620	156875623	P04629	0	+	156875620	156875623	102,0,51	1	3	0	.	Breakpoint for translocation to form TRK-T1.
chr1	156875650	156875653	P04629	0	+	156875650	156875653	102,0,51	1	3	0	.	Interaction with SHC1.
chr1	156881621	156881624	P04629	0	+	156881621	156881624	102,0,51	1	3	0	.	Interaction with PLCG1.
chr1	157589456	157596331	Q96PJ5	0	-	157589456	157596331	102,0,51	1	6875	0	.	Breakpoint for insertion to form FCRL4-IGHA1 fusion protein.
chr1	159171837	159171840	Q8N126	0	+	159171837	159171840	102,0,51	1	3	0	.	Not glycosylated.
chr1	160042058	160042061	P78508	0	-	160042058	160042061	102,0,51	1	3	0	.	Role in the control of polyamine-mediated channel gating and in the blocking by intracellular magnesium.
chr1	160084477	160084480	Q92806	0	+	160084477	160084480	102,0,51	1	3	0	.	Role in the control of polyamine-mediated channel gating and in the blocking by intracellular magnesium.
chr1	161846515	161846521	P18850	0	+	161846515	161846521	102,0,51	1	6	0	.	Cleavage; by PS1.
chr1	164563307	164792495	P40424	0	+	164563307	164792495	102,0,51	1	229188	0	.	Breakpoint for translocation to form TCF3-PBX1 oncogene.
chr1	169540367	169540373	P12259	0	-	169540367	169540373	102,0,51	1	6	0	.	Cleavage; by thrombin.
chr1	169541948	169541954	P12259	0	-	169541948	169541954	102,0,51	1	6	0	.	Cleavage; by thrombin.
chr1	169542020	169542026	P12259	0	-	169542020	169542026	102,0,51	1	6	0	.	Cleavage; by activated protein C.
chr1	169542875	169542881	P12259	0	-	169542875	169542881	102,0,51	1	6	0	.	Cleavage; by thrombin.
chr1	169542965	169542971	P12259	0	-	169542965	169542971	102,0,51	1	6	0	.	Cleavage; by activated protein C.
chr1	169549806	169549812	P12259	0	-	169549806	169549812	102,0,51	1	6	0	.	Cleavage; by activated protein C.
chr1	169555294	169555300	P12259	0	-	169555294	169555300	102,0,51	1	6	0	.	Cleavage; by activated protein C.
chr1	171638645	171638651	Q99972	0	-	171638645	171638651	102,0,51	1	6	0	.	Cleavage; by CAPN2.
chr1	172659441	172659447	P48023	0	+	172659441	172659447	102,0,51	1	6	0	.	Cleavage; by SPPL2A.
chr1	172660130	172660136	P48023	0	+	172660130	172660136	102,0,51	1	6	0	.	Cleavage; by ADAM10.
chr1	173904005	173904011	P01008	0	-	173904005	173904011	102,0,51	1	6	0	.	Reactive bond.
chr1	174637401	174637404	Q5R372	0	+	174637401	174637404	102,0,51	1	3	0	.	Arginine finger.
chr1	174683557	174683560	Q5R372	0	+	174683557	174683560	102,0,51	1	3	0	.	Glutamine finger.
chr1	176043766	176043769	Q8NHY2	0	-	176043766	176043769	102,0,51	1	3	0	.	Interaction with TRIB1. Pubmed:27041596
chr1	176046185	176046188	Q8NHY2	0	-	176046185	176046188	102,0,51	1	3	0	.	Interaction with TRIB1. Pubmed:27041596
chr1	180632264	180632267	Q9UBH6	0	+	180632264	180632267	102,0,51	1	3	0	.	Important for inositol polyphosphate binding. Pubmed:27080106
chr1	180682365	180682368	Q9UBH6	0	+	180682365	180682368	102,0,51	1	3	0	.	Important for inositol polyphosphate binding. Pubmed:27080106
chr1	181580749	181580752	Q15878	0	+	181580749	181580752	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chr1	181721769	181721772	Q15878	0	+	181721769	181721772	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chr1	181756079	181756082	Q15878	0	+	181756079	181756082	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chr1	181772078	181772081	Q15878	0	+	181772078	181772081	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chr1	182816775	182816778	Q9BXD5	0	+	182816775	182816778	102,0,51	1	3	0	.	Involved in proton transfer during cleavage.
chr1	186362959	186362962	P12270	0	-	186362959	186362962	102,0,51	1	3	0	.	Breakpoint for translocation to form TRK-T1.
chr1	186674619	186674622	P35354	0	-	186674619	186674622	102,0,51	1	3	0	.	Aspirin-acetylated serine.
chr1	193029206	193029209	Q5LJA5	0	-	193029206	193029209	102,0,51	1	3	0	.	Important for enzyme activity.
chr1	193029206	193029209	Q5LJA9	0	-	193029206	193029209	102,0,51	1	3	0	.	Important for enzyme activity.
chr1	193029206	193029209	Q9Y5K5	0	-	193029206	193029209	102,0,51	1	3	0	.	Important for enzyme activity.
chr1	198264151	198264154	Q8TDX7	0	+	198264151	198264154	102,0,51	1	3	0	.	Autoinhibitory.
chr1	201051127	201051130	Q13698	0	-	201051127	201051130	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chr1	201061954	201061957	Q13698	0	-	201061954	201061957	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chr1	201075600	201075603	Q13698	0	-	201075600	201075603	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chr1	201089281	201089284	Q13698	0	-	201089281	201089284	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chr1	202001410	202001413	Q9H4A4	0	+	202001410	202001413	102,0,51	1	3	0	.	Transition state stabilizer.
chr1	203348075	203348078	Q06828	0	-	203348075	203348078	102,0,51	1	3	0	.	Not sulfated.
chr1	203348081	203348084	Q06828	0	-	203348081	203348084	102,0,51	1	3	0	.	Not sulfated.
chr1	204190543	204190549	Q15726	0	-	204190543	204190549	102,0,51	1	6	0	.	Cleavage; by MMP2 and MMP9.
chr1	205772565	205774836	O14966	0	-	205772565	205774836	102,0,51	1	2271	0	.	Cleavage; by S.Typhimurium viral protease GtgE.
chr1	207067631	207067634	O60825	0	+	207067631	207067634	102,0,51	1	3	0	.	Transition state stabilizer.
chr1	207067652	207067655	O60825	0	+	207067652	207067655	102,0,51	1	3	0	.	Transition state stabilizer.
chr1	207070357	207070360	O60825	0	+	207070357	207070360	102,0,51	1	3	0	.	Transition state stabilizer.
chr1	226064444	226064447	P84243	0	+	226064444	226064447	102,0,51	1	3	0	.	Interaction with ZMYND11. Pubmed:24590075
chr1	228022670	228022676	P56704	0	+	228022670	228022676	102,0,51	1	6	0	.	Cleavage; by TIKI1 and TIKI2.
chr1	230274549	230274552	Q10471	0	+	230274549	230274552	102,0,51	1	3	0	.	Not glycosylated.
chr1	233614522	233614525	O00180	0	+	233614522	233614525	102,0,51	1	3	0	.	Important for increased permeability to Na(+) when K(+) levels are subphysiological. Pubmed:21653227
chr1	233666674	233666677	O00180	0	+	233666674	233666677	102,0,51	1	3	0	.	Part of a hydrophobic barrier that is stochastically dewetted and limits ion permeability. Pubmed:22431633, Pubmed:25001086
chr1	233671299	233671302	O00180	0	+	233671299	233671302	102,0,51	1	3	0	.	Part of a hydrophobic barrier that is stochastically dewetted and limits ion permeability. Pubmed:25001086
chr1	236538918	236538921	O00214	0	+	236538918	236538921	102,0,51	1	3	0	.	Critical for binding to sialylated and sulfated oligosaccharides. Pubmed:21288902
chr1	241996225	241996231	Q9BXW4	0	-	241996225	241996231	102,0,51	1	6	0	.	Cleavage; by ATG4B.
chr10	4830839	4830842	Q96JD6	0	+	4830839	4830842	102,0,51	1	3	0	.	Lowers pKa of active site Tyr.
chr10	4965988	4965991	Q04828	0	+	4965988	4965991	102,0,51	1	3	0	.	Important for substrate specificity.
chr10	4966078	4966081	Q04828	0	+	4966078	4966081	102,0,51	1	3	0	.	Lowers pKa of active site Tyr.
chr10	4966079	4966082	H0Y804	0	+	4966079	4966082	102,0,51	1	3	0	.	Lowers pKa of active site Tyr.
chr10	4972293	4972296	Q04828	0	+	4972293	4972296	102,0,51	1	3	0	.	May be involved in the mediating step between the transformation of progesterone and the release of the cofactor.
chr10	5001513	5001516	P52895	0	-	5001513	5001516	102,0,51	1	3	0	.	Lowers pKa of active site Tyr.
chr10	5096484	5096487	P42330	0	+	5096484	5096487	102,0,51	1	3	0	.	Important for substrate specificity.
chr10	5096574	5096577	A0A0A0MSS8	0	+	5096574	5096577	102,0,51	1	3	0	.	Lowers pKa of active site Tyr.
chr10	5096574	5096577	P42330	0	+	5096574	5096577	102,0,51	1	3	0	.	Lowers pKa of active site Tyr.
chr10	5096574	5096577	S4R3Z2	0	+	5096574	5096577	102,0,51	1	3	0	.	Lowers pKa of active site Tyr.
chr10	5102208	5102211	P42330	0	+	5102208	5102211	102,0,51	1	3	0	.	Involved in ligand recognition and product release.
chr10	5105663	5105666	P42330	0	+	5105663	5105666	102,0,51	1	3	0	.	Involved in ligand recognition and product release.
chr10	5200255	5200258	P17516	0	+	5200255	5200258	102,0,51	1	3	0	.	Important for substrate specificity.
chr10	5200345	5200348	P17516	0	+	5200345	5200348	102,0,51	1	3	0	.	Lowers pKa of active site Tyr.
chr10	6220790	6220793	Q16875	0	+	6220790	6220793	102,0,51	1	3	0	.	Transition state stabilizer. Pubmed:22275052
chr10	6220811	6220814	Q16875	0	+	6220811	6220814	102,0,51	1	3	0	.	Transition state stabilizer. Pubmed:22275052
chr10	6222932	6222935	Q16875	0	+	6222932	6222935	102,0,51	1	3	0	.	Transition state stabilizer. Pubmed:22275052
chr10	13344854	13344857	P49903	0	-	13344854	13344857	102,0,51	1	3	0	.	Important for catalytic activity.
chr10	17129657	17129663	O60494	0	-	17129657	17129663	102,0,51	1	6	0	.	Cleavage; by furin.
chr10	17235210	17235213	P08670	0	+	17235210	17235213	102,0,51	1	3	0	.	Stutter.
chr10	18539385	18539388	Q08289	0	+	18539385	18539388	102,0,51	1	3	0	.	Required for CaMK2D-binding.
chr10	21670448	21670451	P55197	0	+	21670448	21670451	102,0,51	1	3	0	.	KMT2A/MLL1 fusion point (in acute myeloid leukemia patient B).
chr10	21726243	21726246	P55197	0	+	21726243	21726246	102,0,51	1	3	0	.	KMT2A/MLL1 fusion point (in acute myeloid leukemia patient C).
chr10	21727854	21727857	P55197	0	+	21727854	21727857	102,0,51	1	3	0	.	KMT2A/MLL1 fusion point (in acute myeloid leukemia patient A).
chr10	26777238	26823140	Q8IZP0	0	-	26777238	26823140	102,0,51	1	45902	0	.	Breakpoint for translocation to form KMT2A/MLL1-ABI1.
chr10	43113554	43113560	P07949	0	+	43113554	43113560	102,0,51	1	6	0	.	Breakpoint for translocation to form the TRIM27/RET oncogene.
chr10	43114718	43114724	P07949	0	+	43114718	43114724	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr10	43114733	43116586	P07949	0	+	43114733	43116586	102,0,51	1	1853	0	.	Breakpoint for translocation to form PCM1-RET; RET-CCDC6; RET-GOLGA5; RET-TRIM24 and RET-TRIM33 oncogenes.
chr10	43126583	43126589	P07949	0	+	43126583	43126589	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr10	43386837	43386840	P52597	0	-	43386837	43386840	102,0,51	1	3	0	.	Interaction with RNA.
chr10	43386906	43386909	P52597	0	-	43386906	43386909	102,0,51	1	3	0	.	Interaction with RNA.
chr10	43386990	43386993	P52597	0	-	43386990	43386993	102,0,51	1	3	0	.	Interaction with RNA.
chr10	43387002	43387005	P52597	0	-	43387002	43387005	102,0,51	1	3	0	.	Interaction with RNA.
chr10	43387365	43387368	P52597	0	-	43387365	43387368	102,0,51	1	3	0	.	Interaction with RNA.
chr10	43387434	43387437	P52597	0	-	43387434	43387437	102,0,51	1	3	0	.	Interaction with RNA.
chr10	43387524	43387527	P52597	0	-	43387524	43387527	102,0,51	1	3	0	.	Interaction with RNA.
chr10	43387536	43387539	P52597	0	-	43387536	43387539	102,0,51	1	3	0	.	Interaction with RNA.
chr10	43387659	43387662	P52597	0	-	43387659	43387662	102,0,51	1	3	0	.	Interaction with RNA.
chr10	43387728	43387731	P52597	0	-	43387728	43387731	102,0,51	1	3	0	.	Interaction with RNA.
chr10	43387824	43387827	P52597	0	-	43387824	43387827	102,0,51	1	3	0	.	Interaction with RNA.
chr10	43387836	43387839	P52597	0	-	43387836	43387839	102,0,51	1	3	0	.	Interaction with RNA.
chr10	44380803	44380806	P48061	0	-	44380803	44380806	102,0,51	1	3	0	.	Important for dimer formation.
chr10	45382638	45382641	P09917	0	+	45382638	45382641	102,0,51	1	3	0	.	Essential for stabilizing binding to COTL1.
chr10	45398701	45398704	P09917	0	+	45398701	45398704	102,0,51	1	3	0	.	Essential for stabilizing binding to COTL1.
chr10	46011203	46012885	Q13772	0	-	46011203	46012885	102,0,51	1	1682	0	.	Breakpoint for rearrangement to form RET/PTC3 oncogene.
chr10	58386289	58386292	Q00059	0	+	58386289	58386292	102,0,51	1	3	0	.	Intercalates between bases and promotes DNA bending.
chr10	58394363	58394366	Q00059	0	+	58394363	58394366	102,0,51	1	3	0	.	Intercalates between bases and promotes DNA bending.
chr10	59852699	59906124	Q16204	0	-	59852699	59906124	102,0,51	1	53425	0	.	Breakpoint for translocation to form RET-CCDC6 oncogene.
chr10	68673042	68681401	Q8NFU7	0	+	68673042	68681401	102,0,51	1	8359	0	.	Breakpoint for translocation to form KMT2A/MLL1-TET1 oncogene.
chr10	70146253	70146259	Q2T9J0	0	-	70146253	70146259	102,0,51	1	6	0	.	Cleavage.
chr10	70598688	70598691	P14222	0	-	70598688	70598691	102,0,51	1	3	0	.	Important for oligomerization.
chr10	70599078	70599081	P14222	0	-	70599078	70599081	102,0,51	1	3	0	.	Important for oligomerization.
chr10	71291048	71291054	Q8IZJ1	0	+	71291048	71291054	102,0,51	1	6	0	.	Cleavage; by caspase-3. Pubmed:12598906
chr10	71828088	71828091	P07602	0	-	71828088	71828091	102,0,51	1	3	0	.	Not glycosylated; in variant MLD-SAPB Ile-217.
chr10	75028487	75028493	Q8WYB5	0	+	75028487	75028493	102,0,51	1	6	0	.	Breakpoint for translocation to form KAT6B-CREBBP.
chr10	75219161	75219164	P45880	0	+	75219161	75219164	102,0,51	1	3	0	.	Involved in hexokinase binding.
chr10	88914628	88914631	Q96FJ0	0	+	88914628	88914631	102,0,51	1	3	0	.	Indirect zinc-binding.
chr10	89402374	89402377	P09914	0	+	89402374	89402377	102,0,51	1	3	0	.	Interaction with PPP-RNA.
chr10	89402398	89402401	P09914	0	+	89402398	89402401	102,0,51	1	3	0	.	Interaction with PPP-RNA.
chr10	89402725	89402728	P09914	0	+	89402725	89402728	102,0,51	1	3	0	.	Interaction with PPP-RNA.
chr10	89402833	89402836	P09914	0	+	89402833	89402836	102,0,51	1	3	0	.	Interaction with PPP-RNA.
chr10	89403028	89403031	P09914	0	+	89403028	89403031	102,0,51	1	3	0	.	Interaction with PPP-RNA.
chr10	89403142	89403145	P09914	0	+	89403142	89403145	102,0,51	1	3	0	.	Interaction with the 5'-triphosphate group of PPP-RNA.
chr10	89417295	89417298	Q13325	0	+	89417295	89417298	102,0,51	1	3	0	.	Interaction with PPP-RNA.
chr10	89417307	89417310	Q13325	0	+	89417307	89417310	102,0,51	1	3	0	.	Interaction with PPP-RNA.
chr10	89417319	89417322	Q13325	0	+	89417319	89417322	102,0,51	1	3	0	.	Interaction with PPP-RNA.
chr10	89417646	89417649	Q13325	0	+	89417646	89417649	102,0,51	1	3	0	.	Interaction with PPP-RNA.
chr10	89417754	89417757	Q13325	0	+	89417754	89417757	102,0,51	1	3	0	.	Interaction with PPP-RNA.
chr10	89417946	89417949	Q13325	0	+	89417946	89417949	102,0,51	1	3	0	.	Interaction with PPP-RNA.
chr10	89418060	89418063	Q13325	0	+	89418060	89418063	102,0,51	1	3	0	.	Interaction with the 5'-triphosphate group of PPP-RNA.
chr10	92111183	92111186	Q8NE35	0	-	92111183	92111186	102,0,51	1	3	0	.	Required for RNA-binding activity. Pubmed:24343026
chr10	92144975	92144978	Q8NE35	0	-	92144975	92144978	102,0,51	1	3	0	.	Required for RNA-binding activity. Pubmed:24343026
chr10	92144981	92144987	Q8NE35	0	-	92144981	92144987	102,0,51	1	6	0	.	Cleavage; by CAPN2.
chr10	97431095	97431098	P18669	0	+	97431095	97431098	102,0,51	1	3	0	.	Transition state stabilizer.
chr10	97599712	97599715	Q86XE5	0	+	97599712	97599715	102,0,51	1	3	0	.	Involved in proton transfer during cleavage.
chr10	100548104	100548107	Q9NWT6	0	+	100548104	100548107	102,0,51	1	3	0	.	Important for dimer formation.
chr10	101799408	101799414	O60502	0	-	101799408	101799414	102,0,51	1	6	0	.	Cleavage; by caspase-3. Pubmed:18586680
chr10	102399608	102399614	Q00653	0	+	102399608	102399614	102,0,51	1	6	0	.	Cleavage (when cotranslationally processed).
chr10	102399716	102400083	Q00653	0	+	102399716	102400083	102,0,51	1	367	0	.	Breakpoint for translocation to form NFKB2-IGHA1 oncogene.
chr10	103458529	103458532	Q8IU99	0	-	103458529	103458532	102,0,51	1	3	0	.	Not glycosylated.
chr10	104002489	104002495	Q9H2G2	0	+	104002489	104002495	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr10	113578081	113578087	Q14520	0	+	113578081	113578087	102,0,51	1	6	0	.	Cleavage.
chr10	113578084	113578090	Q14520	0	+	113578084	113578090	102,0,51	1	6	0	.	Cleavage.
chr10	113585857	113585863	Q14520	0	+	113585857	113585863	102,0,51	1	6	0	.	Cleavage.
chr10	114278816	114278822	Q5GFL6	0	+	114278816	114278822	102,0,51	1	6	0	.	Cleavage.
chr10	117201220	117201223	Q7Z418	0	+	117201220	117201223	102,0,51	1	3	0	.	Not glycosylated.
chr10	122488933	122488936	Q92743	0	+	122488933	122488936	102,0,51	1	3	0	.	Involved in trimer stabilization. Pubmed:21297635
chr10	122488939	122488942	Q92743	0	+	122488939	122488942	102,0,51	1	3	0	.	Involved in trimer stabilization. Pubmed:21297635
chr10	122506744	122506747	Q92743	0	+	122506744	122506747	102,0,51	1	3	0	.	Involved in trimer stabilization. Pubmed:21297635
chr10	129957295	129957298	Q9H4W6	0	-	129957295	129957298	102,0,51	1	3	0	.	Interaction with DNA.
chr10	129957322	129957325	Q9H4W6	0	-	129957322	129957325	102,0,51	1	3	0	.	Interaction with DNA.
chr10	133368944	133368947	P30084	0	-	133368944	133368947	102,0,51	1	3	0	.	Important for catalytic activity.
chr11	1194129	1194135	P98088	0	+	1194129	1194135	102,0,51	1	6	0	.	Cleavage.
chr11	3731575	3735193	P52948	0	-	3731575	3735193	102,0,51	1	3618	0	.	Breakpoint for translocation to form NUP98-CCDC28A.
chr11	3731575	3735193	P52948	0	-	3731575	3735193	102,0,51	1	3618	0	.	Breakpoint for translocation to form NUP98-PHF23 oncogene.
chr11	4118320	4118323	P23921	0	+	4118320	4118323	102,0,51	1	3	0	.	Important for hydrogen atom transfer.
chr11	4118344	4118347	P23921	0	+	4118344	4118347	102,0,51	1	3	0	.	Allosteric effector binding, determines substrate specificity.
chr11	4118434	4118437	P23921	0	+	4118434	4118437	102,0,51	1	3	0	.	Allosteric effector binding, determines substrate specificity.
chr11	4126692	4126695	P23921	0	+	4126692	4126695	102,0,51	1	3	0	.	Important for hydrogen atom transfer.
chr11	4138212	4138215	P23921	0	+	4138212	4138215	102,0,51	1	3	0	.	Important for electron transfer.
chr11	4138215	4138218	P23921	0	+	4138215	4138218	102,0,51	1	3	0	.	Important for electron transfer.
chr11	4138362	4138365	P23921	0	+	4138362	4138365	102,0,51	1	3	0	.	Interacts with thioredoxin/glutaredoxin.
chr11	4138371	4138374	P23921	0	+	4138371	4138374	102,0,51	1	3	0	.	Interacts with thioredoxin/glutaredoxin.
chr11	5226603	5226606	P68871	0	-	5226603	5226606	102,0,51	1	3	0	.	Not glycated.
chr11	5226642	5226645	P68871	0	-	5226642	5226645	102,0,51	1	3	0	.	Not glycated.
chr11	5226711	5226714	P68871	0	-	5226711	5226714	102,0,51	1	3	0	.	Not glycated.
chr11	13358440	13358443	O00327	0	+	13358440	13358443	102,0,51	1	3	0	.	Interaction with E-box DNA. Pubmed:23229515
chr11	13358449	13358452	O00327	0	+	13358449	13358452	102,0,51	1	3	0	.	Interaction with E-box DNA. Pubmed:23229515
chr11	13358452	13358455	O00327	0	+	13358452	13358455	102,0,51	1	3	0	.	Interaction with E-box DNA. Pubmed:23229515
chr11	13358464	13358467	O00327	0	+	13358464	13358467	102,0,51	1	3	0	.	Interaction with E-box DNA. Pubmed:23229515
chr11	13358584	13358587	O00327	0	+	13358584	13358587	102,0,51	1	3	0	.	Important for interaction with CLOCK. Pubmed:23229515
chr11	17168943	17168946	O00443	0	-	17168943	17168946	102,0,51	1	3	0	.	Not phosphorylated.
chr11	17168955	17168958	O00443	0	-	17168955	17168958	102,0,51	1	3	0	.	Not phosphorylated.
chr11	17168979	17168982	O00443	0	-	17168979	17168982	102,0,51	1	3	0	.	Not phosphorylated.
chr11	17168988	17168991	O00443	0	-	17168988	17168991	102,0,51	1	3	0	.	Not phosphorylated.
chr11	17168994	17168997	O00443	0	-	17168994	17168997	102,0,51	1	3	0	.	Not phosphorylated.
chr11	17169009	17169012	O00443	0	-	17169009	17169012	102,0,51	1	3	0	.	Not phosphorylated.
chr11	17387611	17387614	B2RC52	0	-	17387611	17387614	102,0,51	1	3	0	.	Role in the control of polyamine-mediated channel gating and in the blocking by intracellular magnesium.
chr11	22811905	22811911	O43903	0	+	22811905	22811911	102,0,51	1	6	0	.	Cleavage; by a caspase during apoptosis.
chr11	27658390	27658396	P23560	0	-	27658390	27658396	102,0,51	1	6	0	.	Cleavage; by S1P.
chr11	36575989	36575992	P15918	0	+	36575989	36575992	102,0,51	1	3	0	.	Essential for DNA hairpin formation, participates in base-stacking interactions near the cleavage site.
chr11	46320280	46320286	Q96BA8	0	+	46320280	46320286	102,0,51	1	6	0	.	Cleavage; by S1P.
chr11	46680256	46680259	Q07960	0	-	46680256	46680259	102,0,51	1	3	0	.	Involved in G-protein binding to GAPs.
chr11	46725890	46725896	P00734	0	+	46725890	46725896	102,0,51	1	6	0	.	Cleavage; by thrombin.
chr11	46726601	46726607	P00734	0	+	46726601	46726607	102,0,51	1	6	0	.	Cleavage; by factor Xa.
chr11	46726793	46726799	P00734	0	+	46726793	46726799	102,0,51	1	6	0	.	Cleavage; by factor Xa.
chr11	57330372	57330378	Q08945	0	-	57330372	57330378	102,0,51	1	6	0	.	Cleavage; by caspase-3 and/or caspase-7.
chr11	57614470	57614476	P05155	0	+	57614470	57614476	102,0,51	1	6	0	.	Reactive bond for chymotrypsin.
chr11	57614473	57614479	P05155	0	+	57614473	57614479	102,0,51	1	6	0	.	Reactive bond.
chr11	57801976	57801979	O60716	0	+	57801976	57801979	102,0,51	1	3	0	.	Essential for interaction with cadherins.
chr11	57803631	57803634	O60716	0	+	57803631	57803634	102,0,51	1	3	0	.	Essential for interaction with cadherins.
chr11	61777428	61777434	Q9Y2G1	0	+	61777428	61777434	102,0,51	1	6	0	.	Cleavage; by autolysis. Pubmed:23966832
chr11	62615754	62615757	O94766	0	-	62615754	62615757	102,0,51	1	3	0	.	Interaction with galactose moiety of substrate glycoprotein.
chr11	62616733	62616736	O94766	0	-	62616733	62616736	102,0,51	1	3	0	.	Interaction with galactose moiety of substrate glycoprotein.
chr11	62979534	62979537	Q4U2R8	0	-	62979534	62979537	102,0,51	1	3	0	.	Important for interaction with cidofovir and PAH.
chr11	62981948	62981951	Q4U2R8	0	-	62981948	62981951	102,0,51	1	3	0	.	Important for interaction with cidofovir.
chr11	63766029	63766032	C9JLR9	0	-	63766029	63766032	102,0,51	1	3	0	.	Breakpoint for translocation to form C11orf95-MLK2 fusion protein.
chr11	63952759	63952762	Q86UY6	0	+	63952759	63952762	102,0,51	1	3	0	.	Essential for catalytic activity. Pubmed:25619998
chr11	63988344	63988347	Q96FW1	0	+	63988344	63988347	102,0,51	1	3	0	.	Required for proximal ubiquitin-binding. Pubmed:19211026
chr11	64152391	64152394	Q9BQ69	0	-	64152391	64152394	102,0,51	1	3	0	.	Breakpoint for translocation to form RUNX1-MACROD1. Pubmed:17532767
chr11	64313994	64313997	P11474	0	+	64313994	64313997	102,0,51	1	3	0	.	Required for DNA-dependent dimerization.
chr11	64758305	64758308	P11217	0	-	64758305	64758308	102,0,51	1	3	0	.	May be involved in allosteric control.
chr11	64758344	64758347	P11217	0	-	64758344	64758347	102,0,51	1	3	0	.	Involved in the association of subunits.
chr11	64758620	64758623	P11217	0	-	64758620	64758623	102,0,51	1	3	0	.	Involved in the association of subunits.
chr11	65182743	65182749	P07384	0	+	65182743	65182749	102,0,51	1	6	0	.	Cleavage; for 78 kDa form.
chr11	65182779	65182785	P07384	0	+	65182779	65182785	102,0,51	1	6	0	.	Cleavage; for 75 kDa form.
chr11	66012149	66012152	Q15828	0	+	66012149	66012152	102,0,51	1	3	0	.	Reactive site.
chr11	66845885	66845888	Q9Y256	0	+	66845885	66845888	102,0,51	1	3	0	.	Transition state stabilizer.
chr11	66845897	66845900	Q9Y256	0	+	66845897	66845900	102,0,51	1	3	0	.	Transition state stabilizer.
chr11	67405642	67405645	Q8IV04	0	+	67405642	67405645	102,0,51	1	3	0	.	Arginine finger.
chr11	67405966	67405969	Q8IV04	0	+	67405966	67405969	102,0,51	1	3	0	.	Glutamine finger.
chr11	74493250	74493253	A6NK58	0	-	74493250	74493253	102,0,51	1	3	0	.	Lowers pKa of active site Cys.
chr11	75571954	75571960	P50454	0	+	75571954	75571960	102,0,51	1	6	0	.	Reactive bond homolog.
chr11	85959057	85974710	Q13492	0	-	85959057	85974710	102,0,51	1	15653	0	.	Breakpoint for translocation to form CALM/MLLT10 fusion protein.
chr11	86465097	86465100	Q16798	0	-	86465097	86465100	102,0,51	1	3	0	.	Important for activity.
chr11	88113999	88114002	P57729	0	-	88113999	88114002	102,0,51	1	3	0	.	Not methylated.
chr11	96093514	96341385	Q8IZL2	0	-	96093514	96341385	102,0,51	1	247871	0	.	Breakpoint for translocation to form the CRTC1-MAML2 and MAML2-CRTC1 fusion proteins. Pubmed:15729701
chr11	102335964	102335970	Q13489	0	+	102335964	102335970	102,0,51	1	6	0	.	Breakpoint for translocation to form BIRC3-MALT1.
chr11	102795262	102795268	P03956	0	-	102795262	102795268	102,0,51	1	6	0	.	Cleavage; by autolysis. Pubmed:2557822
chr11	102797083	102797086	P03956	0	-	102797083	102797086	102,0,51	1	3	0	.	Not glycosylated. Pubmed:10092871
chr11	103943473	103943479	Q9GZP0	0	-	103943473	103943479	102,0,51	1	6	0	.	Cleavage.
chr11	103943479	103943485	Q9GZP0	0	-	103943479	103943485	102,0,51	1	6	0	.	Cleavage.
chr11	111840807	111840810	Q9H6U8	0	-	111840807	111840810	102,0,51	1	3	0	.	Breakpoint for translocation. Pubmed:12030331
chr11	111910446	111910449	P02511	0	-	111910446	111910449	102,0,51	1	3	0	.	Susceptible to oxidation.
chr11	111911544	111911547	P02511	0	-	111911544	111911547	102,0,51	1	3	0	.	Susceptible to oxidation.
chr11	111911580	111911583	P02511	0	-	111911580	111911583	102,0,51	1	3	0	.	Susceptible to oxidation.
chr11	113415552	113415555	P14416	0	-	113415552	113415555	102,0,51	1	3	0	.	Important for receptor activation.
chr11	113415561	113415564	P14416	0	-	113415561	113415564	102,0,51	1	3	0	.	Important for receptor activation.
chr11	113694608	113694614	Q9H3S3	0	-	113694608	113694614	102,0,51	1	6	0	.	Cleavage.
chr11	114064479	114064485	Q05516	0	+	114064479	114064485	102,0,51	1	6	0	.	Breakpoint for translocation to form PLZF-RAR-alpha oncogene.
chr11	116830825	116830828	P02656	0	+	116830825	116830828	102,0,51	1	3	0	.	May interact with the LDL receptor. Pubmed:18408013
chr11	116830837	116830840	P02656	0	+	116830837	116830840	102,0,51	1	3	0	.	May interact with the LDL receptor. Pubmed:18408013
chr11	116830846	116830849	P02656	0	+	116830846	116830849	102,0,51	1	3	0	.	May interact with the LDL receptor. Pubmed:18408013
chr11	117229418	117229424	Q16549	0	-	117229418	117229424	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr11	118111766	118111772	Q9NRS4	0	+	118111766	118111772	102,0,51	1	6	0	.	Cleavage.
chr11	118482079	118482085	Q03164	0	+	118482079	118482085	102,0,51	1	6	0	.	Breakpoint for translocation to form KMT2A-ZFYVE19 oncogene.
chr11	118482492	118482495	Q03164	0	+	118482492	118482495	102,0,51	1	3	0	.	Breakpoint for translocation to form KMT2A-FRYL fusion protein.
chr11	118482492	118484185	Q03164	0	+	118482492	118484185	102,0,51	1	1693	0	.	Breakpoint for translocation to form KMT2A-AF3P21 and KMT2A-KNL1 oncogenes.
chr11	118482492	118484185	Q03164	0	+	118482492	118484185	102,0,51	1	1693	0	.	Breakpoint for translocation to form KMT2A-CENPK oncogene.
chr11	118484311	118484864	Q03164	0	+	118484311	118484864	102,0,51	1	553	0	.	Breakpoint for translocation to form KMT2A-AFF4 fusion protein.
chr11	118484972	118488616	Q03164	0	+	118484972	118488616	102,0,51	1	3644	0	.	Breakpoint for translocation to form KMT2A-GAS7 oncogene.
chr11	118484972	118488616	Q03164	0	+	118484972	118488616	102,0,51	1	3644	0	.	Breakpoint for translocation to form KMT2A-LPP.
chr11	118503896	118503902	Q03164	0	+	118503896	118503902	102,0,51	1	6	0	.	Cleavage; by TASP1, site 1. Pubmed:14636557
chr11	118504052	118504058	Q03164	0	+	118504052	118504058	102,0,51	1	6	0	.	Cleavage; by TASP1, site 2. Pubmed:14636557
chr11	118519772	118519775	Q03164	0	+	118519772	118519775	102,0,51	1	3	0	.	Important for WDR5-recognition and binding. Pubmed:19556245
chr11	120431908	120437310	Q9NZN5	0	+	120431908	120437310	102,0,51	1	5402	0	.	Breakpoint for translocation to form KMT2A/MLL1-ARHGEF12 oncogene.
chr11	124745598	124745601	Q92686	0	+	124745598	124745601	102,0,51	1	3	0	.	Crucial for interaction with calmodulin.
chr11	128839787	128839790	A0A024R3K6	0	-	128839787	128839790	102,0,51	1	3	0	.	Role in the control of polyamine-mediated channel gating and in the blocking by intracellular magnesium.
chr11	128839787	128839790	P48048	0	-	128839787	128839790	102,0,51	1	3	0	.	Role in the control of polyamine-mediated channel gating and in the blocking by intracellular magnesium.
chr11	128911807	128911810	P48544	0	+	128911807	128911810	102,0,51	1	3	0	.	Role in the control of polyamine-mediated channel gating and in the blocking by intracellular magnesium.
chr11	130123646	130123652	Q06481	0	+	130123646	130123652	102,0,51	1	6	0	.	Reactive bond.
chr11	134381979	134381982	Q9P2W7	0	-	134381979	134381982	102,0,51	1	3	0	.	Interaction with galactose moiety of substrate glycoprotein.
chr11	134382943	134382946	Q9P2W7	0	-	134382943	134382946	102,0,51	1	3	0	.	Interaction with galactose moiety of substrate glycoprotein.
chr12	1183418	1189861	Q8IUD2	0	+	1183418	1189861	102,0,51	1	6443	0	.	Breakpoint for translocation to form ERC1-RET oncogene.
chr12	1190346	1196789	Q8IUD2	0	+	1190346	1196789	102,0,51	1	6443	0	.	Breakpoint for translocation to form ERC1-RET oncogene.
chr12	4352469	4352472	Q9NQ88	0	+	4352469	4352472	102,0,51	1	3	0	.	Transition state stabilizer.
chr12	4370558	4370564	Q9GZV9	0	-	4370558	4370564	102,0,51	1	6	0	.	Cleavage; by proprotein convertases.
chr12	6537592	6537595	P04406	0	+	6537592	6537595	102,0,51	1	3	0	.	Activates thiol group during catalysis.
chr12	6537592	6537595	V9HVZ4	0	+	6537592	6537595	102,0,51	1	3	0	.	Activates thiol group during catalysis.
chr12	6935591	6935597	P54259	0	+	6935591	6935597	102,0,51	1	6	0	.	Cleavage.
chr12	6974419	6974422	Q92979	0	+	6974419	6974422	102,0,51	1	3	0	.	Interaction with substrate rRNA.
chr12	6974425	6974428	Q92979	0	+	6974425	6974428	102,0,51	1	3	0	.	Stabilizes Arg-84.
chr12	6974653	6974656	Q92979	0	+	6974653	6974656	102,0,51	1	3	0	.	Interaction with substrate rRNA.
chr12	6974662	6974665	Q92979	0	+	6974662	6974665	102,0,51	1	3	0	.	Interaction with substrate rRNA.
chr12	6974674	6974677	Q92979	0	+	6974674	6974677	102,0,51	1	3	0	.	Interaction with substrate rRNA.
chr12	7496828	7496834	Q86VB7	0	-	7496828	7496834	102,0,51	1	6	0	.	Cleavage; in calcium-free condition.
chr12	7496909	7496915	Q86VB7	0	-	7496909	7496915	102,0,51	1	6	0	.	Cleavage; in calcium-free condition.
chr12	7497065	7497071	Q86VB7	0	-	7497065	7497071	102,0,51	1	6	0	.	Cleavage; in calcium-free condition.
chr12	7497101	7497107	Q86VB7	0	-	7497101	7497107	102,0,51	1	6	0	.	Cleavage; in calcium-free condition.
chr12	10160800	10160803	P78380	0	-	10160800	10160803	102,0,51	1	3	0	.	Not glycosylated.
chr12	10221840	10221846	Q9H0R8	0	+	10221840	10221846	102,0,51	1	6	0	.	Cleavage; by RavZ.
chr12	10221843	10221849	Q9H0R8	0	+	10221843	10221849	102,0,51	1	6	0	.	Cleavage; by ATG4B.
chr12	11650157	11752452	P41212	0	+	11650157	11752452	102,0,51	1	102295	0	.	Breakpoint for translocation to form CHIC2-ETV6 in AML.
chr12	11752575	11839141	P41212	0	+	11752575	11839141	102,0,51	1	86566	0	.	Breakpoint for translocation to form ETV6-MDS2 in MDS.
chr12	11839138	11839144	P41212	0	+	11839138	11839144	102,0,51	1	6	0	.	Breakpoint for translocation to form PAX5-ETV6.
chr12	11869965	11884446	P41212	0	+	11869965	11884446	102,0,51	1	14481	0	.	Breakpoint for translocation to form ETV6-AML1 in ALL.
chr12	13608767	13608770	Q13224	0	-	13608767	13608770	102,0,51	1	3	0	.	Functional determinant of NMDA receptors.
chr12	14674637	14674640	P25092	0	-	14674637	14674640	102,0,51	1	3	0	.	Not glycosylated.
chr12	16357625	16357628	P10620	0	+	16357625	16357628	102,0,51	1	3	0	.	Activates the enzyme when modified.
chr12	21527149	21527155	Q9BT56	0	+	21527149	21527155	102,0,51	1	6	0	.	Cleavage; by prohormone convertase 2.
chr12	21527734	21527740	Q9BT56	0	+	21527734	21527740	102,0,51	1	6	0	.	Cleavage; by prohormone convertase 2.
chr12	21529005	21529011	Q9BT56	0	+	21529005	21529011	102,0,51	1	6	0	.	Cleavage; by prohormone convertase 2.
chr12	21766487	21766490	A0A024RAV6	0	-	21766487	21766490	102,0,51	1	3	0	.	Role in the control of polyamine-mediated channel gating and in the blocking by intracellular magnesium.
chr12	21766487	21766490	Q15842	0	-	21766487	21766490	102,0,51	1	3	0	.	Role in the control of polyamine-mediated channel gating and in the blocking by intracellular magnesium.
chr12	26957740	26960517	Q9NVK5	0	+	26957740	26960517	102,0,51	1	2777	0	.	Breakpoint for translocation to form FGFR1OP2-FGFR1.
chr12	47785811	47785814	J3KPH8	0	-	47785811	47785814	102,0,51	1	3	0	.	Contributes to catalysis.
chr12	47785811	47785814	Q8WUI4	0	-	47785811	47785814	102,0,51	1	3	0	.	Contributes to catalysis.
chr12	47975476	47975482	P02458	0	-	47975476	47975482	102,0,51	1	6	0	.	Cleavage; by procollagen C-endopeptidase.
chr12	47996610	47996616	P02458	0	-	47996610	47996616	102,0,51	1	6	0	.	Cleavage; by procollagen N-endopeptidase.
chr12	48694430	48694433	O60563	0	-	48694430	48694433	102,0,51	1	3	0	.	Essential for interacting with HIV-1 Tat.
chr12	49090236	49090239	O43323	0	-	49090236	49090239	102,0,51	1	3	0	.	Essential for auto-cleavage.
chr12	49090245	49090248	O43323	0	-	49090245	49090248	102,0,51	1	3	0	.	Involved in auto-cleavage.
chr12	49090317	49090320	O43323	0	-	49090317	49090320	102,0,51	1	3	0	.	Involved in cholesterol transfer.
chr12	49090452	49090458	O43323	0	-	49090452	49090458	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr12	49127960	49127963	P68363	0	-	49127960	49127963	102,0,51	1	3	0	.	Involved in polymerization.
chr12	49185012	49185015	Q71U36	0	-	49185012	49185015	102,0,51	1	3	0	.	Involved in polymerization.
chr12	49273221	49273224	Q9BQE3	0	+	49273221	49273224	102,0,51	1	3	0	.	Involved in polymerization.
chr12	50058976	50058979	P78348	0	+	50058976	50058979	102,0,51	1	3	0	.	Important for channel gating.
chr12	50059000	50059003	P78348	0	+	50059000	50059003	102,0,51	1	3	0	.	Important for channel desensitizing.
chr12	50078441	50078444	P78348	0	+	50078441	50078444	102,0,51	1	3	0	.	Important for channel gating.
chr12	50814008	50814011	P18846	0	+	50814008	50814011	102,0,51	1	3	0	.	Breakpoint for translocation to form chimeric EWSR1/ATF1 protein.
chr12	50814014	50814017	P18846	0	+	50814014	50814017	102,0,51	1	3	0	.	Breakpoint for translocation to form chimeric FUS/ATF1 protein.
chr12	52172373	52172376	Q6KB66	0	-	52172373	52172376	102,0,51	1	3	0	.	Stutter.
chr12	52245453	52245456	P08729	0	+	52245453	52245456	102,0,51	1	3	0	.	Stutter.
chr12	52428437	52428440	O95678	0	-	52428437	52428440	102,0,51	1	3	0	.	Stutter.
chr12	52447959	52447962	P04259	0	-	52447959	52447962	102,0,51	1	3	0	.	Stutter.
chr12	52469851	52469854	P48668	0	-	52469851	52469854	102,0,51	1	3	0	.	Stutter.
chr12	52488509	52488512	P02538	0	-	52488509	52488512	102,0,51	1	3	0	.	Stutter.
chr12	52516818	52516821	P13647	0	-	52516818	52516821	102,0,51	1	3	0	.	Stutter.
chr12	52546467	52546470	Q3SY84	0	-	52546467	52546470	102,0,51	1	3	0	.	Stutter.
chr12	52568350	52568353	Q7RTS7	0	-	52568350	52568353	102,0,51	1	3	0	.	Stutter.
chr12	52587812	52587815	Q14CN4	0	-	52587812	52587815	102,0,51	1	3	0	.	Stutter.
chr12	52610796	52610799	Q86Y46	0	-	52610796	52610799	102,0,51	1	3	0	.	Stutter.
chr12	52646921	52646924	P35908	0	-	52646921	52646924	102,0,51	1	3	0	.	Stutter.
chr12	52676450	52676453	P04264	0	-	52676450	52676453	102,0,51	1	3	0	.	Stutter.
chr12	52692593	52692596	Q7Z794	0	-	52692593	52692596	102,0,51	1	3	0	.	Stutter.
chr12	52823197	52823200	Q5XKE5	0	-	52823197	52823200	102,0,51	1	3	0	.	Stutter.
chr12	52839945	52839948	Q8N1N4	0	-	52839945	52839948	102,0,51	1	3	0	.	Stutter.
chr12	52898854	52898857	P05787	0	-	52898854	52898857	102,0,51	1	3	0	.	Stutter.
chr12	52951534	52951540	P05783	0	+	52951534	52951540	102,0,51	1	6	0	.	Cleavage; by caspase-3, caspase-6 or caspase-7.
chr12	52951633	52951636	P05783	0	+	52951633	52951636	102,0,51	1	3	0	.	Stutter.
chr12	52952160	52952163	P05783	0	+	52952160	52952163	102,0,51	1	3	0	.	Stutter.
chr12	53288310	53288316	Q14674	0	+	53288310	53288316	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr12	53288593	53288599	Q14674	0	+	53288593	53288599	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr12	53382133	53382139	P08047	0	+	53382133	53382139	102,0,51	1	6	0	.	Cleavage.
chr12	53467250	53467256	Q15366	0	+	53467250	53467256	102,0,51	1	6	0	.	Cleavage, by viral proteinase 3CD. Pubmed:24371074
chr12	53665367	53665370	Q06055	0	-	53665367	53665370	102,0,51	1	3	0	.	Reversibly protonated during proton transport.
chr12	55696357	55696363	Q13683	0	-	55696357	55696363	102,0,51	1	6	0	.	Cleavage; by urokinase.
chr12	55967032	55967035	P24941	0	+	55967032	55967035	102,0,51	1	3	0	.	CDK7 binding.
chr12	55968115	55968121	P24941	0	+	55968115	55968121	102,0,51	1	6	0	.	CDK7 binding.
chr12	55969483	55969486	P24941	0	+	55969483	55969486	102,0,51	1	3	0	.	CDK7 binding.
chr12	56453668	56453671	P30301	0	-	56453668	56453671	102,0,51	1	3	0	.	Important for water channel gating.
chr12	57823990	57823993	O14595	0	-	57823990	57823993	102,0,51	1	3	0	.	Transition state stabilizer.
chr12	57824241	57824244	O14595	0	-	57824241	57824244	102,0,51	1	3	0	.	Transition state stabilizer.
chr12	68867004	68867007	P14384	0	-	68867004	68867007	102,0,51	1	3	0	.	Probable structural role. Pubmed:12457462
chr12	72499626	72499629	Q9UKU6	0	+	72499626	72499629	102,0,51	1	3	0	.	Transition state stabilizer.
chr12	88518768	88518771	P21583	0	-	88518768	88518771	102,0,51	1	3	0	.	Not glycosylated.
chr12	96014921	96014924	P09960	0	-	96014921	96014924	102,0,51	1	3	0	.	Covalently modified during suicide inhibition by leukotrienes.
chr12	96014930	96014933	P09960	0	-	96014930	96014933	102,0,51	1	3	0	.	Essential for epoxide hydrolase activity, but not for aminopeptidase activity.
chr12	101761691	101761697	Q3T906	0	-	101761691	101761697	102,0,51	1	6	0	.	Cleavage; by MBTPS1.
chr12	105068820	105068823	Q3SY69	0	-	105068820	105068823	102,0,51	1	3	0	.	Essential for catalytic activity.
chr12	105203701	105203707	Q8NEU8	0	-	105203701	105203707	102,0,51	1	6	0	.	Breakpoint for chromosomal translocation. Pubmed:11431708
chr12	110459797	110459800	Q9UHW5	0	-	110459797	110459800	102,0,51	1	3	0	.	Stabilizes the phosphate intermediate; shared with dimeric partner.
chr12	110722197	110722200	P36873	0	-	110722197	110722200	102,0,51	1	3	0	.	Inhibition by microcystin toxin binding.
chr12	111790436	111790439	P05091	0	+	111790436	111790439	102,0,51	1	3	0	.	Transition state stabilizer.
chr12	112911052	112911055	P00973	0	+	112911052	112911055	102,0,51	1	3	0	.	Interaction with dsRNA.
chr12	112944477	112944480	Q9Y6K5	0	+	112944477	112944480	102,0,51	1	3	0	.	Interaction with dsRNA. Pubmed:25775560
chr12	112946835	112946838	Q9Y6K5	0	+	112946835	112946838	102,0,51	1	3	0	.	Interaction with dsRNA. Pubmed:25775560
chr12	116576299	116576305	A6NCE7	0	+	116576299	116576305	102,0,51	1	6	0	.	Cleavage; by ATG4B.
chr12	120446249	120446252	O43715	0	-	120446249	120446252	102,0,51	1	3	0	.	Important for interaction with PRELID3A. Pubmed:26071602
chr12	120446291	120446294	O43715	0	-	120446291	120446294	102,0,51	1	3	0	.	Important for interaction with PRELID3A. Pubmed:26071602
chr12	121420301	121420307	Q969K3	0	+	121420301	121420307	102,0,51	1	6	0	.	Cleavage; by caspase-3. Pubmed:12118383
chr12	124913567	124913570	P0CG48	0	-	124913567	124913570	102,0,51	1	3	0	.	Essential for function.
chr12	130354632	130354635	Q96J94	0	+	130354632	130354635	102,0,51	1	3	0	.	Required for binding 2'-O-methylated 3'-end of piRNAs.
chr12	132808132	132808138	Q08378	0	-	132808132	132808138	102,0,51	1	6	0	.	Cleavage; by caspase-7.
chr12	132813405	132813411	Q08378	0	-	132813405	132813411	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr12	132816765	132816771	Q08378	0	-	132816765	132816771	102,0,51	1	6	0	.	Cleavage; by caspase-2.
chr13	19173865	19173868	Q13748	0	-	19173865	19173868	102,0,51	1	3	0	.	Involved in polymerization.
chr13	19633922	19633925	Q99549	0	+	19633922	19633925	102,0,51	1	3	0	.	Interaction with histone H3K9me3. Pubmed:21419134
chr13	20059559	20061055	Q9UBW7	0	+	20059559	20061055	102,0,51	1	1496	0	.	Breakpoint for translocation to form ZMYM2-FGFR1.
chr13	20439595	20439598	A0A024RDM2	0	-	20439595	20439598	102,0,51	1	3	0	.	Important for catalytic activity.
chr13	20439595	20439598	V9HWG2	0	-	20439595	20439598	102,0,51	1	3	0	.	Important for catalytic activity.
chr13	28345495	28345501	P17948	0	-	28345495	28345501	102,0,51	1	6	0	.	Cleavage; by PSEN1.
chr13	30463298	30463304	P09429	0	-	30463298	30463304	102,0,51	1	6	0	.	Cleavage; by CASP1. Pubmed:24474694
chr13	30463647	30463653	P09429	0	-	30463647	30463653	102,0,51	1	6	0	.	Cleavage; by thrombin:thrombomodulin.
chr13	40560815	40560818	Q12778	0	-	40560815	40560818	102,0,51	1	3	0	.	DNA-binding.
chr13	40665717	40665720	Q12778	0	-	40665717	40665720	102,0,51	1	3	0	.	DNA-binding.
chr13	40665738	40665741	Q12778	0	-	40665738	40665741	102,0,51	1	3	0	.	DNA-binding.
chr13	42600778	42600784	O14788	0	+	42600778	42600784	102,0,51	1	6	0	.	Cleavage.
chr13	46058202	46058208	Q96IY4	0	-	46058202	46058208	102,0,51	1	6	0	.	Cleavage; by thrombin.
chr13	47988588	47988591	Q9P2R7	0	-	47988588	47988591	102,0,51	1	3	0	.	Important for substrate specificity.
chr13	47988970	47988973	Q9P2R7	0	-	47988970	47988973	102,0,51	1	3	0	.	Important for substrate specificity.
chr13	48261149	48261155	Q9Y287	0	+	48261149	48261155	102,0,51	1	6	0	.	Cleavage; by furin.
chr13	51361826	51361832	A8MV23	0	+	51361826	51361832	102,0,51	1	6	0	.	Reactive bond.
chr13	75604767	75604770	P15374	0	+	75604767	75604770	102,0,51	1	3	0	.	Important for enzyme activity.
chr13	79533390	79533393	Q9NV92	0	+	79533390	79533393	102,0,51	1	3	0	.	Not phosphorylated by SRC.
chr13	80337270	80337276	O43597	0	-	80337270	80337276	102,0,51	1	6	0	.	Cleavage; by FAP. Pubmed:21288888
chr13	98461884	98461890	Q9Y6E0	0	-	98461884	98461890	102,0,51	1	6	0	.	Cleavage; by caspase-3, caspase-7 and caspase-8.
chr13	103046195	103046198	Q12908	0	-	103046195	103046198	102,0,51	1	3	0	.	Not glycosylated.
chr13	108270396	108270402	Q9Y275	0	+	108270396	108270402	102,0,51	1	6	0	.	Cleavage.
chr13	113113866	113113869	P08709	0	+	113113866	113113869	102,0,51	1	3	0	.	Important for S-112 for O-xylosylation.
chr13	113116827	113116833	P08709	0	+	113116827	113116833	102,0,51	1	6	0	.	Cleavage; by factor Xa, factor XIIa, factor IXa, or thrombin.
chr14	20455945	20455951	P27695	0	+	20455945	20455951	102,0,51	1	6	0	.	Cleavage; by granzyme A.
chr14	20457184	20457187	P27695	0	+	20457184	20457187	102,0,51	1	3	0	.	Transition state stabilizer.
chr14	20457397	20457400	P27695	0	+	20457397	20457400	102,0,51	1	3	0	.	Important for catalytic activity.
chr14	20457475	20457478	P27695	0	+	20457475	20457478	102,0,51	1	3	0	.	Interaction with DNA substrate.
chr14	20891863	20891866	P12724	0	+	20891863	20891866	102,0,51	1	3	0	.	May be involved in LPS-binding.
chr14	20891869	20891872	P12724	0	+	20891869	20891872	102,0,51	1	3	0	.	May be involved in LPS- and LTA-binding.
chr14	22924667	22924670	O14744	0	-	22924667	22924670	102,0,51	1	3	0	.	Critical for specifying symmetric addition of methyl groups.
chr14	23061613	23061619	Q9UKV3	0	-	23061613	23061619	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr14	24218149	24218152	Q15843	0	-	24218149	24218152	102,0,51	1	3	0	.	Interaction with UBE1C.
chr14	24218425	24218428	Q15843	0	-	24218425	24218428	102,0,51	1	3	0	.	Interaction with UBE1C.
chr14	24631130	24631133	P10144	0	-	24631130	24631133	102,0,51	1	3	0	.	Mediates preference for Asp-containing substrates.
chr14	50931732	50931735	P06737	0	-	50931732	50931735	102,0,51	1	3	0	.	May be involved in allosteric control.
chr14	50931771	50931774	P06737	0	-	50931771	50931774	102,0,51	1	3	0	.	Involved in the association of subunits.
chr14	50937753	50937756	P06737	0	-	50937753	50937756	102,0,51	1	3	0	.	Involved in the association of subunits.
chr14	65015645	65015648	P49356	0	+	65015645	65015648	102,0,51	1	3	0	.	Important for selectivity against geranylgeranyl diphosphate.
chr14	67887201	68291886	O15315	0	+	67887201	68291886	102,0,51	1	404685	0	.	Breakpoint for translocation to form HMGA2-RAD51B.
chr14	73206387	73206393	P49768	0	+	73206387	73206393	102,0,51	1	6	0	.	Cleavage; alternate. Pubmed:9173929
chr14	73206390	73206396	P49768	0	+	73206390	73206396	102,0,51	1	6	0	.	Cleavage; alternate. Pubmed:9173929
chr14	73206408	73206414	P49768	0	+	73206408	73206414	102,0,51	1	6	0	.	Cleavage. Pubmed:9173929
chr14	73211845	73211851	P49768	0	+	73211845	73211851	102,0,51	1	6	0	.	Cleavage; by caspase. Pubmed:9485372
chr14	76482053	76482056	O95718	0	+	76482053	76482056	102,0,51	1	3	0	.	Important for stabilizing DNA-binding.
chr14	76762905	76762911	Q7L8A9	0	+	76762905	76762911	102,0,51	1	6	0	.	Cleavage.
chr14	76763046	76763052	Q7L8A9	0	+	76763046	76763052	102,0,51	1	6	0	.	Cleavage.
chr14	77694793	77694796	Q13686	0	-	77694793	77694796	102,0,51	1	3	0	.	Primary catalytic residue forming the imine linkage with DNA. Pubmed:23577621
chr14	77694793	77694796	Q13686	0	-	77694793	77694796	102,0,51	1	3	0	.	Secondary catalytic residue forming the imine linkage with DNA. Pubmed:23577621
chr14	81192626	81192632	P52655	0	-	81192626	81192632	102,0,51	1	6	0	.	Cleavage; by TASP1.
chr14	90019325	90019328	Q9NUW8	0	+	90019325	90019328	102,0,51	1	3	0	.	Interaction with DNA. Pubmed:12470949
chr14	91976184	91976190	Q15643	0	-	91976184	91976190	102,0,51	1	6	0	.	Breakpoint for translocation to form TRIP11-PDGFRB.
chr14	92709719	92709725	Q99538	0	-	92709719	92709725	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr14	92816418	92819710	Q8TBA6	0	+	92816418	92819710	102,0,51	1	3292	0	.	Breakpoint for translocation to form RET-GOLGA5 oncogene.
chr14	94045892	94045895	Q96DC9	0	+	94045892	94045895	102,0,51	1	3	0	.	Required to orient and stabilize the active site H-224. Pubmed:15258613
chr14	94284072	94284078	Q9UK55	0	-	94284072	94284078	102,0,51	1	6	0	.	Reactive bond.
chr14	94288335	94288338	Q9UK55	0	-	94288335	94288338	102,0,51	1	3	0	.	Essential for interaction with PROZ.
chr14	94288494	94288497	Q9UK55	0	-	94288494	94288497	102,0,51	1	3	0	.	Essential for interaction with PROZ.
chr14	94309869	94309872	P08185	0	-	94309869	94309872	102,0,51	1	3	0	.	Conserved cysteine within steroid binding domain.
chr14	94378556	94378562	P01009	0	-	94378556	94378562	102,0,51	1	6	0	.	Reactive bond.
chr14	94569472	94569478	P29622	0	+	94569472	94569478	102,0,51	1	6	0	.	Reactive bond.
chr14	94592134	94592140	P05154	0	+	94592134	94592140	102,0,51	1	6	0	.	Reactive bond.
chr14	94623688	94623694	P01011	0	+	94623688	94623694	102,0,51	1	6	0	.	Reactive bond.
chr14	95091311	95091314	Q9UPY3	0	-	95091311	95091314	102,0,51	1	3	0	.	Important for activity.
chr14	96527967	96527970	P51003	0	+	96527967	96527970	102,0,51	1	3	0	.	Interaction with RNA.
chr14	96527982	96527985	P51003	0	+	96527982	96527985	102,0,51	1	3	0	.	Interaction with RNA.
chr14	96535950	96535953	P51003	0	+	96535950	96535953	102,0,51	1	3	0	.	Interaction with RNA.
chr14	96542798	96542801	P51003	0	+	96542798	96542801	102,0,51	1	3	0	.	Interaction with RNA.
chr14	96552527	96552530	P51003	0	+	96552527	96552530	102,0,51	1	3	0	.	Interaction with RNA.
chr14	105643812	105643815	P01859	0	-	105643812	105643815	102,0,51	1	3	0	.	At or near the complement-binding site.
chr14	105644583	105644586	P01859	0	-	105644583	105644586	102,0,51	1	3	0	.	At or near the complement-binding site.
chr15	33836983	33836986	Q15413	0	+	33836983	33836986	102,0,51	1	3	0	.	Important for activation by Ca(2+).
chr15	34346031	34347970	Q86Y26	0	+	34346031	34347970	102,0,51	1	1939	0	.	Breakpoint for translocation to form BRD4-NUT and BRD3-NUT fusion proteins.
chr15	40206183	40206189	O60566	0	+	40206183	40206189	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr15	40206276	40206282	O60566	0	+	40206276	40206282	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr15	40625637	40628072	Q8NG31	0	+	40625637	40628072	102,0,51	1	2435	0	.	Breakpoint for translocation to form KMT2A-KNL1. Pubmed:12618766
chr15	40809438	40809444	Q96K21	0	+	40809438	40809444	102,0,51	1	6	0	.	Breakpoint for translocation to form KMT2A/MLL1-ZFYVE19.
chr15	40853745	40853751	O43278	0	+	40853745	40853751	102,0,51	1	6	0	.	Reactive bond.
chr15	40855926	40855932	O43278	0	+	40855926	40855932	102,0,51	1	6	0	.	Reactive bond.
chr15	40930107	40930110	Q9NR61	0	+	40930107	40930110	102,0,51	1	3	0	.	Interaction with Notch1.
chr15	40931753	40931756	Q9NR61	0	+	40931753	40931756	102,0,51	1	3	0	.	Interaction with Notch1.
chr15	43348966	43348969	Q6DHV7	0	+	43348966	43348969	102,0,51	1	3	0	.	Important for catalytic activity.
chr15	43753827	43753830	P30101	0	+	43753827	43753830	102,0,51	1	3	0	.	Contributes to redox potential value.
chr15	43753830	43753833	P30101	0	+	43753830	43753833	102,0,51	1	3	0	.	Contributes to redox potential value.
chr15	43756756	43756759	P30101	0	+	43756756	43756759	102,0,51	1	3	0	.	Lowers pKa of C-terminal Cys of first active site.
chr15	43769598	43769601	P30101	0	+	43769598	43769601	102,0,51	1	3	0	.	Contributes to redox potential value.
chr15	43769601	43769604	P30101	0	+	43769601	43769604	102,0,51	1	3	0	.	Contributes to redox potential value.
chr15	43771110	43771113	P30101	0	+	43771110	43771113	102,0,51	1	3	0	.	Lowers pKa of C-terminal Cys of second active site.
chr15	49201234	49201237	Q01415	0	+	49201234	49201237	102,0,51	1	3	0	.	Transition state stabilizer.
chr15	51341963	51341969	Q6ZMI3	0	+	51341963	51341969	102,0,51	1	6	0	.	Cleavage; by furin-like protease.
chr15	51400211	51400217	Q6ZMI3	0	+	51400211	51400217	102,0,51	1	6	0	.	Cleavage; by BMP1.
chr15	57993067	57993070	O94788	0	-	57993067	57993070	102,0,51	1	3	0	.	Transition state stabilizer.
chr15	66387368	66387374	Q02750	0	+	66387368	66387374	102,0,51	1	6	0	.	Cleavage; by anthrax lethal factor.
chr15	67066271	67066274	P84022	0	+	67066271	67066274	102,0,51	1	3	0	.	Required for trimerization.
chr15	67066274	67066277	P84022	0	+	67066274	67066277	102,0,51	1	3	0	.	Required for interaction with DNA and JUN and for functional cooperation with JUN.
chr15	68290381	68290387	Q9UK73	0	+	68290381	68290387	102,0,51	1	6	0	.	Cleavage; by a caspase-3-like protease.
chr15	72202461	72202464	P14618	0	-	72202461	72202464	102,0,51	1	3	0	.	Crucial for phosphotyrosine binding.
chr15	72208646	72208649	P14618	0	-	72208646	72208649	102,0,51	1	3	0	.	Transition state stabilizer.
chr15	73884782	73884785	Q8IYX1	0	+	73884782	73884785	102,0,51	1	3	0	.	Arginine finger.
chr15	73885010	73885013	Q8IYX1	0	+	73885010	73885013	102,0,51	1	3	0	.	Glutamine finger.
chr15	74023404	74024858	P29590	0	+	74023404	74024858	102,0,51	1	1454	0	.	Breakpoint for translocation to form PML-RARA oncogene in type A APL.
chr15	74033410	74034479	P29590	0	+	74033410	74034479	102,0,51	1	1069	0	.	Breakpoint for translocation to form PML-RARA oncogene in type B APL.
chr15	75598612	75598615	O95149	0	-	75598612	75598615	102,0,51	1	3	0	.	Interaction with m3G-cap structure. Pubmed:15920472
chr15	75609627	75609630	O95149	0	-	75609627	75609630	102,0,51	1	3	0	.	Interaction with m3G-cap structure. Pubmed:15920472
chr15	75609982	75609985	O95149	0	-	75609982	75609985	102,0,51	1	3	0	.	Interaction with m3G-cap structure. Pubmed:15920472
chr15	78161747	78161750	P50213	0	+	78161747	78161750	102,0,51	1	3	0	.	Critical for catalysis.
chr15	78162353	78162356	P50213	0	+	78162353	78162356	102,0,51	1	3	0	.	Critical for catalysis.
chr15	78629902	78629905	P30926	0	-	78629902	78629905	102,0,51	1	3	0	.	Key residue for a low dissociation (K(off)) from the conotoxin BuIA.
chr15	78631290	78631293	P30926	0	-	78631290	78631293	102,0,51	1	3	0	.	Key residue that facilitates effective access of the conotoxin BuIA to the channel binding site.
chr15	87876952	87876955	Q16288	0	-	87876952	87876955	102,0,51	1	3	0	.	Interaction with PLC-gamma-1.
chr15	88032893	88032896	Q16288	0	-	88032893	88032896	102,0,51	1	3	0	.	Interaction with SHC1.
chr15	89803652	89803655	P15144	0	-	89803652	89803655	102,0,51	1	3	0	.	Transition state stabilizer. Pubmed:22932899
chr15	90087500	90087503	P48735	0	-	90087500	90087503	102,0,51	1	3	0	.	Critical for catalysis.
chr15	90088499	90088502	P48735	0	-	90088499	90088502	102,0,51	1	3	0	.	Critical for catalysis.
chr15	90876299	90876305	P09958	0	+	90876299	90876305	102,0,51	1	6	0	.	Cleavage, second; by autolysis.
chr15	90876503	90876509	P09958	0	+	90876503	90876509	102,0,51	1	6	0	.	Cleavage, first; by autolysis.
chr15	100893956	100893959	P47895	0	+	100893956	100893959	102,0,51	1	3	0	.	Transition state stabilizer.
chr15	101432052	101432058	P29122	0	-	101432052	101432058	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr16	172945	172948	P69905	0	+	172945	172948	102,0,51	1	3	0	.	Not glycated.
chr16	173197	173200	P69905	0	+	173197	173200	102,0,51	1	3	0	.	Not glycated.
chr16	173209	173212	P69905	0	+	173209	173212	102,0,51	1	3	0	.	Not glycated.
chr16	173299	173302	P69905	0	+	173299	173302	102,0,51	1	3	0	.	Not glycated.
chr16	173326	173329	P69905	0	+	173326	173329	102,0,51	1	3	0	.	Not glycated.
chr16	176749	176752	P69905	0	+	176749	176752	102,0,51	1	3	0	.	Not glycated.
chr16	177001	177004	P69905	0	+	177001	177004	102,0,51	1	3	0	.	Not glycated.
chr16	177013	177016	P69905	0	+	177013	177016	102,0,51	1	3	0	.	Not glycated.
chr16	177103	177106	P69905	0	+	177103	177106	102,0,51	1	3	0	.	Not glycated.
chr16	177130	177133	P69905	0	+	177130	177133	102,0,51	1	3	0	.	Not glycated.
chr16	284400	284403	Q13087	0	+	284400	284403	102,0,51	1	3	0	.	Contributes to redox potential value.
chr16	284403	284406	Q13087	0	+	284403	284406	102,0,51	1	3	0	.	Contributes to redox potential value.
chr16	284663	284666	Q13087	0	+	284663	284666	102,0,51	1	3	0	.	Lowers pKa of C-terminal Cys of first active site.
chr16	286567	286570	Q13087	0	+	286567	286570	102,0,51	1	3	0	.	Contributes to redox potential value.
chr16	286570	286573	Q13087	0	+	286570	286573	102,0,51	1	3	0	.	Contributes to redox potential value.
chr16	286855	286858	Q13087	0	+	286855	286858	102,0,51	1	3	0	.	Lowers pKa of C-terminal Cys of second active site.
chr16	632773	632779	Q96NZ8	0	+	632773	632779	102,0,51	1	6	0	.	Reactive bond.
chr16	1200727	1200730	O95180	0	+	1200727	1200730	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chr16	1207286	1207289	O95180	0	+	1207286	1207289	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chr16	1211748	1211751	O95180	0	+	1211748	1211751	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chr16	1218016	1218019	O95180	0	+	1218016	1218019	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chr16	1314039	1314042	P63279	0	+	1314039	1314042	102,0,51	1	3	0	.	Interaction with RANBP2.
chr16	1314298	1314301	P63279	0	+	1314298	1314301	102,0,51	1	3	0	.	Interaction with RANBP2.
chr16	1315671	1315674	P63279	0	+	1315671	1315674	102,0,51	1	3	0	.	Interaction with RANBP2.
chr16	1320247	1320253	P63279	0	+	1320247	1320253	102,0,51	1	6	0	.	Substrate binding.
chr16	1455769	1455772	P51798	0	-	1455769	1455772	102,0,51	1	3	0	.	Mediates proton transfer from the protein to the inner aqueous phase.
chr16	1457334	1457337	P51798	0	-	1457334	1457337	102,0,51	1	3	0	.	Mediates proton transfer from the outer aqueous phase to the interior of the protein; involved in linking H(+) and Cl(-) transport.
chr16	1501768	1501771	Q9Y4R8	0	+	1501768	1501771	102,0,51	1	3	0	.	Interaction with PIH1D1.
chr16	1501771	1501774	Q9Y4R8	0	+	1501771	1501774	102,0,51	1	3	0	.	Interaction with PIH1D1.
chr16	1502047	1502050	Q9Y4R8	0	+	1502047	1502050	102,0,51	1	3	0	.	Interaction with PIH1D1.
chr16	2040230	2040233	E5KTI5	0	-	2040230	2040233	102,0,51	1	3	0	.	Important for catalytic activity.
chr16	2040230	2040233	P78549	0	-	2040230	2040233	102,0,51	1	3	0	.	Important for catalytic activity.
chr16	2102434	2102440	P98161	0	-	2102434	2102440	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr16	2214165	2214168	A6NDG6	0	-	2214165	2214168	102,0,51	1	3	0	.	Important for substrate specificity.
chr16	2243346	2243349	P42126	0	-	2243346	2243349	102,0,51	1	3	0	.	Important for catalytic activity. Pubmed:15351645
chr16	2519691	2519694	P27449	0	+	2519691	2519694	102,0,51	1	3	0	.	Essential for proton translocation.
chr16	3249697	3249703	O15553	0	-	3249697	3249703	102,0,51	1	6	0	.	Cleavage; by CASP1.
chr16	3476326	3476329	Q9H7X0	0	+	3476326	3476329	102,0,51	1	3	0	.	Required to recognizing and positioning the ethanethioate moiety ofacetyl-CoA to the right location to facilitate acetyl-transfer. Pubmed:27550639
chr16	3810776	3850299	Q92793	0	-	3810776	3850299	102,0,51	1	39523	0	.	Breakpoint for translocation to form KAT6A-CREBBP.
chr16	3851004	3851010	Q92793	0	-	3851004	3851010	102,0,51	1	6	0	.	Breakpoint for translocation to form KAT6B-CREBBP.
chr16	4336807	4336813	Q9BZE0	0	+	4336807	4336813	102,0,51	1	6	0	.	Cleavage.
chr16	7579857	7579860	A0A087X2B1	0	+	7579857	7579860	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7579857	7579860	B7Z1U7	0	+	7579857	7579860	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7579857	7579860	F8VZG9	0	+	7579857	7579860	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7579857	7579860	J3KNW3	0	+	7579857	7579860	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7579857	7579860	Q9NWB1	0	+	7579857	7579860	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7579881	7579884	A0A087X2B1	0	+	7579881	7579884	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7579881	7579884	B7Z1U7	0	+	7579881	7579884	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7579881	7579884	F8VZG9	0	+	7579881	7579884	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7579881	7579884	J3KNW3	0	+	7579881	7579884	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7579881	7579884	Q9NWB1	0	+	7579881	7579884	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7579884	7579887	A0A087X2B1	0	+	7579884	7579887	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7579884	7579887	B7Z1U7	0	+	7579884	7579887	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7579884	7579887	F8VZG9	0	+	7579884	7579887	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7579884	7579887	J3KNW3	0	+	7579884	7579887	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7579884	7579887	Q9NWB1	0	+	7579884	7579887	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7587282	7587285	A0A087X2B1	0	+	7587282	7587285	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7587282	7587285	B7Z1U7	0	+	7587282	7587285	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7587282	7587285	F8VZG9	0	+	7587282	7587285	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7587282	7587285	J3KNW3	0	+	7587282	7587285	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7587282	7587285	Q9NWB1	0	+	7587282	7587285	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7587297	7587300	A0A087X2B1	0	+	7587297	7587300	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7587297	7587300	B7Z1U7	0	+	7587297	7587300	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7587297	7587300	F8VZG9	0	+	7587297	7587300	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7587297	7587300	J3KNW3	0	+	7587297	7587300	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7587297	7587300	Q9NWB1	0	+	7587297	7587300	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7595557	7595560	A0A087X2B1	0	+	7595557	7595560	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7595557	7595560	B7Z1U7	0	+	7595557	7595560	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7595557	7595560	F8VZG9	0	+	7595557	7595560	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7595557	7595560	J3KNW3	0	+	7595557	7595560	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7595557	7595560	Q9NWB1	0	+	7595557	7595560	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7595629	7595632	A0A087X2B1	0	+	7595629	7595632	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7595629	7595632	B7Z1U7	0	+	7595629	7595632	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7595629	7595632	F8VZG9	0	+	7595629	7595632	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7595629	7595632	J3KNW3	0	+	7595629	7595632	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7595629	7595632	Q9NWB1	0	+	7595629	7595632	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7597388	7597391	A0A087X2B1	0	+	7597388	7597391	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7597388	7597391	B7Z1U7	0	+	7597388	7597391	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7597388	7597391	F8VZG9	0	+	7597388	7597391	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7597388	7597391	J3KNW3	0	+	7597388	7597391	102,0,51	1	3	0	.	Interaction with RNA.
chr16	7597388	7597391	Q9NWB1	0	+	7597388	7597391	102,0,51	1	3	0	.	Interaction with RNA.
chr16	9829587	9829590	Q12879	0	-	9829587	9829590	102,0,51	1	3	0	.	Functional determinant of NMDA receptors.
chr16	11965330	11965336	Q02223	0	+	11965330	11965336	102,0,51	1	6	0	.	Breakpoint for translocation to form IL2/TNFRSF17 oncogene.
chr16	14584775	14584778	O95453	0	-	14584775	14584778	102,0,51	1	3	0	.	Interaction with poly(A). Pubmed:16281054
chr16	15047879	15047882	Q96AB6	0	-	15047879	15047882	102,0,51	1	3	0	.	Essential for catalytic activity.
chr16	15048939	15048942	Q96AB6	0	+	15048939	15048942	102,0,51	1	3	0	.	Essential for catalytic activity.
chr16	20336703	20336709	P07911	0	-	20336703	20336709	102,0,51	1	6	0	.	Cleavage. Pubmed:18375198
chr16	21199573	21199579	Q05996	0	-	21199573	21199579	102,0,51	1	6	0	.	Cleavage.
chr16	21205739	21205745	Q05996	0	-	21205739	21205745	102,0,51	1	6	0	.	Cleavage; by ASTL.
chr16	27342161	27342164	P24394	0	+	27342161	27342164	102,0,51	1	3	0	.	Major IL4 binding determinant.
chr16	27342239	27342242	P24394	0	+	27342239	27342242	102,0,51	1	3	0	.	Minor IL4 binding determinant.
chr16	27342245	27342248	P24394	0	+	27342245	27342248	102,0,51	1	3	0	.	Minor IL4 binding determinant.
chr16	27344932	27344935	P24394	0	+	27344932	27344935	102,0,51	1	3	0	.	Minor IL4 binding determinant.
chr16	27344938	27344941	P24394	0	+	27344938	27344941	102,0,51	1	3	0	.	Minor IL4 binding determinant.
chr16	27344947	27344950	P24394	0	+	27344947	27344950	102,0,51	1	3	0	.	Major IL4 binding determinant.
chr16	27346558	27346561	P24394	0	+	27346558	27346561	102,0,51	1	3	0	.	Minor IL4 binding determinant.
chr16	27352647	27352650	P24394	0	+	27352647	27352650	102,0,51	1	3	0	.	Major IL4 binding determinant.
chr16	30070206	30070209	P04075	0	+	30070206	30070209	102,0,51	1	3	0	.	Necessary for preference for fructose 1,6-bisphosphate over fructose 1-phosphate.
chr16	30381346	30381349	J3KNL2	0	-	30381346	30381349	102,0,51	1	3	0	.	Important for dimerization.
chr16	30445538	30445541	Q99611	0	-	30445538	30445541	102,0,51	1	3	0	.	Important for catalytic activity.
chr16	31184937	31184940	P35637	0	+	31184937	31184940	102,0,51	1	3	0	.	Breakpoint for translocation to form chimeric FUS/ATF1 protein.
chr16	31186832	31188326	P35637	0	+	31186832	31188326	102,0,51	1	1494	0	.	Breakpoint for translocation to form FUS/TLS-CHOP oncogene.
chr16	31483253	31483256	P31639	0	+	31483253	31483256	102,0,51	1	3	0	.	Implicated in sodium coupling.
chr16	31488049	31488052	P31639	0	+	31488049	31488052	102,0,51	1	3	0	.	Implicated in sodium coupling.
chr16	56434368	56434371	O43809	0	-	56434368	56434371	102,0,51	1	3	0	.	Interaction with RNA.
chr16	56447916	56447919	O43809	0	-	56447916	56447919	102,0,51	1	3	0	.	Interaction with RNA.
chr16	56447940	56447943	O43809	0	-	56447940	56447943	102,0,51	1	3	0	.	Interaction with RNA.
chr16	57382852	57382858	P78423	0	+	57382852	57382858	102,0,51	1	6	0	.	Cleavage; to produce soluble form.
chr16	57566727	57566733	Q8IZF4	0	+	57566727	57566733	102,0,51	1	6	0	.	Cleavage; by autolysis. Pubmed:25713288
chr16	57656593	57656599	Q9Y653	0	+	57656593	57656599	102,0,51	1	6	0	.	Cleavage; by autolysis. Pubmed:22333914
chr16	66817475	66817478	Q13564	0	-	66817475	66817478	102,0,51	1	3	0	.	Interaction with UBA3.
chr16	67082305	67082311	Q13951	0	+	67082305	67082311	102,0,51	1	6	0	.	Breakpoint for translocation to form CBF-beta-MYH11 oncogene in AML, subtype M4EO.
chr16	67482785	67482791	O00253	0	-	67482785	67482791	102,0,51	1	6	0	.	Cleavage; by PCSK1. Pubmed:16384863
chr16	67936421	67936427	P40306	0	-	67936421	67936427	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr16	67942674	67942677	P04180	0	-	67942674	67942677	102,0,51	1	3	0	.	Determinant for substrate specificity. Pubmed:14636062
chr16	68364769	68364772	Q9NY59	0	-	68364769	68364772	102,0,51	1	3	0	.	Important for substrate recognition.
chr16	68823559	68823565	P12830	0	+	68823559	68823565	102,0,51	1	6	0	.	Cleavage; by a metalloproteinase.
chr16	68828199	68828205	P12830	0	+	68828199	68828205	102,0,51	1	6	0	.	Cleavage; by gamma-secretase/PS1.
chr16	68828256	68828262	P12830	0	+	68828256	68828262	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr16	74695499	74695502	Q8NB16	0	-	74695499	74695502	102,0,51	1	3	0	.	Target of necrosulfonamide inhibitor.
chr16	75577360	75577366	P60520	0	+	75577360	75577366	102,0,51	1	6	0	.	Cleavage; by ATG4.
chr16	83907088	83907091	O95822	0	+	83907088	83907091	102,0,51	1	3	0	.	Essential for catalytic activity.
chr16	84095665	84095671	Q14703	0	-	84095665	84095671	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr16	87403076	87403082	Q9GZQ8	0	+	87403076	87403082	102,0,51	1	6	0	.	Cleavage; by ATG4B.
chr16	88892480	88892486	O75081	0	-	88892480	88892486	102,0,51	1	6	0	.	Breakpoint for translocation to form type-2 RUNX1-CBFA2T3 fusion protein.
chr16	88901651	88901657	O75081	0	-	88901651	88901657	102,0,51	1	6	0	.	Breakpoint for translocation to form type-1 RUNX1-CBFA2T3 fusion protein.
chr17	1264058	1264061	P62258	0	-	1264058	1264061	102,0,51	1	3	0	.	Interaction with phosphoserine on interacting protein.
chr17	1267730	1267733	P62258	0	-	1267730	1267733	102,0,51	1	3	0	.	Interaction with phosphoserine on interacting protein.
chr17	1361279	1361282	P62258	0	-	1361279	1361282	102,0,51	1	3	0	.	Interaction with phosphoserine on interacting protein.
chr17	1364951	1364954	P62258	0	-	1364951	1364954	102,0,51	1	3	0	.	Interaction with phosphoserine on interacting protein.
chr17	1436685	1436688	P46108	0	-	1436685	1436688	102,0,51	1	3	0	.	Proline switch.
chr17	1745344	1745350	P08697	0	+	1745344	1745350	102,0,51	1	6	0	.	Cleavage; by prolyl endopeptidase FAP, antiplasmin-cleaving enzyme FAP soluble form. Pubmed:14751930, Pubmed:16223769
chr17	1754264	1754270	P08697	0	+	1754264	1754270	102,0,51	1	6	0	.	Reactive bond for plasmin.
chr17	1754267	1754273	P08697	0	+	1754267	1754273	102,0,51	1	6	0	.	Reactive bond for chymotrypsin.
chr17	3577639	3577642	Q8NER1	0	-	3577639	3577642	102,0,51	1	3	0	.	Important for agonist binding.
chr17	5521664	5521670	Q9C000	0	-	5521664	5521670	102,0,51	1	6	0	.	Cleavage; by autolysis. Pubmed:22665479
chr17	5521748	5521751	Q9C000	0	-	5521748	5521751	102,0,51	1	3	0	.	Trigger for autolytic processing. Pubmed:22665479
chr17	6641211	6641214	Q9BRA2	0	+	6641211	6641214	102,0,51	1	3	0	.	Contributes to redox potential value. Pubmed:15355959
chr17	6641214	6641217	Q9BRA2	0	+	6641214	6641217	102,0,51	1	3	0	.	Contributes to redox potential value. Pubmed:15355959
chr17	7236563	7236569	Q9BUL5	0	-	7236563	7236569	102,0,51	1	6	0	.	Breakpoint for translocation to form NUP98-PHF23 oncogene.
chr17	7240856	7240862	O95166	0	-	7240856	7240862	102,0,51	1	6	0	.	Cleavage; by ATG4B.
chr17	7550188	7550194	O43508	0	+	7550188	7550194	102,0,51	1	6	0	.	Cleavage.
chr17	7559674	7559680	O75888	0	+	7559674	7559680	102,0,51	1	6	0	.	Cleavage; by furin.
chr17	7676008	7676011	P04637	0	-	7676008	7676011	102,0,51	1	3	0	.	Interaction with DNA.
chr17	12054905	12054911	P45985	0	+	12054905	12054911	102,0,51	1	6	0	.	Cleavage; by anthrax lethal factor.
chr17	12054944	12054950	P45985	0	+	12054944	12054950	102,0,51	1	6	0	.	Cleavage; by anthrax lethal factor.
chr17	16382108	16382111	P0CG47	0	+	16382108	16382111	102,0,51	1	3	0	.	Essential for function.
chr17	17817268	17817274	P36956	0	-	17817268	17817274	102,0,51	1	6	0	.	Cleavage; by S1P.
chr17	17817388	17817394	P36956	0	-	17817388	17817394	102,0,51	1	6	0	.	Cleavage; by S2P.
chr17	17817716	17817722	P36956	0	-	17817716	17817722	102,0,51	1	6	0	.	Cleavage; by caspase-3 and caspase-7.
chr17	21415858	21415861	Q14500	0	+	21415858	21415861	102,0,51	1	3	0	.	Role in the control of polyamine-mediated channel gating and in the blocking by intracellular magnesium.
chr17	28367841	28367847	P04004	0	-	28367841	28367847	102,0,51	1	6	0	.	Cleavage.
chr17	28573528	28573531	P09972	0	-	28573528	28573531	102,0,51	1	3	0	.	Necessary for preference for fructose 1,6-bisphosphate over fructose 1-phosphate.
chr17	31940287	31940293	Q15022	0	+	31940287	31940293	102,0,51	1	6	0	.	Breakpoint for translocation to form JAZF1-SUZ12 oncogene.
chr17	32487911	32487917	Q15078	0	+	32487911	32487917	102,0,51	1	6	0	.	Cleavage; by calpain.
chr17	32995632	32995638	Q8IXA5	0	+	32995632	32995638	102,0,51	1	6	0	.	Cleavage; to produce processed form.
chr17	34256235	34256238	P13500	0	+	34256235	34256238	102,0,51	1	3	0	.	Involved in dimerization.
chr17	34256250	34256253	P13500	0	+	34256250	34256253	102,0,51	1	3	0	.	Involved in dimerization, receptor binding and signaling.
chr17	34256265	34256268	P13500	0	+	34256265	34256268	102,0,51	1	3	0	.	Involved in GAG binding.
chr17	34256268	34256271	P13500	0	+	34256268	34256271	102,0,51	1	3	0	.	Involved in GAG binding.
chr17	34256283	34256286	P13500	0	+	34256283	34256286	102,0,51	1	3	0	.	Involved in GAG binding and receptor binding.
chr17	34256316	34256319	P13500	0	+	34256316	34256319	102,0,51	1	3	0	.	Involved in dimerization.
chr17	34256325	34256328	P13500	0	+	34256325	34256328	102,0,51	1	3	0	.	Involved in dimerization.
chr17	34256740	34256743	P13500	0	+	34256740	34256743	102,0,51	1	3	0	.	Involved in GAG binding and receptor binding.
chr17	34256767	34256770	P13500	0	+	34256767	34256770	102,0,51	1	3	0	.	Involved in GAG binding.
chr17	34256791	34256794	P13500	0	+	34256791	34256794	102,0,51	1	3	0	.	Involved in GAG binding.
chr17	35878637	35880233	P13501	0	-	35878637	35880233	102,0,51	1	1596	0	.	Cleavage; by DPP4.
chr17	36088740	36088743	P10147	0	-	36088740	36088743	102,0,51	1	3	0	.	Involved in GAG binding.
chr17	36088746	36088749	P10147	0	-	36088746	36088749	102,0,51	1	3	0	.	Involved in GAG binding.
chr17	36089082	36089085	P10147	0	-	36089082	36089085	102,0,51	1	3	0	.	Involved in GAG binding.
chr17	36089088	36089091	P10147	0	-	36089088	36089091	102,0,51	1	3	0	.	Involved in GAG binding.
chr17	36089250	36089253	P10147	0	-	36089250	36089253	102,0,51	1	3	0	.	Involved in GAG binding.
chr17	36089592	36089595	P10147	0	-	36089592	36089595	102,0,51	1	3	0	.	Involved in GAG binding.
chr17	36195910	36196601	P16619	0	-	36195910	36196601	102,0,51	1	691	0	.	Cleavage; by DPP4.
chr17	36195947	36196638	P16619	0	-	36195947	36196638	102,0,51	1	691	0	.	Cleavage; by DPP4.
chr17	36196282	36196973	P16619	0	-	36196282	36196973	102,0,51	1	691	0	.	Cleavage; by DPP4.
chr17	36297521	36298212	P16619	0	-	36297521	36298212	102,0,51	1	691	0	.	Cleavage; by DPP4.
chr17	39744120	39744123	Q14451	0	+	39744120	39744123	102,0,51	1	3	0	.	Important for lipid binding and for stimulation of cell migration.
chr17	39746828	39746831	Q14451	0	+	39746828	39746831	102,0,51	1	3	0	.	Important for dimerization and for HRAS activation.
chr17	40348314	40348320	P10276	0	+	40348314	40348320	102,0,51	1	6	0	.	Breakpoint for translocation to form PLZF-RAR-alpha, RAR-alpha1-PLZF and PML-RAR-alpha oncogenes.
chr17	40400534	40400537	P11388	0	-	40400534	40400537	102,0,51	1	3	0	.	Interaction with DNA. Pubmed:22841979
chr17	40400945	40400948	P11388	0	-	40400945	40400948	102,0,51	1	3	0	.	Important for DNA bending; intercalates between base pairs of target DNA.
chr17	40402925	40402928	P11388	0	-	40402925	40402928	102,0,51	1	3	0	.	Transition state stabilizer.
chr17	40403048	40403051	P11388	0	-	40403048	40403051	102,0,51	1	3	0	.	Interaction with DNA. Pubmed:22841979
chr17	40404163	40404166	P11388	0	-	40404163	40404166	102,0,51	1	3	0	.	Interaction with DNA. Pubmed:22841979
chr17	40404265	40404268	P11388	0	-	40404265	40404268	102,0,51	1	3	0	.	Interaction with DNA. Pubmed:22841979
chr17	40404850	40404853	P11388	0	-	40404850	40404853	102,0,51	1	3	0	.	Interaction with DNA. Pubmed:22841979
chr17	40404853	40404856	P11388	0	-	40404853	40404856	102,0,51	1	3	0	.	Interaction with DNA. Pubmed:22841979
chr17	40407990	40407993	P11388	0	-	40407990	40407993	102,0,51	1	3	0	.	Interaction with DNA. Pubmed:22841979
chr17	40407999	40408002	P11388	0	-	40407999	40408002	102,0,51	1	3	0	.	Interaction with DNA.
chr17	40480727	40480733	Q8IZW8	0	-	40480727	40480733	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr17	40880204	40880210	P35900	0	-	40880204	40880210	102,0,51	1	6	0	.	Cleavage; by caspases.
chr17	40960462	40960465	Q6A163	0	-	40960462	40960465	102,0,51	1	3	0	.	Stutter.
chr17	40960589	40960592	Q6A163	0	-	40960589	40960592	102,0,51	1	3	0	.	Stutter.
chr17	40978985	40978988	Q6A162	0	-	40978985	40978988	102,0,51	1	3	0	.	Stutter.
chr17	40979112	40979115	Q6A162	0	-	40979112	40979115	102,0,51	1	3	0	.	Stutter.
chr17	41346629	41346632	O76009	0	-	41346629	41346632	102,0,51	1	3	0	.	Stutter.
chr17	41364960	41364963	Q14525	0	-	41364960	41364963	102,0,51	1	3	0	.	Stutter.
chr17	41379137	41379140	O76011	0	-	41379137	41379140	102,0,51	1	3	0	.	Stutter.
chr17	41395029	41395032	Q15323	0	-	41395029	41395032	102,0,51	1	3	0	.	Stutter.
chr17	41402329	41402332	Q15323	0	-	41402329	41402332	102,0,51	1	3	0	.	Stutter.
chr17	41421548	41421551	O76014	0	-	41421548	41421551	102,0,51	1	3	0	.	Stutter.
chr17	41428873	41428876	O76014	0	-	41428873	41428876	102,0,51	1	3	0	.	Stutter.
chr17	41438274	41438277	O76015	0	-	41438274	41438277	102,0,51	1	3	0	.	Stutter.
chr17	41463011	41463014	Q14532	0	-	41463011	41463014	102,0,51	1	3	0	.	Stutter.
chr17	41477699	41477702	Q92764	0	-	41477699	41477702	102,0,51	1	3	0	.	Stutter.
chr17	41487131	41487134	O76013	0	-	41487131	41487134	102,0,51	1	3	0	.	Stutter.
chr17	41523964	41523967	P08727	0	-	41523964	41523967	102,0,51	1	3	0	.	Stutter.
chr17	41524399	41524402	P08727	0	-	41524399	41524402	102,0,51	1	3	0	.	Stutter.
chr17	41583416	41583419	P02533	0	-	41583416	41583419	102,0,51	1	3	0	.	Stutter.
chr17	41715553	41715559	P01350	0	+	41715553	41715559	102,0,51	1	6	0	.	Cleavage.
chr17	41715607	41715613	P01350	0	+	41715607	41715613	102,0,51	1	6	0	.	Cleavage.
chr17	41715788	41715794	P01350	0	+	41715788	41715794	102,0,51	1	6	0	.	Cleavage.
chr17	41715848	41715854	P01350	0	+	41715848	41715854	102,0,51	1	6	0	.	Cleavage.
chr17	43953390	43953396	P10082	0	-	43953390	43953396	102,0,51	1	6	0	.	Cleavage; by FAP. Pubmed:21314817
chr17	44254509	44254512	P02730	0	-	44254509	44254512	102,0,51	1	3	0	.	Important for anion-proton cotransport.
chr17	44255702	44255705	P02730	0	-	44255702	44255705	102,0,51	1	3	0	.	Important for anion transport.
chr17	45962406	45962409	P10636	0	+	45962406	45962409	102,0,51	1	3	0	.	Not glycated.
chr17	45962466	45962469	P10636	0	+	45962466	45962469	102,0,51	1	3	0	.	Not glycated.
chr17	45971923	45971926	P10636	0	+	45971923	45971926	102,0,51	1	3	0	.	Not glycated.
chr17	45987053	45987056	P10636	0	+	45987053	45987056	102,0,51	1	3	0	.	Not glycated.
chr17	45987083	45987086	P10636	0	+	45987083	45987086	102,0,51	1	3	0	.	Not glycated.
chr17	45987086	45987089	P10636	0	+	45987086	45987089	102,0,51	1	3	0	.	Not glycated.
chr17	45987092	45987095	P10636	0	+	45987092	45987095	102,0,51	1	3	0	.	Not glycated.
chr17	45991471	45991474	P10636	0	+	45991471	45991474	102,0,51	1	3	0	.	Not glycated.
chr17	45991567	45991570	P10636	0	+	45991567	45991570	102,0,51	1	3	0	.	Not glycated.
chr17	45996409	45996412	P10636	0	+	45996409	45996412	102,0,51	1	3	0	.	Not glycated.
chr17	45996511	45996514	P10636	0	+	45996511	45996514	102,0,51	1	3	0	.	Not glycated.
chr17	45996559	45996562	P10636	0	+	45996559	45996562	102,0,51	1	3	0	.	Not glycated.
chr17	45996601	45996604	P10636	0	+	45996601	45996604	102,0,51	1	3	0	.	Not glycated.
chr17	45996610	45996613	P10636	0	+	45996610	45996613	102,0,51	1	3	0	.	Not glycated.
chr17	45996640	45996643	P10636	0	+	45996640	45996643	102,0,51	1	3	0	.	Not glycated.
chr17	45996661	45996664	P10636	0	+	45996661	45996664	102,0,51	1	3	0	.	Not glycated.
chr17	46010354	46010357	P10636	0	+	46010354	46010357	102,0,51	1	3	0	.	Not glycated.
chr17	46010366	46010369	P10636	0	+	46010366	46010369	102,0,51	1	3	0	.	Not glycated.
chr17	46010378	46010381	P10636	0	+	46010378	46010381	102,0,51	1	3	0	.	Not glycated.
chr17	46014257	46014260	P10636	0	+	46014257	46014260	102,0,51	1	3	0	.	Not glycated.
chr17	46014275	46014278	P10636	0	+	46014275	46014278	102,0,51	1	3	0	.	Not glycated.
chr17	46014287	46014290	P10636	0	+	46014287	46014290	102,0,51	1	3	0	.	Not glycated.
chr17	46014317	46014320	P10636	0	+	46014317	46014320	102,0,51	1	3	0	.	Not glycated.
chr17	46018637	46018640	P10636	0	+	46018637	46018640	102,0,51	1	3	0	.	Not glycated.
chr17	46018646	46018649	P10636	0	+	46018646	46018649	102,0,51	1	3	0	.	Not glycated.
chr17	46018727	46018730	P10636	0	+	46018727	46018730	102,0,51	1	3	0	.	Not glycated.
chr17	46023967	46023970	P10636	0	+	46023967	46023970	102,0,51	1	3	0	.	Not glycated.
chr17	46023991	46023994	P10636	0	+	46023991	46023994	102,0,51	1	3	0	.	Not glycated.
chr17	46023997	46024000	P10636	0	+	46023997	46024000	102,0,51	1	3	0	.	Not glycated.
chr17	46024027	46024030	P10636	0	+	46024027	46024030	102,0,51	1	3	0	.	Not glycated.
chr17	46024156	46024159	P10636	0	+	46024156	46024159	102,0,51	1	3	0	.	Not glycated.
chr17	47592006	47592009	P55786	0	+	47592006	47592009	102,0,51	1	3	0	.	Transition state stabilizer.
chr17	48895712	48895715	P05496	0	+	48895712	48895715	102,0,51	1	3	0	.	Reversibly protonated during proton transport.
chr17	50573032	50573035	O43497	0	+	50573032	50573035	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chr17	50591951	50591954	O43497	0	+	50591951	50591954	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chr17	50605993	50605996	O43497	0	+	50605993	50605996	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chr17	50618223	50618226	O43497	0	+	50618223	50618226	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chr17	50839705	50839711	Q8TEU8	0	+	50839705	50839711	102,0,51	1	6	0	.	Reactive bond.
chr17	57616080	57627230	Q96DH6	0	+	57616080	57627230	102,0,51	1	11150	0	.	Breakpoint for translocation to form MSI2/HOXA9 fusion protein.
chr17	58087210	58087213	Q96FJ2	0	+	58087210	58087213	102,0,51	1	3	0	.	Interaction with myosin V motor complex.
chr17	58199047	58199050	P11678	0	+	58199047	58199050	102,0,51	1	3	0	.	Transition state stabilizer.
chr17	58254818	58254821	P22079	0	+	58254818	58254821	102,0,51	1	3	0	.	Transition state stabilizer.
chr17	58275691	58275694	P05164	0	-	58275691	58275694	102,0,51	1	3	0	.	Transition state stabilizer.
chr17	58521974	58521977	J3KSZ7	0	-	58521974	58521977	102,0,51	1	3	0	.	Important for dimerization.
chr17	58521974	58521977	J3QLR2	0	-	58521974	58521977	102,0,51	1	3	0	.	Important for dimerization.
chr17	58521974	58521977	J3QRT6	0	-	58521974	58521977	102,0,51	1	3	0	.	Important for dimerization.
chr17	61368325	61368331	Q9H6U6	0	+	61368325	61368331	102,0,51	1	6	0	.	Breakpoint for translocation to form BCAS4-BCAS3.
chr17	63496966	63496969	P12821	0	+	63496966	63496969	102,0,51	1	3	0	.	Not glycosylated.
chr17	69505802	69505808	P52564	0	+	69505802	69505808	102,0,51	1	6	0	.	Cleavage; by anthrax lethal factor.
chr17	70132567	70132570	K7EJR9	0	+	70132567	70132570	102,0,51	1	3	0	.	Role in the control of polyamine-mediated channel gating and in the blocking by intracellular magnesium.
chr17	70132567	70132570	Q9NPI9	0	+	70132567	70132570	102,0,51	1	3	0	.	Role in the control of polyamine-mediated channel gating and in the blocking by intracellular magnesium.
chr17	70175552	70175555	P63252	0	+	70175552	70175555	102,0,51	1	3	0	.	Role in the control of polyamine-mediated channel gating and in the blocking by intracellular magnesium.
chr17	73169583	73169586	P30874	0	+	73169583	73169586	102,0,51	1	3	0	.	Important for ligand binding.
chr17	74522869	74522872	A8K4G0	0	-	74522869	74522872	102,0,51	1	3	0	.	Interaction with TYROBP.
chr17	74695826	74695829	Q8TDQ1	0	-	74695826	74695829	102,0,51	1	3	0	.	Phosphatase-binding.
chr17	74847472	74847475	Q14957	0	-	74847472	74847475	102,0,51	1	3	0	.	Functional determinant of NMDA receptors.
chr17	75765025	75765028	P51570	0	-	75765025	75765028	102,0,51	1	3	0	.	Transition state stabilizer.
chr17	75779078	75779081	P84243	0	-	75779078	75779081	102,0,51	1	3	0	.	Interaction with ZMYND11. Pubmed:24590075
chr17	76469703	76469706	Q16613	0	+	76469703	76469706	102,0,51	1	3	0	.	Important for the catalytic mechanism; involved in substrate deprotonation.
chr17	76469709	76469712	Q16613	0	+	76469709	76469712	102,0,51	1	3	0	.	Important for the catalytic mechanism; involved in substrate deprotonation.
chr17	78995084	78995087	Q8WVQ1	0	-	78995084	78995087	102,0,51	1	3	0	.	Important for dimer formation. Pubmed:16835225
chr17	78997016	78997019	Q8WVQ1	0	-	78997016	78997019	102,0,51	1	3	0	.	Important for dimer formation. Pubmed:16835225
chr17	78997022	78997025	Q8WVQ1	0	-	78997022	78997025	102,0,51	1	3	0	.	Important for dimer formation. Pubmed:16835225
chr17	78997142	78997145	Q8WVQ1	0	-	78997142	78997145	102,0,51	1	3	0	.	Important for dimer formation. Pubmed:16835225
chr17	79101623	79101626	A6NFN3	0	-	79101623	79101626	102,0,51	1	3	0	.	Interaction with RNA.
chr17	79101623	79101626	J3QRF4	0	-	79101623	79101626	102,0,51	1	3	0	.	Interaction with RNA.
chr17	79103170	79103173	A6NFN3	0	-	79103170	79103173	102,0,51	1	3	0	.	Interaction with RNA.
chr17	79103170	79103173	J3QRF4	0	-	79103170	79103173	102,0,51	1	3	0	.	Interaction with RNA.
chr17	79103242	79103245	A6NFN3	0	-	79103242	79103245	102,0,51	1	3	0	.	Interaction with RNA.
chr17	79103242	79103245	J3QRF4	0	-	79103242	79103245	102,0,51	1	3	0	.	Interaction with RNA.
chr17	79104072	79104075	A6NFN3	0	-	79104072	79104075	102,0,51	1	3	0	.	Interaction with RNA.
chr17	79104072	79104075	J3QRF4	0	-	79104072	79104075	102,0,51	1	3	0	.	Interaction with RNA.
chr17	79104087	79104090	A6NFN3	0	-	79104087	79104090	102,0,51	1	3	0	.	Interaction with RNA.
chr17	79104087	79104090	J3QRF4	0	-	79104087	79104090	102,0,51	1	3	0	.	Interaction with RNA.
chr17	79106683	79106686	A6NFN3	0	-	79106683	79106686	102,0,51	1	3	0	.	Interaction with RNA.
chr17	79106683	79106686	J3QRF4	0	-	79106683	79106686	102,0,51	1	3	0	.	Interaction with RNA.
chr17	79106686	79106689	A6NFN3	0	-	79106686	79106689	102,0,51	1	3	0	.	Interaction with RNA.
chr17	79106686	79106689	J3QRF4	0	-	79106686	79106689	102,0,51	1	3	0	.	Interaction with RNA.
chr17	79106710	79106713	A6NFN3	0	-	79106710	79106713	102,0,51	1	3	0	.	Interaction with RNA.
chr17	79106710	79106713	J3QRF4	0	-	79106710	79106713	102,0,51	1	3	0	.	Interaction with RNA.
chr17	80421869	80421872	Q8N8Q3	0	+	80421869	80421872	102,0,51	1	3	0	.	Interaction with target RNA.
chr17	81845206	81845209	P07237	0	-	81845206	81845209	102,0,51	1	3	0	.	Lowers pKa of C-terminal Cys of second active site.
chr17	81845722	81845725	P07237	0	-	81845722	81845725	102,0,51	1	3	0	.	Contributes to redox potential value.
chr17	81845725	81845728	P07237	0	-	81845725	81845728	102,0,51	1	3	0	.	Contributes to redox potential value.
chr17	81855578	81855581	P07237	0	-	81855578	81855581	102,0,51	1	3	0	.	Lowers pKa of C-terminal Cys of first active site.
chr17	81859367	81859370	P07237	0	-	81859367	81859370	102,0,51	1	3	0	.	Contributes to redox potential value.
chr17	81859370	81859373	P07237	0	-	81859370	81859373	102,0,51	1	3	0	.	Contributes to redox potential value.
chr17	81996843	82009039	Q9BZE9	0	+	81996843	82009039	102,0,51	1	12196	0	.	Breakpoint for translocation to form ASPSCR1-TFE3.
chr18	12420397	12420400	Q96N28	0	+	12420397	12420400	102,0,51	1	3	0	.	Important for interaction with TRIAP1. Pubmed:26071602
chr18	12420436	12420439	Q96N28	0	+	12420436	12420439	102,0,51	1	3	0	.	Important for interaction with TRIAP1. Pubmed:26071602
chr18	13737077	13737080	O43148	0	+	13737077	13737080	102,0,51	1	3	0	.	mRNA cap binding.
chr18	13737095	13737098	O43148	0	+	13737095	13737098	102,0,51	1	3	0	.	mRNA cap binding.
chr18	13740201	13740204	O43148	0	+	13740201	13740204	102,0,51	1	3	0	.	mRNA cap binding.
chr18	20966926	20966932	Q13464	0	-	20966926	20966932	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr18	23568961	23568964	O15118	0	-	23568961	23568964	102,0,51	1	3	0	.	Important for cholesterol binding.
chr18	25322008	25322014	Q96K83	0	-	25322008	25322014	102,0,51	1	6	0	.	Breakpoint for translocation to form PAX5-ZNF521.
chr18	26018377	26032401	Q15532	0	-	26018377	26032401	102,0,51	1	14024	0	.	Breakpoint for translocation to form the SSXT-SSX1 or SSXT-SSX2 fusion proteins. Pubmed:7539744
chr18	26032527	26032533	Q15532	0	-	26032527	26032533	102,0,51	1	6	0	.	Breakpoint for translocation to form the SSXT-SSX1 fusion protein (rare). Pubmed:7539744
chr18	32207415	32207418	Q16820	0	+	32207415	32207418	102,0,51	1	3	0	.	Mediates preference for acidic residues at subsite P1'.
chr18	45749795	45749798	B3KXJ3	0	+	45749795	45749798	102,0,51	1	3	0	.	Important for channel permeability.
chr18	45749795	45749798	B4DFJ8	0	+	45749795	45749798	102,0,51	1	3	0	.	Important for channel permeability.
chr18	45749795	45749798	F5GWS2	0	+	45749795	45749798	102,0,51	1	3	0	.	Important for channel permeability.
chr18	45749795	45749798	G0W2N5	0	+	45749795	45749798	102,0,51	1	3	0	.	Important for channel permeability.
chr18	45749795	45749798	Q13336	0	+	45749795	45749798	102,0,51	1	3	0	.	Important for channel permeability.
chr18	46086431	46086434	P25705	0	-	46086431	46086434	102,0,51	1	3	0	.	Required for activity.
chr18	50920555	50920558	P23368	0	+	50920555	50920558	102,0,51	1	3	0	.	Important for activity.
chr18	51078350	51078353	Q13485	0	+	51078350	51078353	102,0,51	1	3	0	.	Necessary for heterotrimerization.
chr18	58696364	58696370	Q9UDY8	0	+	58696364	58696370	102,0,51	1	6	0	.	Breakpoint for translocation to form BIRC2-MALT1.
chr18	58700587	58709379	Q9UDY8	0	+	58700587	58709379	102,0,51	1	8792	0	.	Breakpoint for translocation to form BIRC2-MALT1.
chr18	58714081	58714087	Q9UDY8	0	+	58714081	58714087	102,0,51	1	6	0	.	Breakpoint for translocation to form BIRC2-MALT1.
chr18	58714090	58714096	Q9UDY8	0	+	58714090	58714096	102,0,51	1	6	0	.	Breakpoint for translocation to form BIRC2-MALT1.
chr18	58715933	58715939	Q9UDY8	0	+	58715933	58715939	102,0,51	1	6	0	.	Breakpoint for translocation to form BIRC2-MALT1.
chr18	59331122	59331125	P49257	0	-	59331122	59331125	102,0,51	1	3	0	.	Required for ER export.
chr18	63318561	63318567	P10415	0	-	63318561	63318567	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr18	63503611	63503617	P36952	0	+	63503611	63503617	102,0,51	1	6	0	.	Reactive bond homolog.
chr18	63566900	63566906	Q96P63	0	+	63566900	63566906	102,0,51	1	6	0	.	Reactive bond.
chr18	63597252	63597258	Q9UIV8	0	+	63597252	63597258	102,0,51	1	6	0	.	Reactive bond.
chr18	63637826	63637832	P48594	0	-	63637826	63637832	102,0,51	1	6	0	.	Reactive bond.
chr18	63655764	63655770	P29508	0	-	63655764	63655770	102,0,51	1	6	0	.	Reactive bond.
chr18	63804530	63804536	O75635	0	+	63804530	63804536	102,0,51	1	6	0	.	Reactive bond.
chr18	63903194	63903200	P05120	0	+	63903194	63903200	102,0,51	1	6	0	.	Reactive bond.
chr18	63935131	63935137	P48595	0	+	63935131	63935137	102,0,51	1	6	0	.	Reactive bond.
chr18	63987167	63987173	P50452	0	+	63987167	63987173	102,0,51	1	6	0	.	Reactive bond.
chr18	74512471	74512474	Q96KP4	0	+	74512471	74512474	102,0,51	1	3	0	.	Important for catalytic activity.
chr19	1615819	1619114	P15923	0	-	1615819	1619114	102,0,51	1	3295	0	.	Breakpoint for translocation to form TCF3-PBX1 oncogene.
chr19	2405408	2405414	Q7Z410	0	+	2405408	2405414	102,0,51	1	6	0	.	Cleavage.
chr19	2415704	2415710	Q7Z410	0	+	2415704	2415710	102,0,51	1	6	0	.	Cleavage.
chr19	2424117	2424123	Q7Z410	0	+	2424117	2424123	102,0,51	1	6	0	.	Cleavage.
chr19	3905609	3905615	Q86WG3	0	+	3905609	3905615	102,0,51	1	6	0	.	Cleavage; by CASP3.
chr19	3978067	3978073	P13639	0	-	3978067	3978073	102,0,51	1	6	0	.	Cleavage. Pubmed:24648518
chr19	3978124	3978130	P13639	0	-	3978124	3978130	102,0,51	1	6	0	.	Cleavage. Pubmed:24648518
chr19	4123842	4123848	P36507	0	-	4123842	4123848	102,0,51	1	6	0	.	Cleavage; by anthrax lethal factor.
chr19	4171669	4171675	Q68CJ9	0	+	4171669	4171675	102,0,51	1	6	0	.	Cleavage; by PS1.
chr19	4366991	4400326	Q99961	0	-	4366991	4400326	102,0,51	1	33335	0	.	Breakpoint for translocation to form KMT2A/MLL1-EEN oncogene.
chr19	4538065	4538068	P02750	0	-	4538065	4538068	102,0,51	1	3	0	.	Not glycosylated.
chr19	4947128	4947131	Q96T88	0	+	4947128	4947131	102,0,51	1	3	0	.	Required to confer preferential recognition of cytosine over thymine.
chr19	4947158	4947161	Q96T88	0	+	4947158	4947161	102,0,51	1	3	0	.	Required to discriminate between hemimethylated DNA versus symmetrically methylated DNA.
chr19	4947164	4947167	Q96T88	0	+	4947164	4947167	102,0,51	1	3	0	.	Required for affinity and specificity for 5-mCpG sequence.
chr19	5220109	5220115	Q13332	0	-	5220109	5220115	102,0,51	1	6	0	.	Cleavage.
chr19	6667419	6667425	O43557	0	-	6667419	6667425	102,0,51	1	6	0	.	Cleavage.
chr19	6684993	6684999	P01024	0	-	6684993	6684999	102,0,51	1	6	0	.	Cleavage; by factor I.
chr19	6685044	6685050	P01024	0	-	6685044	6685050	102,0,51	1	6	0	.	Cleavage; by factor I.
chr19	6696463	6696596	P01024	0	-	6696463	6696596	102,0,51	1	133	0	.	Cleavage; by factor I.
chr19	6702577	6707079	P01024	0	-	6702577	6707079	102,0,51	1	4502	0	.	Cleavage; by C3 convertase.
chr19	6707076	6707082	P01024	0	-	6707076	6707082	102,0,51	1	6	0	.	Cleavage; by carboxypeptidases.
chr19	6743580	6743583	Q15642	0	+	6743580	6743583	102,0,51	1	3	0	.	Mediates end-to-end attachment of dimers.
chr19	7267798	7267801	P06213	0	-	7267798	7267801	102,0,51	1	3	0	.	Insulin-binding.
chr19	7696843	7696849	P06734	0	-	7696843	7696849	102,0,51	1	6	0	.	Cleavage.
chr19	7849058	7849061	Q96CN4	0	+	7849058	7849061	102,0,51	1	3	0	.	Arginine finger.
chr19	7849291	7849294	Q96CN4	0	+	7849291	7849294	102,0,51	1	3	0	.	Glutamine finger.
chr19	7909759	7909765	O14733	0	+	7909759	7909765	102,0,51	1	6	0	.	Cleavage; by anthrax lethal factor.
chr19	7909855	7909861	O14733	0	+	7909855	7909861	102,0,51	1	6	0	.	Cleavage; by anthrax lethal factor.
chr19	10154973	10154976	P26358	0	-	10154973	10154976	102,0,51	1	3	0	.	Important for activity.
chr19	10420968	10420974	P27815	0	+	10420968	10420974	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr19	10463828	10463831	P27815	0	+	10463828	10463831	102,0,51	1	3	0	.	Binds AMP, but not cAMP.
chr19	10544276	10544282	Q86TL0	0	+	10544276	10544282	102,0,51	1	6	0	.	Cleavage; by CASP3.
chr19	11058868	11058874	P51532	0	+	11058868	11058874	102,0,51	1	6	0	.	Required for binding to 'Lys-15'-acetylated histone 3.
chr19	11378055	11378058	P19235	0	-	11378055	11378058	102,0,51	1	3	0	.	Required for CrkL binding.
chr19	11378142	11378145	P19235	0	-	11378142	11378145	102,0,51	1	3	0	.	Required for STAT1/STAT3 activation.
chr19	11378148	11378151	P19235	0	-	11378148	11378151	102,0,51	1	3	0	.	Interaction with PTPN6.
chr19	11378232	11378235	P19235	0	-	11378232	11378235	102,0,51	1	3	0	.	Required for STAT5/PTPN11/SOCS3 binding.
chr19	11378406	11378409	P19235	0	-	11378406	11378409	102,0,51	1	3	0	.	Interaction with APS and STAT5, and activation.
chr19	11382005	11382008	P19235	0	-	11382005	11382008	102,0,51	1	3	0	.	Required for ligand binding.
chr19	13766083	13766086	Q9BV20	0	+	13766083	13766086	102,0,51	1	3	0	.	Transition state stabilizer.
chr19	14157914	14157920	O94910	0	-	14157914	14157920	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr19	14404520	14404526	P48960	0	+	14404520	14404526	102,0,51	1	6	0	.	Cleavage.
chr19	14443468	14443474	Q16512	0	+	14443468	14443474	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr19	14458315	14458321	Q16512	0	+	14458315	14458321	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr19	14464093	14464099	Q16512	0	+	14464093	14464099	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr19	14644140	14644146	Q9BY15	0	-	14644140	14644146	102,0,51	1	6	0	.	Cleavage.
chr19	14754989	14754995	Q9UHX3	0	-	14754989	14754995	102,0,51	1	6	0	.	Cleavage; by autolysis. Pubmed:15150276
chr19	15174087	15174093	Q9UM47	0	-	15174087	15174093	102,0,51	1	6	0	.	Cleavage; by furin-like protease.
chr19	15244760	15254155	O60885	0	-	15244760	15254155	102,0,51	1	9395	0	.	Breakpoint for translocation to form BDR4-NUT fusion protein.
chr19	15471891	15471894	Q96PD5	0	-	15471891	15471894	102,0,51	1	3	0	.	Important for catalytic activity; essential for amidase activity and zinc hydrate coordination.
chr19	16889601	16889607	Q96RI0	0	+	16889601	16889607	102,0,51	1	6	0	.	Cleavage; by thrombin or trypsin.
chr19	18211902	18211905	Q08493	0	-	18211902	18211905	102,0,51	1	3	0	.	Binds AMP, but not cAMP.
chr19	18472879	18472882	P55199	0	-	18472879	18472882	102,0,51	1	3	0	.	KMT2A/MLL1 fusion point (in acute myeloid leukemia patient). Pubmed:7991593
chr19	18574880	18574883	P62987	0	+	18574880	18574883	102,0,51	1	3	0	.	Essential for function.
chr19	18683825	18742912	Q6UUV9	0	+	18683825	18742912	102,0,51	1	59087	0	.	Breakpoint for translocation to form the MECT1-MAML2 and MAML2-MECT1 fusion proteins. Pubmed:12539049, Pubmed:14720503
chr19	18777199	18777202	Q6UUV9	0	+	18777199	18777202	102,0,51	1	3	0	.	Required for ubiquitination and degradation.
chr19	35302470	35302473	P20916	0	+	35302470	35302473	102,0,51	1	3	0	.	Not glycosylated. Pubmed:7505568
chr19	35351983	35351986	O14842	0	+	35351983	35351986	102,0,51	1	3	0	.	Important for receptor activation. Pubmed:19068482
chr19	35352064	35352067	O14842	0	+	35352064	35352067	102,0,51	1	3	0	.	Important for receptor activation. Pubmed:19068482
chr19	35543348	35543351	O14556	0	+	35543348	35543351	102,0,51	1	3	0	.	Activates thiol group during catalysis.
chr19	35907512	35907515	O43914	0	-	35907512	35907515	102,0,51	1	3	0	.	Important for interaction with transmembrane receptors.
chr19	38283661	38283667	O43291	0	+	38283661	38283667	102,0,51	1	6	0	.	Reactive bond.
chr19	38290153	38290159	O43291	0	+	38290153	38290159	102,0,51	1	6	0	.	Reactive bond.
chr19	38816496	38816499	Q13011	0	-	38816496	38816499	102,0,51	1	3	0	.	Important for catalytic activity.
chr19	38816520	38816523	Q13011	0	-	38816520	38816523	102,0,51	1	3	0	.	Important for catalytic activity.
chr19	39731400	39731403	Q05315	0	-	39731400	39731403	102,0,51	1	3	0	.	Not glycosylated.
chr19	41880926	41880929	P11912	0	+	41880926	41880929	102,0,51	1	3	0	.	Required for binding to BLNK.
chr19	42433045	42433051	Q6UXB2	0	-	42433045	42433051	102,0,51	1	6	0	.	Cleavage.
chr19	43656614	43656620	Q03405	0	-	43656614	43656620	102,0,51	1	6	0	.	Cleavage; by U-PA.
chr19	43656632	43656638	Q03405	0	-	43656632	43656638	102,0,51	1	6	0	.	Cleavage; by U-PA.
chr19	46621513	46621516	P43119	0	-	46621513	46621516	102,0,51	1	3	0	.	Not S-palmitoylated.
chr19	48121169	48121172	P18858	0	-	48121169	48121172	102,0,51	1	3	0	.	Interaction with target DNA.
chr19	48121244	48121247	P18858	0	-	48121244	48121247	102,0,51	1	3	0	.	Interaction with target DNA.
chr19	48131126	48131129	P18858	0	-	48131126	48131129	102,0,51	1	3	0	.	Interaction with target DNA.
chr19	48143541	48143544	P18858	0	-	48143541	48143544	102,0,51	1	3	0	.	Interaction with target DNA.
chr19	48419646	48419649	O15399	0	+	48419646	48419649	102,0,51	1	3	0	.	Functional determinant of NMDA receptors.
chr19	48936039	48936042	Q9UQ10	0	+	48936039	48936042	102,0,51	1	3	0	.	May play an important role in coenzyme binding.
chr19	48936063	48936066	Q9UQ10	0	+	48936063	48936066	102,0,51	1	3	0	.	May play an important role in coenzyme binding.
chr19	48936117	48936120	Q9UQ10	0	+	48936117	48936120	102,0,51	1	3	0	.	May play an important role in coenzyme binding.
chr19	48939607	48939610	Q9UQ10	0	+	48939607	48939610	102,0,51	1	3	0	.	May play an important role for the adaptation of the alcohol substrate into the binding site.
chr19	48939619	48939622	Q9UQ10	0	+	48939619	48939622	102,0,51	1	3	0	.	May play an important role in catalytic activity.
chr19	49448060	49448063	Q9NWS0	0	-	49448060	49448063	102,0,51	1	3	0	.	Interacts with TELO2.
chr19	49449619	49449622	Q9NWS0	0	-	49449619	49449622	102,0,51	1	3	0	.	Interacts with TELO2. Pubmed:24656813
chr19	49449640	49449643	Q9NWS0	0	-	49449640	49449643	102,0,51	1	3	0	.	Interacts with TELO2. Pubmed:24656813
chr19	50963503	50963509	Q92876	0	-	50963503	50963509	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr19	50980381	50980384	P49862	0	-	50980381	50980384	102,0,51	1	3	0	.	Major binding site for inhibitory zinc or copper.
chr19	54124539	54124542	Q8WWY3	0	+	54124539	54124542	102,0,51	1	3	0	.	Interaction with U4 snRNA.
chr19	54124608	54124611	Q8WWY3	0	+	54124608	54124611	102,0,51	1	3	0	.	Interaction with U4 snRNA.
chr19	54124664	54124667	Q8WWY3	0	+	54124664	54124667	102,0,51	1	3	0	.	Interaction with U4 snRNA.
chr19	54124733	54124736	Q8WWY3	0	+	54124733	54124736	102,0,51	1	3	0	.	Interaction with U4 snRNA.
chr19	55154821	55154824	P19429	0	-	55154821	55154824	102,0,51	1	3	0	.	Involved in TNI-TNT interactions.
chr19	55156242	55156245	P19429	0	-	55156242	55156245	102,0,51	1	3	0	.	Involved in TNI-TNT interactions.
chr19	55366102	55366105	P20809	0	-	55366102	55366105	102,0,51	1	3	0	.	Important for interaction with IL6ST and for the stimulation of cell proliferation.
chr2	1477451	1477454	P07202	0	+	1477451	1477454	102,0,51	1	3	0	.	Transition state stabilizer.
chr2	1648848	1648851	Q92626	0	-	1648848	1648851	102,0,51	1	3	0	.	Transition state stabilizer.
chr2	9591428	9591431	P27348	0	-	9591428	9591431	102,0,51	1	3	0	.	Interaction with phosphoserine on interacting protein.
chr2	9630284	9630287	P27348	0	-	9630284	9630287	102,0,51	1	3	0	.	Interaction with phosphoserine on interacting protein.
chr2	10443564	10443567	P11926	0	-	10443564	10443567	102,0,51	1	3	0	.	Stacks against the aromatic ring of pyridoxal phosphate and stabilizes reaction intermediates.
chr2	10789820	10789823	Q15084	0	-	10789820	10789823	102,0,51	1	3	0	.	Lowers pKa of C-terminal Cys of second active site.
chr2	10791802	10791805	Q15084	0	-	10791802	10791805	102,0,51	1	3	0	.	Contributes to redox potential value.
chr2	10791805	10791808	Q15084	0	-	10791805	10791808	102,0,51	1	3	0	.	Contributes to redox potential value.
chr2	10793194	10793197	Q15084	0	-	10793194	10793197	102,0,51	1	3	0	.	Lowers pKa of C-terminal Cys of first active site.
chr2	10797747	10797750	Q15084	0	-	10797747	10797750	102,0,51	1	3	0	.	Contributes to redox potential value.
chr2	10797750	10797753	Q15084	0	-	10797750	10797753	102,0,51	1	3	0	.	Contributes to redox potential value.
chr2	11197231	11197237	O75116	0	-	11197231	11197237	102,0,51	1	6	0	.	Cleavage; by granzyme B.
chr2	20203120	20203126	P18827	0	-	20203120	20203126	102,0,51	1	6	0	.	Cleavage.
chr2	24726587	24726593	Q15788	0	+	24726587	24726593	102,0,51	1	6	0	.	Breakpoint for translocation to form PAX3-NCOA1 oncogene.
chr2	25845557	25845563	Q76L83	0	-	25845557	25845563	102,0,51	1	6	0	.	Breakpoint for translocation to form KAT6A-ASXL2 protein.
chr2	26232213	26232216	P40939	0	-	26232213	26232216	102,0,51	1	3	0	.	Important for catalytic activity.
chr2	26234216	26234219	P40939	0	-	26234216	26234219	102,0,51	1	3	0	.	Important for catalytic activity.
chr2	27631849	27631852	Q9HCN4	0	+	27631849	27631852	102,0,51	1	3	0	.	Stabilizes the phosphate intermediate; shared with dimeric partner.
chr2	38071168	38071171	Q16678	0	-	38071168	38071171	102,0,51	1	3	0	.	Major determinant of CYP1B1 17beta-estradiol hydroxylation regiospecificity.
chr2	55234842	55234845	P62979	0	+	55234842	55234845	102,0,51	1	3	0	.	Essential for function.
chr2	60770472	60770475	Q9BWT3	0	+	60770472	60770475	102,0,51	1	3	0	.	Interaction with RNA.
chr2	60770487	60770490	Q9BWT3	0	+	60770487	60770490	102,0,51	1	3	0	.	Interaction with RNA.
chr2	60781956	60781959	Q9BWT3	0	+	60781956	60781959	102,0,51	1	3	0	.	Interaction with RNA.
chr2	60786971	60786974	Q9BWT3	0	+	60786971	60786974	102,0,51	1	3	0	.	Interaction with RNA.
chr2	60792203	60792206	Q9BWT3	0	+	60792203	60792206	102,0,51	1	3	0	.	Interaction with RNA.
chr2	73228877	73228880	Q9BSG0	0	-	73228877	73228880	102,0,51	1	3	0	.	Not glycosylated.
chr2	73849457	73849460	O95630	0	+	73849457	73849460	102,0,51	1	3	0	.	Indirect zinc-binding.
chr2	85579101	85579104	Q9BV40	0	+	85579101	85579104	102,0,51	1	3	0	.	Interaction with STX8.
chr2	86529359	86529362	Q9Y3E7	0	-	86529359	86529362	102,0,51	1	3	0	.	Important for autoinhibitory function.
chr2	99408127	99408130	Q9UBZ9	0	-	99408127	99408130	102,0,51	1	3	0	.	Interaction with target DNA.
chr2	99410729	99410732	Q9UBZ9	0	-	99410729	99410732	102,0,51	1	3	0	.	Interaction with target DNA.
chr2	101033543	101033546	O95759	0	-	101033543	101033546	102,0,51	1	3	0	.	Glutamine finger.
chr2	101033660	101033663	O95759	0	-	101033660	101033663	102,0,51	1	3	0	.	Arginine finger.
chr2	112832767	112832770	P01584	0	-	112832767	112832770	102,0,51	1	3	0	.	Involved in receptor binding.
chr2	119248158	119248164	Q658P3	0	+	119248158	119248164	102,0,51	1	6	0	.	Cleavage; by RHBDL4/RHBDD1.
chr2	126656284	126656287	P04921	0	+	126656284	126656287	102,0,51	1	3	0	.	Not glycosylated; in variant Webb antigen.
chr2	127426179	127426185	P04070	0	+	127426179	127426185	102,0,51	1	6	0	.	Cleavage; by thrombin.
chr2	130191833	130191836	Q6PEY2	0	-	130191833	130191836	102,0,51	1	3	0	.	Involved in polymerization.
chr2	131482842	131482845	Q13748	0	+	131482842	131482845	102,0,51	1	3	0	.	Involved in polymerization.
chr2	154699291	154699294	P48549	0	+	154699291	154699294	102,0,51	1	3	0	.	Role in the control of polyamine-mediated channel gating and in the blocking by intracellular magnesium.
chr2	162144124	162144130	P01275	0	-	162144124	162144130	102,0,51	1	6	0	.	Cleavage; by PCSK1.
chr2	162145538	162145544	P01275	0	-	162145538	162145544	102,0,51	1	6	0	.	Cleavage; by PCSK1.
chr2	162145637	162145643	P01275	0	-	162145637	162145643	102,0,51	1	6	0	.	Cleavage; by PCSK1.
chr2	162145655	162145661	P01275	0	-	162145655	162145661	102,0,51	1	6	0	.	Cleavage; by PCSK1.
chr2	162147354	162147360	P01275	0	-	162147354	162147360	102,0,51	1	6	0	.	Cleavage; by PCSK1 and PCSK2.
chr2	162147447	162147453	P01275	0	-	162147447	162147453	102,0,51	1	6	0	.	Cleavage; by PCSK2.
chr2	162242926	162242932	Q12884	0	-	162242926	162242932	102,0,51	1	6	0	.	Cleavage. Pubmed:14751930
chr2	162306721	162306727	Q9BYX4	0	-	162306721	162306727	102,0,51	1	6	0	.	Cleavage.
chr2	162306826	162306832	Q9BYX4	0	-	162306826	162306832	102,0,51	1	6	0	.	Cleavage.
chr2	162306850	162306856	Q9BYX4	0	-	162306850	162306856	102,0,51	1	6	0	.	Cleavage.
chr2	165381110	165381113	Q99250	0	+	165381110	165381113	102,0,51	1	3	0	.	Important for channel closure.
chr2	172485192	172485198	P23229	0	+	172485192	172485198	102,0,51	1	6	0	.	Cleavage; by PLAU in invasive prostate cancer. Pubmed:17303120
chr2	175178341	175178344	P48201	0	-	175178341	175178344	102,0,51	1	3	0	.	Reversibly protonated during proton transport.
chr2	177493168	177493171	O00116	0	+	177493168	177493171	102,0,51	1	3	0	.	Important for enzyme activity.
chr2	181509732	181509738	P13612	0	+	181509732	181509738	102,0,51	1	6	0	.	Cleavage.
chr2	187467792	187467795	P10646	0	-	187467792	187467795	102,0,51	1	3	0	.	Not glycosylated.
chr2	187467876	187467882	P10646	0	-	187467876	187467882	102,0,51	1	6	0	.	Reactive bond.
chr2	187484937	187484943	P10646	0	-	187484937	187484943	102,0,51	1	6	0	.	Reactive bond.
chr2	187497004	187497010	P10646	0	-	187497004	187497010	102,0,51	1	6	0	.	Reactive bond.
chr2	202036351	202036354	O75084	0	+	202036351	202036354	102,0,51	1	3	0	.	Essential for SDCBP-mediated plasma membrane phosphatidylinositol-4,5-bisphosphate recognition. Pubmed:27386966
chr2	202214413	202214416	P63165	0	-	202214413	202214416	102,0,51	1	3	0	.	Interaction with PIAS2.
chr2	207596971	207596974	P16220	0	+	207596971	207596974	102,0,51	1	3	0	.	Required for binding TORCs.
chr2	208243488	208243491	O75874	0	-	208243488	208243491	102,0,51	1	3	0	.	Critical for catalysis.
chr2	208243488	208243491	V9HWJ2	0	-	208243488	208243491	102,0,51	1	3	0	.	Critical for catalysis.
chr2	208245421	208245424	O75874	0	-	208245421	208245424	102,0,51	1	3	0	.	Critical for catalysis.
chr2	208245421	208245424	V9HWJ2	0	-	208245421	208245424	102,0,51	1	3	0	.	Critical for catalysis.
chr2	215332488	215332491	P31939	0	+	215332488	215332491	102,0,51	1	3	0	.	Transition state stabilizer.
chr2	215372025	215372028	P02751	0	-	215372025	215372028	102,0,51	1	3	0	.	Not glycosylated.
chr2	215410057	215410060	P02751	0	-	215410057	215410060	102,0,51	1	3	0	.	Important for superfibronectin formation.
chr2	215410066	215410069	P02751	0	-	215410066	215410069	102,0,51	1	3	0	.	Important for superfibronectin formation.
chr2	218403109	218403112	Q9GZU7	0	+	218403109	218403112	102,0,51	1	3	0	.	Transition state stabilizer. Pubmed:15304220
chr2	218403327	218403330	Q9GZU7	0	+	218403327	218403330	102,0,51	1	3	0	.	Transition state stabilizer. Pubmed:15304220
chr2	218984300	218984306	Q99581	0	-	218984300	218984306	102,0,51	1	6	0	.	Breakpoint for insertion to form EWS-FEV fusion protein.
chr2	219055617	219055620	Q14623	0	-	219055617	219055620	102,0,51	1	3	0	.	Essential for auto-cleavage.
chr2	219055626	219055629	Q14623	0	-	219055626	219055629	102,0,51	1	3	0	.	Involved in auto-cleavage.
chr2	219055698	219055701	Q14623	0	-	219055698	219055701	102,0,51	1	3	0	.	Involved in cholesterol transfer.
chr2	219055833	219055839	Q14623	0	-	219055833	219055839	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr2	219300073	219300079	Q16849	0	-	219300073	219300079	102,0,51	1	6	0	.	Cleavage.
chr2	219572554	219572560	P05111	0	+	219572554	219572560	102,0,51	1	6	0	.	Cleavage.
chr2	219575118	219575124	P05111	0	+	219575118	219575124	102,0,51	1	6	0	.	Cleavage.
chr2	222220352	222221225	P23760	0	-	222220352	222221225	102,0,51	1	873	0	.	Breakpoint for translocation to form PAX3-NCOA1 oncogene.
chr2	223977604	223977610	P07093	0	-	223977604	223977610	102,0,51	1	6	0	.	Reactive bond.
chr2	227032232	227032238	P53420	0	-	227032232	227032238	102,0,51	1	6	0	.	Cleavage; by collagenase.
chr2	227307732	227307738	Q01955	0	+	227307732	227307738	102,0,51	1	6	0	.	Cleavage; by collagenase.
chr2	227379226	227379232	Q53R12	0	-	227379226	227379232	102,0,51	1	6	0	.	Cleavage. Pubmed:27499293
chr2	230878018	230878024	Q9NQX7	0	+	230878018	230878024	102,0,51	1	6	0	.	Cleavage; by furin.
chr2	232210371	232210374	Q8IYB7	0	+	232210371	232210374	102,0,51	1	3	0	.	Important for catalytic activity.
chr2	232770915	232770918	O60928	0	-	232770915	232770918	102,0,51	1	3	0	.	Role in the control of polyamine-mediated channel gating and in the blocking by intracellular magnesium.
chr2	237325683	237325689	P12111	0	-	237325683	237325689	102,0,51	1	6	0	.	Reactive bond.
chr2	240577730	240577733	Q9HAU8	0	+	240577730	240577733	102,0,51	1	3	0	.	Transition state stabilizer.
chr2	241337505	241337508	B5MCX3	0	+	241337505	241337508	102,0,51	1	3	0	.	Important for dimerization.
chr2	241337505	241337508	C9J2Q4	0	+	241337505	241337508	102,0,51	1	3	0	.	Important for dimerization.
chr2	241337505	241337508	Q15019	0	+	241337505	241337508	102,0,51	1	3	0	.	Important for dimerization.
chr20	441948	441951	Q96BZ9	0	-	441948	441951	102,0,51	1	3	0	.	Glutamine finger.
chr20	445071	445074	Q96BZ9	0	-	445071	445074	102,0,51	1	3	0	.	Arginine finger.
chr20	2332066	2332072	Q08188	0	+	2332066	2332072	102,0,51	1	6	0	.	Cleavage; by CTSL.
chr20	2660467	2660470	O43837	0	-	2660467	2660470	102,0,51	1	3	0	.	Critical for catalysis.
chr20	2660714	2660717	O43837	0	-	2660714	2660717	102,0,51	1	3	0	.	Critical for catalysis.
chr20	2709574	2709577	Q9BQW3	0	+	2709574	2709577	102,0,51	1	3	0	.	Interaction with DNA.
chr20	2709601	2709604	Q9BQW3	0	+	2709601	2709604	102,0,51	1	3	0	.	Interaction with DNA.
chr20	3865802	3865808	Q7Z434	0	+	3865802	3865808	102,0,51	1	6	0	.	Cleavage; by HHAV protein 3ABC.
chr20	3866045	3866051	Q7Z434	0	+	3866045	3866051	102,0,51	1	6	0	.	Cleavage; by HCV and hepatitis GB virus B NS3/4A protease complex.
chr20	10299397	10299403	P60880	0	+	10299397	10299403	102,0,51	1	6	0	.	Cleavage; by BONT/E.
chr20	23637751	23637754	P01034	0	-	23637751	23637754	102,0,51	1	3	0	.	Reactive site.
chr20	23688873	23688876	P01036	0	-	23688873	23688876	102,0,51	1	3	0	.	Reactive site.
chr20	23750770	23750773	P01037	0	-	23750770	23750773	102,0,51	1	3	0	.	Reactive site.
chr20	23826564	23826567	P09228	0	-	23826564	23826567	102,0,51	1	3	0	.	Reactive site.
chr20	23879580	23879583	P28325	0	-	23879580	23879583	102,0,51	1	3	0	.	Reactive site.
chr20	24957324	24957327	O76096	0	+	24957324	24957327	102,0,51	1	3	0	.	Reactive site.
chr20	25248403	25248406	P11216	0	+	25248403	25248406	102,0,51	1	3	0	.	Participates in a stacking interaction with the adenine ring of AMP. Pubmed:27402852
chr20	25259317	25259320	P11216	0	+	25259317	25259320	102,0,51	1	3	0	.	Involved in the association of subunits.
chr20	25271384	25271387	P11216	0	+	25271384	25271387	102,0,51	1	3	0	.	Involved in the association of subunits.
chr20	25271423	25271426	P11216	0	+	25271423	25271426	102,0,51	1	3	0	.	May be involved in allosteric control.
chr20	31722032	31722038	Q07817	0	-	31722032	31722038	102,0,51	1	6	0	.	Cleavage; by caspase-1.
chr20	33574257	33606957	O43439	0	+	33574257	33606957	102,0,51	1	32700	0	.	Breakpoint for translocation to form RUNX1-CBFA2T2 in acute myeloid leukemia. Pubmed:20520637
chr20	34559889	34559895	Q9H492	0	+	34559889	34559895	102,0,51	1	6	0	.	Cleavage; by ATG4B.
chr20	35274411	35274417	Q9Y5R2	0	+	35274411	35274417	102,0,51	1	6	0	.	Cleavage; by furin.
chr20	41098307	41098310	P11387	0	+	41098307	41098310	102,0,51	1	3	0	.	Interaction with DNA.
chr20	41100169	41100172	P11387	0	+	41100169	41100172	102,0,51	1	3	0	.	Interaction with DNA.
chr20	41101278	41101281	P11387	0	+	41101278	41101281	102,0,51	1	3	0	.	Interaction with DNA.
chr20	41112799	41112802	P11387	0	+	41112799	41112802	102,0,51	1	3	0	.	Interaction with DNA.
chr20	41114017	41114020	P11387	0	+	41114017	41114020	102,0,51	1	3	0	.	Interaction with DNA.
chr20	41114110	41114113	P11387	0	+	41114110	41114113	102,0,51	1	3	0	.	Interaction with DNA.
chr20	41116289	41116292	P11387	0	+	41116289	41116292	102,0,51	1	3	0	.	Interaction with DNA.
chr20	41118239	41118242	P11387	0	+	41118239	41118242	102,0,51	1	3	0	.	Interaction with DNA.
chr20	41118293	41118296	P11387	0	+	41118293	41118296	102,0,51	1	3	0	.	Interaction with DNA.
chr20	44614601	44614604	Q549H9	0	+	44614601	44614604	102,0,51	1	3	0	.	Important for inhibition.
chr20	44614610	44614613	Q549H9	0	+	44614610	44614613	102,0,51	1	3	0	.	Important for inhibition.
chr20	44614613	44614616	Q549H9	0	+	44614613	44614616	102,0,51	1	3	0	.	Important for inhibition.
chr20	44622894	44622897	P00813	0	-	44622894	44622897	102,0,51	1	3	0	.	Important for catalytic activity.
chr20	44629078	44629081	P00813	0	-	44629078	44629081	102,0,51	1	3	0	.	Important for interaction with adenosine receptors and increasing their affinity for agonists. Pubmed:23193172
chr20	44629090	44629093	P00813	0	-	44629090	44629093	102,0,51	1	3	0	.	Important for interaction with adenosine receptors and increasing their affinity for agonists. Pubmed:23193172
chr20	44901704	44901707	P31946	0	+	44901704	44901707	102,0,51	1	3	0	.	Interaction with phosphoserine on interacting protein.
chr20	44904076	44904079	P31946	0	+	44904076	44904079	102,0,51	1	3	0	.	Interaction with phosphoserine on interacting protein.
chr20	45001181	45001187	Q13043	0	+	45001181	45001187	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr20	45001250	45001256	Q13043	0	+	45001250	45001256	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr20	45253101	45253107	P03973	0	-	45253101	45253107	102,0,51	1	6	0	.	Reactive bond for chymotrypsin, trypsin and elastase. Pubmed:24121345, Pubmed:3366116, Pubmed:18421166
chr20	46009901	46009907	P14780	0	+	46009901	46009907	102,0,51	1	6	0	.	Cleavage; by MMP3.
chr20	46010042	46010048	P14780	0	+	46010042	46010048	102,0,51	1	6	0	.	Cleavage; by MMP3.
chr20	50795170	50818213	Q8TDM0	0	+	50795170	50818213	102,0,51	1	23043	0	.	Breakpoint for translocation to form BCAS4-BCAS3.
chr20	59301705	59301711	P14138	0	+	59301705	59301711	102,0,51	1	6	0	.	Cleavage; by KEL.
chr20	63236249	63236255	Q96CA5	0	+	63236249	63236255	102,0,51	1	6	0	.	Cleavage; by CASP3 and CASP7.
chr20	64097895	64097898	P41146	0	+	64097895	64097898	102,0,51	1	3	0	.	Important for G protein-mediated signaling.
chr20	64097955	64097958	P41146	0	+	64097955	64097958	102,0,51	1	3	0	.	Important for G protein-mediated signaling.
chr21	6560782	6560785	P02489	0	+	6560782	6560785	102,0,51	1	3	0	.	Susceptible to oxidation.
chr21	6560833	6560836	P02489	0	+	6560833	6560836	102,0,51	1	3	0	.	Susceptible to oxidation.
chr21	6560881	6560884	P02489	0	+	6560881	6560884	102,0,51	1	3	0	.	Susceptible to oxidation.
chr21	6563853	6563856	P02489	0	+	6563853	6563856	102,0,51	1	3	0	.	Susceptible to oxidation.
chr21	25881762	25881768	P05067	0	-	25881762	25881768	102,0,51	1	6	0	.	Cleavage; by caspase-6, caspase-8 or caspase-9.
chr21	25891769	25891775	P05067	0	-	25891769	25891775	102,0,51	1	6	0	.	Cleavage; by gamma-secretase; site 3.
chr21	25891790	25891796	P05067	0	-	25891790	25891796	102,0,51	1	6	0	.	Cleavage; by gamma-secretase; site 2.
chr21	25891796	25891802	P05067	0	-	25891796	25891802	102,0,51	1	6	0	.	Cleavage; by gamma-secretase; site 1.
chr21	25891814	25891817	P05067	0	-	25891814	25891817	102,0,51	1	3	0	.	Susceptible to oxidation. Pubmed:10535332
chr21	25891820	25891823	P05067	0	-	25891820	25891823	102,0,51	1	3	0	.	Implicated in free radical propagation.
chr21	25891859	25891865	P05067	0	-	25891859	25891865	102,0,51	1	6	0	.	Cleavage; by theta-secretase. Pubmed:16816112
chr21	25897572	25897578	P05067	0	-	25897572	25897578	102,0,51	1	6	0	.	Cleavage; by alpha-secretase.
chr21	25897617	25897623	P05067	0	-	25897617	25897623	102,0,51	1	6	0	.	Cleavage; by caspase-6; when associated with variant 670-N-L-671.
chr21	25897620	25897626	P05067	0	-	25897620	25897626	102,0,51	1	6	0	.	Cleavage; by beta-secretase.
chr21	26000141	26000147	P05067	0	-	26000141	26000147	102,0,51	1	6	0	.	Reactive bond.
chr21	26053271	26053274	P05067	0	-	26053271	26053274	102,0,51	1	3	0	.	Required for Cu(2+) reduction.
chr21	33504303	33504306	P22102	0	-	33504303	33504306	102,0,51	1	3	0	.	Raises pKa of active site His.
chr21	34799460	34834413	Q01196	0	-	34799460	34834413	102,0,51	1	34953	0	.	Breakpoint for translocation to form AML1-EAP in T-MDS and CML, to form type II MACROD1-RUNX1 fusion protein and to form RUNX1-CBFA2T2 in acute myeloid leukemia. Pubmed:20520637
chr21	34834599	34859477	Q01196	0	-	34834599	34859477	102,0,51	1	24878	0	.	Breakpoint for translocation to form AML1-EMV-1 (or AML1-EAP) in CML and T-MDS, to form AML1-MTG8 (ETO) in AML-M2, to form AML1-CBFA2T3 in therapy-related myeloid malignancies.
chr21	37714610	37714613	P48051	0	-	37714610	37714613	102,0,51	1	3	0	.	Role in the control of polyamine-mediated channel gating and in the blocking by intracellular magnesium.
chr21	38299729	38299732	Q99712	0	+	38299729	38299732	102,0,51	1	3	0	.	Role in the control of polyamine-mediated channel gating and in the blocking by intracellular magnesium.
chr21	38383453	38383459	P11308	0	-	38383453	38383459	102,0,51	1	6	0	.	Breakpoint for translocation to form ELF4-ERG oncogene.
chr21	41473455	41473461	O15393	0	-	41473455	41473461	102,0,51	1	6	0	.	Cleavage.
chr21	41743939	41743945	P57078	0	-	41743939	41743945	102,0,51	1	6	0	.	Cleavage.
chr21	41744053	41744059	P57078	0	-	41744053	41744059	102,0,51	1	6	0	.	Cleavage.
chr21	42383163	42383169	P57727	0	-	42383163	42383169	102,0,51	1	6	0	.	Cleavage.
chr21	43169099	43169102	P02489	0	+	43169099	43169102	102,0,51	1	3	0	.	Susceptible to oxidation.
chr21	43169150	43169153	P02489	0	+	43169150	43169153	102,0,51	1	3	0	.	Susceptible to oxidation.
chr21	43169198	43169201	P02489	0	+	43169198	43169201	102,0,51	1	3	0	.	Susceptible to oxidation.
chr21	43172169	43172172	P02489	0	+	43172169	43172172	102,0,51	1	3	0	.	Susceptible to oxidation.
chr21	43776257	43776260	P04080	0	-	43776257	43776260	102,0,51	1	3	0	.	Reactive site.
chr21	45265583	45265586	Q9Y2G5	0	-	45265583	45265586	102,0,51	1	3	0	.	Essential for catalytic activity.
chr22	17739411	17739417	P55957	0	-	17739411	17739417	102,0,51	1	6	0	.	Cleavage.
chr22	17739480	17739486	P55957	0	-	17739480	17739486	102,0,51	1	6	0	.	Cleavage.
chr22	17743839	17743845	P55957	0	-	17743839	17743845	102,0,51	1	6	0	.	Cleavage.
chr22	19720443	19720446	B4DJ62	0	+	19720443	19720446	102,0,51	1	3	0	.	Important for dimerization.
chr22	19720443	19720446	C9JM82	0	+	19720443	19720446	102,0,51	1	3	0	.	Important for dimerization.
chr22	19720443	19720446	E7EPG2	0	+	19720443	19720446	102,0,51	1	3	0	.	Important for dimerization.
chr22	19720443	19720446	E7EQM7	0	+	19720443	19720446	102,0,51	1	3	0	.	Important for dimerization.
chr22	19720443	19720446	G3XAH0	0	+	19720443	19720446	102,0,51	1	3	0	.	Important for dimerization.
chr22	19720443	19720446	X5DNA9	0	+	19720443	19720446	102,0,51	1	3	0	.	Important for dimerization.
chr22	20786952	20786958	P05546	0	+	20786952	20786958	102,0,51	1	6	0	.	Reactive bond.
chr22	23182235	23253800	P11274	0	+	23182235	23253800	102,0,51	1	71565	0	.	Breakpoint for translocation to form BCR-ABL oncogene.
chr22	26536473	26536476	O60704	0	-	26536473	26536476	102,0,51	1	3	0	.	Transition state stabilizer.
chr22	26541156	26541159	O60704	0	-	26541156	26541159	102,0,51	1	3	0	.	Transition state stabilizer.
chr22	28796060	28796066	P17861	0	-	28796060	28796066	102,0,51	1	6	0	.	Cleavage; by HM13/SPP. Pubmed:25239945
chr22	29288604	29288607	Q01844	0	+	29288604	29288607	102,0,51	1	3	0	.	Breakpoint for translocation to form chimeric EWSR1/ATF1 protein.
chr22	29292165	29292489	Q01844	0	+	29292165	29292489	102,0,51	1	324	0	.	Breakpoint for insertion to form EWSR1-FEV fusion protein.
chr22	30294988	30294991	Q9BXI6	0	-	30294988	30294991	102,0,51	1	3	0	.	Glutamine finger.
chr22	30295792	30295795	Q9BXI6	0	-	30295792	30295795	102,0,51	1	3	0	.	Arginine finger.
chr22	30345076	30345079	Q15459	0	-	30345076	30345079	102,0,51	1	3	0	.	Critical for binding to SF3A3.
chr22	31619707	31619713	A0A024R1K5	0	-	31619707	31619713	102,0,51	1	6	0	.	Cleavage (non-hydrolytic); by autocatalysis.
chr22	31619707	31619713	Q9UG56	0	-	31619707	31619713	102,0,51	1	6	0	.	Cleavage (non-hydrolytic); by autocatalysis.
chr22	31956219	31956222	Q04917	0	+	31956219	31956222	102,0,51	1	3	0	.	Interaction with phosphoserine on interacting protein.
chr22	31956444	31956447	Q04917	0	+	31956444	31956447	102,0,51	1	3	0	.	Interaction with phosphoserine on interacting protein.
chr22	32043407	32043410	P13866	0	+	32043407	32043410	102,0,51	1	3	0	.	Implicated in sodium coupling.
chr22	32084911	32084914	P13866	0	+	32084911	32084914	102,0,51	1	3	0	.	Implicated in sodium coupling.
chr22	32099279	32099282	P13866	0	+	32099279	32099282	102,0,51	1	3	0	.	Involved in sugar-binding/transport and inhibitor binding.
chr22	35765462	35765465	B0QYV1	0	-	35765462	35765465	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35765462	35765465	B0QYY4	0	-	35765462	35765465	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35768265	35768268	B0QYV1	0	-	35768265	35768268	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35768265	35768268	B0QYY4	0	-	35768265	35768268	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35768337	35768340	B0QYV1	0	-	35768337	35768340	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35768337	35768340	B0QYY4	0	-	35768337	35768340	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35771693	35771696	A0A0G2JRA5	0	-	35771693	35771696	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35771693	35771696	B0QYV1	0	-	35771693	35771696	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35771693	35771696	B0QYY4	0	-	35771693	35771696	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35774496	35774499	A0A0G2JRA5	0	-	35774496	35774499	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35774496	35774499	B0QYV1	0	-	35774496	35774499	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35774496	35774499	B0QYY4	0	-	35774496	35774499	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35774568	35774571	A0A0G2JRA5	0	-	35774568	35774571	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35774568	35774571	B0QYV1	0	-	35774568	35774571	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35774568	35774571	B0QYY4	0	-	35774568	35774571	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35778024	35778027	B0QYV1	0	-	35778024	35778027	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35778024	35778027	B0QYY4	0	-	35778024	35778027	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35778039	35778042	B0QYV1	0	-	35778039	35778042	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35778039	35778042	B0QYY4	0	-	35778039	35778042	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35781632	35781635	B0QYV1	0	-	35781632	35781635	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35781632	35781635	B0QYY4	0	-	35781632	35781635	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35781635	35781638	B0QYV1	0	-	35781635	35781638	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35781635	35781638	B0QYY4	0	-	35781635	35781638	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35781659	35781662	B0QYV1	0	-	35781659	35781662	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35781659	35781662	B0QYY4	0	-	35781659	35781662	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35784255	35784258	A0A0G2JRA5	0	-	35784255	35784258	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35784255	35784258	B0QYV1	0	-	35784255	35784258	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35784255	35784258	B0QYY4	0	-	35784255	35784258	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35784270	35784273	A0A0G2JRA5	0	-	35784270	35784273	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35784270	35784273	B0QYV1	0	-	35784270	35784273	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35784270	35784273	B0QYY4	0	-	35784270	35784273	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35787863	35787866	A0A0G2JRA5	0	-	35787863	35787866	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35787863	35787866	B0QYV1	0	-	35787863	35787866	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35787863	35787866	B0QYY4	0	-	35787863	35787866	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35787866	35787869	A0A0G2JRA5	0	-	35787866	35787869	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35787866	35787869	B0QYV1	0	-	35787866	35787869	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35787866	35787869	B0QYY4	0	-	35787866	35787869	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35787890	35787893	A0A0G2JRA5	0	-	35787890	35787893	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35787890	35787893	B0QYV1	0	-	35787890	35787893	102,0,51	1	3	0	.	Interaction with RNA.
chr22	35787890	35787893	B0QYY4	0	-	35787890	35787893	102,0,51	1	3	0	.	Interaction with RNA.
chr22	36476843	36476846	Q99757	0	-	36476843	36476846	102,0,51	1	3	0	.	Contributes to redox potential value.
chr22	36476846	36476849	Q99757	0	-	36476846	36476849	102,0,51	1	3	0	.	Contributes to redox potential value.
chr22	36480585	36480588	Q99757	0	-	36480585	36480588	102,0,51	1	3	0	.	Deprotonates C-terminal active site Cys.
chr22	38427640	38427643	A0A024R1L8	0	-	38427640	38427643	102,0,51	1	3	0	.	Role in the control of polyamine-mediated channel gating and in the blocking by intracellular magnesium.
chr22	38427640	38427643	P48050	0	-	38427640	38427643	102,0,51	1	3	0	.	Role in the control of polyamine-mediated channel gating and in the blocking by intracellular magnesium.
chr22	39083878	39083881	Q9HC16	0	+	39083878	39083881	102,0,51	1	3	0	.	Interaction with DNA.
chr22	39231744	39231747	P01127	0	-	39231744	39231747	102,0,51	1	3	0	.	Involved in receptor binding.
chr22	39231753	39231756	P01127	0	-	39231753	39231756	102,0,51	1	3	0	.	Involved in receptor binding.
chr22	39430156	39430159	Q15750	0	+	39430156	39430159	102,0,51	1	3	0	.	Required for interaction with MAP3K7. Pubmed:11323434
chr22	39642808	39642811	Q9P0X4	0	+	39642808	39642811	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chr22	39659708	39659711	Q9P0X4	0	+	39659708	39659711	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chr22	39668324	39668327	Q9P0X4	0	+	39668324	39668327	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chr22	39678084	39678087	Q9P0X4	0	+	39678084	39678087	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chr22	40435549	40435555	Q969V6	0	-	40435549	40435555	102,0,51	1	6	0	.	Breakpoint for translocation to form RBM15-MKL1.
chr22	41093094	41117188	Q09472	0	+	41093094	41117188	102,0,51	1	24094	0	.	Breakpoint for translocation to form KAT6A-EP300 and EP300-KAT6A.
chr22	41177972	41177975	Q09472	0	+	41177972	41177975	102,0,51	1	3	0	.	Interaction with NCOA2.
chr22	41178134	41178137	Q09472	0	+	41178134	41178137	102,0,51	1	3	0	.	Interaction with NCOA2.
chr22	41249328	41249331	P46060	0	-	41249328	41249331	102,0,51	1	3	0	.	Hydrophobic interaction with UBC9.
chr22	41249337	41249340	P46060	0	-	41249337	41249340	102,0,51	1	3	0	.	Hydrophobic interaction with UBC9.
chr22	41877243	41877249	Q12772	0	+	41877243	41877249	102,0,51	1	6	0	.	Cleavage; by caspase-3 and caspase-7.
chr22	41877291	41877297	Q12772	0	+	41877291	41877297	102,0,51	1	6	0	.	Cleavage; by S2P.
chr22	41877405	41877411	Q12772	0	+	41877405	41877411	102,0,51	1	6	0	.	Cleavage; by S1P.
chr22	43129278	43129284	Q13323	0	+	43129278	43129284	102,0,51	1	6	0	.	Cleavage; by RHBDL4/RHBDD1.
chr22	46235269	46235272	Q07869	0	+	46235269	46235272	102,0,51	1	3	0	.	Essential for heterodimerization with RXRA.
chr22	46346444	46346447	O75648	0	+	46346444	46346447	102,0,51	1	3	0	.	Interaction with tRNA.
chr22	46353792	46353795	O75648	0	+	46353792	46353795	102,0,51	1	3	0	.	Interaction with tRNA.
chr22	46356069	46356072	O75648	0	+	46356069	46356072	102,0,51	1	3	0	.	Interaction with tRNA.
chr22	50281592	50281598	O15031	0	-	50281592	50281598	102,0,51	1	6	0	.	Cleavage; by proprotein convertases.
chr3	389308	389314	O00533	0	+	389308	389314	102,0,51	1	6	0	.	Cleavage; by ADAM8.
chr3	398294	398300	O00533	0	+	398294	398300	102,0,51	1	6	0	.	Cleavage; by ADAM8.
chr3	17383912	17383915	Q92609	0	-	17383912	17383915	102,0,51	1	3	0	.	Glutamine finger.
chr3	17403182	17403185	Q92609	0	-	17403182	17403185	102,0,51	1	3	0	.	Arginine finger.
chr3	18394902	18394908	Q01826	0	-	18394902	18394908	102,0,51	1	6	0	.	Cleavage; by caspases.
chr3	25620687	25620690	Q02880	0	-	25620687	25620690	102,0,51	1	3	0	.	Interaction with DNA.
chr3	25623610	25623613	Q02880	0	-	25623610	25623613	102,0,51	1	3	0	.	Important for DNA bending; intercalates between base pairs of target DNA.
chr3	25624316	25624319	Q02880	0	-	25624316	25624319	102,0,51	1	3	0	.	Transition state stabilizer.
chr3	25624693	25624696	Q02880	0	-	25624693	25624696	102,0,51	1	3	0	.	Interaction with DNA.
chr3	25624795	25624798	Q02880	0	-	25624795	25624798	102,0,51	1	3	0	.	Interaction with DNA.
chr3	25626831	25626834	Q02880	0	-	25626831	25626834	102,0,51	1	3	0	.	Interaction with DNA.
chr3	25626834	25626837	Q02880	0	-	25626834	25626837	102,0,51	1	3	0	.	Interaction with DNA.
chr3	25630335	25630338	Q02880	0	-	25630335	25630338	102,0,51	1	3	0	.	Interaction with DNA.
chr3	25630344	25630347	Q02880	0	-	25630344	25630347	102,0,51	1	3	0	.	Interaction with DNA.
chr3	37629189	37629195	Q13797	0	+	37629189	37629195	102,0,51	1	6	0	.	Cleavage.
chr3	37971481	37971484	O15194	0	+	37971481	37971484	102,0,51	1	3	0	.	Transition state stabilizer.
chr3	37975804	37975807	O15194	0	+	37975804	37975807	102,0,51	1	3	0	.	Transition state stabilizer.
chr3	39410843	39410849	A0A024R2P0	0	+	39410843	39410849	102,0,51	1	6	0	.	Cleavage; by ST3; site 1.
chr3	39410843	39410849	A0A0C4DG17	0	+	39410843	39410849	102,0,51	1	6	0	.	Cleavage; by ST3; site 1.
chr3	39410843	39410849	P08865	0	+	39410843	39410849	102,0,51	1	6	0	.	Cleavage; by ST3; site 1.
chr3	39410897	39410903	A0A024R2P0	0	+	39410897	39410903	102,0,51	1	6	0	.	Cleavage; by ST3; site 2.
chr3	39410897	39410903	A0A0C4DG17	0	+	39410897	39410903	102,0,51	1	6	0	.	Cleavage; by ST3; site 2.
chr3	39410897	39410903	P08865	0	+	39410897	39410903	102,0,51	1	6	0	.	Cleavage; by ST3; site 2.
chr3	45095485	45095491	Q9H5V8	0	-	45095485	45095491	102,0,51	1	6	0	.	Cleavage; by ST14/MT-SP1.
chr3	46454320	46454323	P02788	0	-	46454320	46454323	102,0,51	1	3	0	.	Important for iron binding.
chr3	48319579	48319585	P0C7L1	0	-	48319579	48319585	102,0,51	1	6	0	.	Reactive bond.
chr3	48410529	48410532	O43157	0	-	48410529	48410532	102,0,51	1	3	0	.	Important for interaction with RAC1 and RND1.
chr3	48415223	48415229	O43157	0	-	48415223	48415229	102,0,51	1	6	0	.	Cleavage; by proprotein convertases.
chr3	48523749	48523752	Q16877	0	-	48523749	48523752	102,0,51	1	3	0	.	Transition state stabilizer.
chr3	48564939	48564945	Q02388	0	-	48564939	48564945	102,0,51	1	6	0	.	Reactive bond.
chr3	48683009	48685639	Q9NZQ3	0	-	48683009	48685639	102,0,51	1	2630	0	.	Breakpoint for translocation to form KMT2A/MLL1-AF3P21 oncogene.
chr3	49358131	49358134	P07203	0	-	49358131	49358134	102,0,51	1	3	0	.	Subject to oxidation and hydroselenide loss to dehydroalanine.
chr3	49360220	49360226	P61586	0	-	49360220	49360226	102,0,51	1	6	0	.	Cleavage; by yopT.
chr3	49532467	49532473	Q14118	0	+	49532467	49532473	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr3	49532653	49532659	Q14118	0	+	49532653	49532659	102,0,51	1	6	0	.	Cleavage; by MMP9.
chr3	52407201	52407204	Q92560	0	-	52407201	52407204	102,0,51	1	3	0	.	Important for enzyme activity.
chr3	52819402	52819408	Q14624	0	-	52819402	52819408	102,0,51	1	6	0	.	Cleavage; by kallikrein.
chr3	53179602	53179605	Q05655	0	+	53179602	53179605	102,0,51	1	3	0	.	Interaction with phosphotyrosine-containing peptide.
chr3	53179644	53179647	Q05655	0	+	53179644	53179647	102,0,51	1	3	0	.	Interaction with phosphotyrosine-containing peptide.
chr3	53179659	53179662	Q05655	0	+	53179659	53179662	102,0,51	1	3	0	.	Interaction with phosphotyrosine-containing peptide.
chr3	53181257	53181260	Q05655	0	+	53181257	53181260	102,0,51	1	3	0	.	Interaction with phosphotyrosine-containing peptide.
chr3	53185925	53185931	Q05655	0	+	53185925	53185931	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr3	53231524	53231527	P29401	0	-	53231524	53231527	102,0,51	1	3	0	.	Important for catalytic activity.
chr3	53242238	53242241	P29401	0	-	53242238	53242241	102,0,51	1	3	0	.	Important for catalytic activity.
chr3	53666508	53666511	Q01668	0	+	53666508	53666511	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chr3	53726890	53726893	Q01668	0	+	53726890	53726893	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chr3	53747434	53747437	Q01668	0	+	53747434	53747437	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chr3	53775898	53775901	Q01668	0	+	53775898	53775901	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chr3	53885860	53885866	Q9Y6D0	0	-	53885860	53885866	102,0,51	1	6	0	.	Cleavage; by CAPN2.
chr3	58428156	58428159	P11177	0	-	58428156	58428159	102,0,51	1	3	0	.	Important for interaction with DLAT. Pubmed:20160912
chr3	59922351	59922354	P49789	0	-	59922351	59922354	102,0,51	1	3	0	.	Important for induction of apoptosis.
chr3	62282864	62282867	P23470	0	+	62282864	62282867	102,0,51	1	3	0	.	Ancestral active site.
chr3	67520610	67520613	Q96I99	0	-	67520610	67520613	102,0,51	1	3	0	.	Important for substrate specificity.
chr3	67529175	67529178	Q96I99	0	-	67529175	67529178	102,0,51	1	3	0	.	Important for substrate specificity.
chr3	69063041	69063044	Q8TBC4	0	-	69063041	69063044	102,0,51	1	3	0	.	Determines specificity for NEDD8.
chr3	71198201	71198207	Q9H334	0	-	71198201	71198207	102,0,51	1	6	0	.	Breakpoint for translocation to form PAX5-FOXP1.
chr3	93879309	93879312	P07225	0	-	93879309	93879312	102,0,51	1	3	0	.	Not glycosylated; in variant Heerlen.
chr3	98585631	98585634	P36551	0	-	98585631	98585634	102,0,51	1	3	0	.	Important for dimerization.
chr3	100732668	100736577	Q92734	0	+	100732668	100736577	102,0,51	1	3909	0	.	Breakpoint for translocation to form TRK-T3.
chr3	112538145	112538151	Q9NT62	0	-	112538145	112538151	102,0,51	1	6	0	.	Cleavage; by CASP8.
chr3	122325301	122325304	P01040	0	+	122325301	122325304	102,0,51	1	3	0	.	Reactive site.
chr3	126157444	126157447	O75891	0	-	126157444	126157447	102,0,51	1	3	0	.	Essential for catalytic activity.
chr3	132328290	132328293	P15309	0	+	132328290	132328293	102,0,51	1	3	0	.	Important for substrate specificity.
chr3	132332299	132332302	P15309	0	+	132332299	132332302	102,0,51	1	3	0	.	Required for homodimerization.
chr3	132332317	132332320	P15309	0	+	132332317	132332320	102,0,51	1	3	0	.	Required for homodimerization.
chr3	132342611	132342614	P15309	0	+	132342611	132342614	102,0,51	1	3	0	.	Required for structural stability.
chr3	143121269	143121272	Q9Y4C5	0	+	143121269	143121272	102,0,51	1	3	0	.	Not glycosylated.
chr3	148996900	148996903	P46976	0	+	148996900	148996903	102,0,51	1	3	0	.	Important for catalytic activity.
chr3	149009280	149009283	P46976	0	+	149009280	149009283	102,0,51	1	3	0	.	Important for catalytic activity.
chr3	158571345	158592437	P58340	0	+	158571345	158592437	102,0,51	1	21092	0	.	Breakpoint for translocation to form NPM-MLF1.
chr3	167446458	167446464	O75830	0	-	167446458	167446464	102,0,51	1	6	0	.	Reactive bond.
chr3	167824489	167824495	Q99574	0	+	167824489	167824495	102,0,51	1	6	0	.	Reactive bond.
chr3	184323172	184323178	Q04637	0	+	184323172	184323178	102,0,51	1	6	0	.	Cleavage; by foot-and-mouth disease virus leader protease.
chr3	184323193	184323199	Q04637	0	+	184323193	184323199	102,0,51	1	6	0	.	Cleavage; by enterovirus/rhinovirus protease 2A.
chr3	185229522	185229525	Q08426	0	-	185229522	185229525	102,0,51	1	3	0	.	Important for catalytic activity.
chr3	185235328	185235331	Q08426	0	-	185235328	185235331	102,0,51	1	3	0	.	Important for catalytic activity.
chr3	186677619	186677625	P04196	0	+	186677619	186677625	102,0,51	1	6	0	.	Cleavage; by plasmin.
chr3	186717683	186717686	P01042	0	+	186717683	186717686	102,0,51	1	3	0	.	Not glycosylated.
chr3	186741530	186741536	P01042	0	+	186741530	186741536	102,0,51	1	6	0	.	Cleavage; by kallikrein.
chr3	186741560	186741566	P01042	0	+	186741560	186741566	102,0,51	1	6	0	.	Cleavage; by kallikrein.
chr3	186853241	186853244	Q15848	0	+	186853241	186853244	102,0,51	1	3	0	.	Not hydroxylated.
chr3	186854224	186854227	Q15848	0	+	186854224	186854227	102,0,51	1	3	0	.	Not hydroxylated.
chr3	186854278	186854281	Q15848	0	+	186854278	186854281	102,0,51	1	3	0	.	Not hydroxylated.
chr3	186854656	186854659	Q15848	0	+	186854656	186854659	102,0,51	1	3	0	.	Not glycosylated.
chr3	187229853	187229859	P48740	0	-	187229853	187229859	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr3	188609841	188708269	Q93052	0	+	188609841	188708269	102,0,51	1	98428	0	.	Breakpoint for translocation to form HMGA2-LPP.
chr3	188760279	188866202	Q93052	0	+	188760279	188866202	102,0,51	1	105923	0	.	Breakpoint for translocation to form HMGA2-LPP and KMT2A/MLL1-LPP.
chr3	196074060	196074066	P02786	0	-	196074060	196074066	102,0,51	1	6	0	.	Cleavage; by trypsin; to produce soluble form.
chr3	196807838	196807844	Q13177	0	+	196807838	196807844	102,0,51	1	6	0	.	Cleavage; by caspase-3 or caspase-3-like proteases.
chr4	3127391	3127397	P42858	0	+	3127391	3127397	102,0,51	1	6	0	.	Cleavage; by apopain.
chr4	3127442	3127448	P42858	0	+	3127442	3127448	102,0,51	1	6	0	.	Cleavage; by apopain.
chr4	3127508	3127514	P42858	0	+	3127508	3127514	102,0,51	1	6	0	.	Cleavage; by apopain.
chr4	3129938	3129944	P42858	0	+	3129938	3129944	102,0,51	1	6	0	.	Cleavage; by apopain.
chr4	3766996	3766999	P18825	0	+	3766996	3766999	102,0,51	1	3	0	.	Implicated in ligand binding.
chr4	3767245	3767248	P18825	0	+	3767245	3767248	102,0,51	1	3	0	.	Implicated in catechol agonist binding and receptor activation.
chr4	3767257	3767260	P18825	0	+	3767257	3767260	102,0,51	1	3	0	.	Implicated in catechol agonist binding and receptor activation.
chr4	15707519	15707522	Q10588	0	+	15707519	15707522	102,0,51	1	3	0	.	Crucial for NAD binding and catalysis.
chr4	15711868	15711871	Q10588	0	+	15711868	15711871	102,0,51	1	3	0	.	Crucial for NAD binding and catalysis.
chr4	15715722	15715725	Q10588	0	+	15715722	15715725	102,0,51	1	3	0	.	Crucial for NAD binding and catalysis.
chr4	20596454	20596460	O94813	0	+	20596454	20596460	102,0,51	1	6	0	.	Cleavage.
chr4	24799641	24799644	P08294	0	+	24799641	24799644	102,0,51	1	3	0	.	Not glycated.
chr4	24799794	24799797	P08294	0	+	24799794	24799797	102,0,51	1	3	0	.	Not glycated.
chr4	24800232	24800235	P08294	0	+	24800232	24800235	102,0,51	1	3	0	.	Not glycated.
chr4	25158999	25159002	Q9HD40	0	-	25158999	25159002	102,0,51	1	3	0	.	May act as a substrate filter by repelling compounds with a negatively charged alpha-carboxylate.
chr4	25664326	25666129	O95436	0	+	25664326	25666129	102,0,51	1	1803	0	.	Breakpoint for translocation to form a SLC34A2-ROS1 fusion protein.
chr4	40348951	40348954	Q9UGM1	0	+	40348951	40348954	102,0,51	1	3	0	.	Key residue important for potent inhibition of the CHRNA9-CHRNA10 receptor by the alpha-conotoxin RgIA (AC P0C1D0).
chr4	41256976	41256979	P09936	0	+	41256976	41256979	102,0,51	1	3	0	.	Susceptible to oxidation. Pubmed:14722078
chr4	41256991	41256994	P09936	0	+	41256991	41256994	102,0,51	1	3	0	.	Susceptible to oxidation. Pubmed:14722078
chr4	41257114	41257117	P09936	0	+	41257114	41257117	102,0,51	1	3	0	.	Susceptible to oxidation. Pubmed:14722078
chr4	41261758	41261761	P09936	0	+	41261758	41261761	102,0,51	1	3	0	.	Susceptible to oxidation. Pubmed:14722078
chr4	41264101	41264104	P09936	0	+	41264101	41264104	102,0,51	1	3	0	.	Important for enzyme activity. Pubmed:8639624
chr4	41264110	41264113	P09936	0	+	41264110	41264113	102,0,51	1	3	0	.	Susceptible to oxidation. Pubmed:14722078
chr4	41268058	41268061	P09936	0	+	41268058	41268061	102,0,51	1	3	0	.	Susceptible to oxidation. Pubmed:14722078
chr4	47623704	47623710	Q9Y5Q5	0	-	47623704	47623710	102,0,51	1	6	0	.	Cleavage.
chr4	47674465	47674471	Q9Y5Q5	0	-	47674465	47674471	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr4	47763500	47763506	Q9Y5Q5	0	-	47763500	47763506	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr4	48422071	48422074	Q9P270	0	+	48422071	48422074	102,0,51	1	3	0	.	Important for interaction with CLIP1.
chr4	48483819	48483825	Q96EP9	0	+	48483819	48483825	102,0,51	1	6	0	.	Cleavage; by thrombin.
chr4	48528333	48528336	O94915	0	-	48528333	48528336	102,0,51	1	3	0	.	Breakpoint for insertion to form KMT2A/MLL1-AFF4 fusion protein.
chr4	53425962	53428029	Q6UN15	0	+	53425962	53428029	102,0,51	1	2067	0	.	Breakpoint for interstitial deletion to form the FIP1L1-PDGFRA fusion protein.
chr4	54014113	54014119	Q9UKJ5	0	-	54014113	54014119	102,0,51	1	6	0	.	Breakpoint for translocation to form CHIC2-ETV6 in AML.
chr4	54274918	54274924	P16234	0	+	54274918	54274924	102,0,51	1	6	0	.	Breakpoint for interstitial deletion to form the FIP1L1-PDGFRA fusion protein.
chr4	54738431	54738434	A0A024RDA0	0	+	54738431	54738434	102,0,51	1	3	0	.	Important for interaction with phosphotyrosine-binding proteins.
chr4	54738431	54738434	P10721	0	+	54738431	54738434	102,0,51	1	3	0	.	Important for interaction with phosphotyrosine-binding proteins.
chr4	55087743	55087746	P35968	0	-	55087743	55087746	102,0,51	1	3	0	.	Interaction with SHB.
chr4	55478818	55478821	O15516	0	-	55478818	55478821	102,0,51	1	3	0	.	Important for interaction with ARNTL/BMAL1. Pubmed:23229515
chr4	55478929	55478932	O15516	0	-	55478929	55478932	102,0,51	1	3	0	.	Interaction with E-box DNA. Pubmed:23229515
chr4	55478941	55478944	O15516	0	-	55478941	55478944	102,0,51	1	3	0	.	Interaction with E-box DNA. Pubmed:23229515
chr4	55478953	55478956	O15516	0	-	55478953	55478956	102,0,51	1	3	0	.	Interaction with E-box DNA. Pubmed:23229515
chr4	56453649	56453652	P22234	0	+	56453649	56453652	102,0,51	1	3	0	.	Essential for AIR carboxylase activity.
chr4	56811752	56811758	P20155	0	-	56811752	56811758	102,0,51	1	6	0	.	Reactive bond.
chr4	70032098	70032101	P15516	0	+	70032098	70032101	102,0,51	1	3	0	.	Important for candidacidal activity.
chr4	70033184	70033187	P15516	0	+	70033184	70033187	102,0,51	1	3	0	.	Important for candidacidal activity.
chr4	70033190	70033193	P15516	0	+	70033190	70033193	102,0,51	1	3	0	.	Not sulfated.
chr4	70033202	70033205	P15516	0	+	70033202	70033205	102,0,51	1	3	0	.	Not sulfated.
chr4	70033208	70033211	P15516	0	+	70033208	70033211	102,0,51	1	3	0	.	Not sulfated.
chr4	70249258	70249264	P07498	0	+	70249258	70249264	102,0,51	1	6	0	.	Cleavage; by chymosin/rennin.
chr4	73405117	73405120	P02768	0	+	73405117	73405120	102,0,51	1	3	0	.	Not glycated.
chr4	73405165	73405168	P02768	0	+	73405165	73405168	102,0,51	1	3	0	.	Not glycated.
chr4	73406683	73406686	P02768	0	+	73406683	73406686	102,0,51	1	3	0	.	Not glycated.
chr4	73406752	73406755	P02768	0	+	73406752	73406755	102,0,51	1	3	0	.	Not glycated.
chr4	73408611	73408614	P02768	0	+	73408611	73408614	102,0,51	1	3	0	.	Not glycated.
chr4	73408671	73408674	P02768	0	+	73408671	73408674	102,0,51	1	3	0	.	Not glycated.
chr4	73408710	73408713	P02768	0	+	73408710	73408713	102,0,51	1	3	0	.	Not glycated.
chr4	73408800	73408803	P02768	0	+	73408800	73408803	102,0,51	1	3	0	.	Not glycated.
chr4	73409418	73409421	P02768	0	+	73409418	73409421	102,0,51	1	3	0	.	Not glycated.
chr4	73409463	73409466	P02768	0	+	73409463	73409466	102,0,51	1	3	0	.	Not glycated.
chr4	73409484	73409487	P02768	0	+	73409484	73409487	102,0,51	1	3	0	.	Not glycated.
chr4	73410335	73410338	P02768	0	+	73410335	73410338	102,0,51	1	3	0	.	Not glycated.
chr4	73410350	73410353	P02768	0	+	73410350	73410353	102,0,51	1	3	0	.	Not glycated.
chr4	73410362	73410365	P02768	0	+	73410362	73410365	102,0,51	1	3	0	.	Aspirin-acetylated lysine.
chr4	73410380	73410383	P02768	0	+	73410380	73410383	102,0,51	1	3	0	.	Not glycated.
chr4	73410401	73410404	P02768	0	+	73410401	73410404	102,0,51	1	3	0	.	Not glycated.
chr4	73412071	73412074	P02768	0	+	73412071	73412074	102,0,51	1	3	0	.	Not glycated.
chr4	73413431	73413434	P02768	0	+	73413431	73413434	102,0,51	1	3	0	.	Not glycated.
chr4	73413467	73413470	P02768	0	+	73413467	73413470	102,0,51	1	3	0	.	Not glycated.
chr4	73413503	73413506	P02768	0	+	73413503	73413506	102,0,51	1	3	0	.	Not glycated.
chr4	73415122	73415125	P02768	0	+	73415122	73415125	102,0,51	1	3	0	.	Not glycated.
chr4	73415161	73415164	P02768	0	+	73415161	73415164	102,0,51	1	3	0	.	Not glycated.
chr4	73416300	73416303	P02768	0	+	73416300	73416303	102,0,51	1	3	0	.	Not glycated.
chr4	73416339	73416342	P02768	0	+	73416339	73416342	102,0,51	1	3	0	.	Not glycated.
chr4	73417552	73417555	P02768	0	+	73417552	73417555	102,0,51	1	3	0	.	Not glycated.
chr4	73417606	73417609	P02768	0	+	73417606	73417609	102,0,51	1	3	0	.	Not glycated.
chr4	73417618	73417621	P02768	0	+	73417618	73417621	102,0,51	1	3	0	.	Not glycated.
chr4	73418126	73418129	P02768	0	+	73418126	73418129	102,0,51	1	3	0	.	Not glycated.
chr4	73418153	73418156	P02768	0	+	73418153	73418156	102,0,51	1	3	0	.	Not glycated.
chr4	73418228	73418231	P02768	0	+	73418228	73418231	102,0,51	1	3	0	.	Not glycated.
chr4	73418285	73418288	P02768	0	+	73418285	73418288	102,0,51	1	3	0	.	Not glycated.
chr4	73418300	73418303	P02768	0	+	73418300	73418303	102,0,51	1	3	0	.	Not glycated.
chr4	73419537	73419540	P02768	0	+	73419537	73419540	102,0,51	1	3	0	.	Not glycated.
chr4	73419546	73419549	P02768	0	+	73419546	73419549	102,0,51	1	3	0	.	Not glycated.
chr4	73419594	73419597	P02768	0	+	73419594	73419597	102,0,51	1	3	0	.	Not glycated.
chr4	73419603	73419606	P02768	0	+	73419603	73419606	102,0,51	1	3	0	.	Not glycated.
chr4	73419615	73419618	P02768	0	+	73419615	73419618	102,0,51	1	3	0	.	Not glycated.
chr4	73420259	73420262	P02768	0	+	73420259	73420262	102,0,51	1	3	0	.	Not glycated.
chr4	73741555	73741561	P10145	0	+	73741555	73741561	102,0,51	1	6	0	.	Cleavage; by thrombin.
chr4	73741558	73741564	P10145	0	+	73741558	73741564	102,0,51	1	6	0	.	Cleavage; by MMP9.
chr4	73998312	73998318	P42830	0	-	73998312	73998318	102,0,51	1	6	0	.	Cleavage; by cathepsin G.
chr4	88095585	88095588	Q9UNQ0	0	-	88095585	88095588	102,0,51	1	3	0	.	Not glycosylated.
chr4	88107206	88107209	Q9UNQ0	0	-	88107206	88107209	102,0,51	1	3	0	.	Not glycosylated.
chr4	95220036	95220042	O95185	0	-	95220036	95220042	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr4	99081363	99081366	P11766	0	-	99081363	99081366	102,0,51	1	3	0	.	Important for FDH activity and activation by fatty acids.
chr4	102596136	102596142	P19838	0	+	102596136	102596142	102,0,51	1	6	0	.	Cleavage (when cotranslationally processed).
chr4	103047102	103047105	Q86UD5	0	-	103047102	103047105	102,0,51	1	3	0	.	Important for cation transport.
chr4	103047105	103047108	Q86UD5	0	-	103047105	103047108	102,0,51	1	3	0	.	Important for cation transport.
chr4	108019627	108019630	A0A140VK76	0	+	108019627	108019630	102,0,51	1	3	0	.	Important for catalytic activity.
chr4	108019627	108019630	E9PF18	0	+	108019627	108019630	102,0,51	1	3	0	.	Important for catalytic activity.
chr4	108019627	108019630	Q16836	0	+	108019627	108019630	102,0,51	1	3	0	.	Important for catalytic activity.
chr4	109300610	109300616	Q9BXS0	0	-	109300610	109300616	102,0,51	1	6	0	.	Cleavage; by furin.
chr4	110513540	110513543	Q07075	0	+	110513540	110513543	102,0,51	1	3	0	.	Transition state stabilizer.
chr4	118295800	118295806	P56730	0	-	118295800	118295806	102,0,51	1	6	0	.	Reactive bond homolog.
chr4	140661892	140661895	Q6ZT07	0	-	140661892	140661895	102,0,51	1	3	0	.	Glutamine finger.
chr4	140662009	140662012	Q6ZT07	0	-	140662009	140662012	102,0,51	1	3	0	.	Arginine finger.
chr4	144001218	144001221	P06028	0	-	144001218	144001221	102,0,51	1	3	0	.	Not glycosylated.
chr4	144001221	144001224	P06028	0	-	144001221	144001224	102,0,51	1	3	0	.	Not glycosylated.
chr4	153703951	153703954	A0A0S2Z4S4	0	+	153703951	153703954	102,0,51	1	3	0	.	Interaction with bacterial lipopeptide.
chr4	153703951	153703954	O60603	0	+	153703951	153703954	102,0,51	1	3	0	.	Interaction with bacterial lipopeptide.
chr4	154565822	154565828	P02675	0	+	154565822	154565828	102,0,51	1	6	0	.	Cleavage; by thrombin; to release fibrinopeptide B.
chr4	154566635	154566641	P02675	0	+	154566635	154566641	102,0,51	1	6	0	.	Cleavage; by plasmin; to break down fibrin clots.
chr4	154566659	154566665	P02675	0	+	154566659	154566665	102,0,51	1	6	0	.	Cleavage; by hementin; to prevent blood coagulation.
chr4	154566668	154567594	P02675	0	+	154566668	154567594	102,0,51	1	926	0	.	Cleavage; by plasmin; to break down fibrin clots.
chr4	154587649	154587655	P02671	0	-	154587649	154587655	102,0,51	1	6	0	.	Cleavage; by plasmin; to break down fibrin clots.
chr4	154587655	154588796	P02671	0	-	154587655	154588796	102,0,51	1	1141	0	.	Cleavage; by hementin; to prevent blood coagulation.
chr4	154588853	154588859	P02671	0	-	154588853	154588859	102,0,51	1	6	0	.	Cleavage; by plasmin; to break down fibrin clots.
chr4	154589508	154589514	P02671	0	-	154589508	154589514	102,0,51	1	6	0	.	Cleavage; by thrombin; to release fibrinopeptide A.
chr4	154611896	154612021	P02679	0	-	154611896	154612021	102,0,51	1	125	0	.	Cleavage; by hementin; to prevent blood coagulation.
chr4	154612057	154612063	P02679	0	-	154612057	154612063	102,0,51	1	6	0	.	Cleavage; by plasmin; to break down fibrin clots.
chr4	154612069	154612075	P02679	0	-	154612069	154612075	102,0,51	1	6	0	.	Cleavage; by plasmin; to break down fibrin clots.
chr4	156767988	156772689	Q9NRA1	0	-	156767988	156772689	102,0,51	1	4701	0	.	Cleavage.
chr4	156772692	156772698	Q9NRA1	0	-	156772692	156772698	102,0,51	1	6	0	.	Cleavage.
chr4	156772710	156772716	Q9NRA1	0	-	156772710	156772716	102,0,51	1	6	0	.	Cleavage.
chr4	157152731	157152734	P48167	0	+	157152731	157152734	102,0,51	1	3	0	.	Important for obstruction of the ion pore in the closed conformation.
chr4	163472948	163472951	Q9H0I9	0	-	163472948	163472951	102,0,51	1	3	0	.	Important for catalytic activity.
chr4	169002098	169002101	Q8N4T8	0	-	169002098	169002101	102,0,51	1	3	0	.	Important for interaction with acyl carrier protein (ACP). Pubmed:25203508
chr4	169692227	169692230	P51790	0	+	169692227	169692230	102,0,51	1	3	0	.	Mediates proton transfer from the outer aqueous phase to the interior of the protein; involved in linking H(+) and Cl(-) transport.
chr4	169695689	169695692	P51790	0	+	169695689	169695692	102,0,51	1	3	0	.	Mediates proton transfer from the protein to the inner aqueous phase.
chr4	174677122	174677125	O75311	0	-	174677122	174677125	102,0,51	1	3	0	.	Important for obstruction of the ion pore in the closed conformation. Pubmed:26416729
chr4	177309956	177309959	Q8TAT5	0	+	177309956	177309959	102,0,51	1	3	0	.	Important for monofunctional glycosylase activity.
chr4	177322542	177322545	Q8TAT5	0	+	177322542	177322545	102,0,51	1	3	0	.	Required for glycosylase and lyase activities.
chr5	1266516	1266519	O14746	0	-	1266516	1266519	102,0,51	1	3	0	.	Required for nucleotide incorporation and primer extension rate.
chr5	1294378	1294381	O14746	0	-	1294378	1294381	102,0,51	1	3	0	.	Required for optimal binding of telomeric ssDNA and incorporation of nucleotides at the second position of the template.
chr5	1441461	1441464	Q01959	0	-	1441461	1441464	102,0,51	1	3	0	.	Contributes to high-affinity binding to cocaine.
chr5	1445697	1445700	Q01959	0	-	1445697	1445700	102,0,51	1	3	0	.	Contributes to high-affinity binding to cocaine.
chr5	31410767	31410770	Q9NRR4	0	-	31410767	31410770	102,0,51	1	3	0	.	Important for activity.
chr5	32090921	32090927	O15018	0	+	32090921	32090927	102,0,51	1	6	0	.	Cleavage; by caspases.
chr5	32591637	32591643	P53999	0	+	32591637	32591643	102,0,51	1	6	0	.	Cleavage.
chr5	39315846	39315852	P02748	0	-	39315846	39315852	102,0,51	1	6	0	.	Cleavage; by thrombin.
chr5	42718539	42718542	P10912	0	+	42718539	42718542	102,0,51	1	3	0	.	Required for endocytosis and down-regulation.
chr5	58975800	58975803	Q08499	0	-	58975800	58975803	102,0,51	1	3	0	.	Binds AMP, but not cAMP.
chr5	65529196	65542804	Q9BS16	0	-	65529196	65542804	102,0,51	1	13608	0	.	Breakpoint for translocation to form KMT2A/MLL1-CENPK oncogene.
chr5	76618589	76618595	O00254	0	-	76618589	76618595	102,0,51	1	6	0	.	Cleavage; by thrombin.
chr5	76732345	76732351	P25116	0	+	76732345	76732351	102,0,51	1	6	0	.	Cleavage; by thrombin.
chr5	88722726	88722732	Q06413	0	-	88722726	88722732	102,0,51	1	6	0	.	Cleavage.
chr5	96792066	96792069	Q9NZ08	0	-	96792066	96792069	102,0,51	1	3	0	.	Transition state stabilizer.
chr5	96896495	96896498	Q6P179	0	+	96896495	96896498	102,0,51	1	3	0	.	Transition state stabilizer.
chr5	96979577	96979583	Q9UIQ6	0	+	96979577	96979583	102,0,51	1	6	0	.	Cleavage; to produce pregnancy serum form.
chr5	96998136	96998139	Q9UIQ6	0	+	96998136	96998139	102,0,51	1	3	0	.	Transition state stabilizer.
chr5	98779944	98779950	Q6NW40	0	+	98779944	98779950	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr5	115999893	115999896	Q6Q4G3	0	+	115999893	115999896	102,0,51	1	3	0	.	Transition state stabilizer.
chr5	126577143	126577146	P49419	0	-	126577143	126577146	102,0,51	1	3	0	.	Transition state stabilizer.
chr5	132542050	132542053	P05113	0	-	132542050	132542053	102,0,51	1	3	0	.	Not glycosylated.
chr5	132904401	132927123	Q9UHB7	0	-	132904401	132927123	102,0,51	1	22722	0	.	Breakpoint for insertion to form KMT2A/MLL1-AFF4 fusion protein.
chr5	133991052	133991055	P21796	0	-	133991052	133991055	102,0,51	1	3	0	.	Involved in hexokinase binding.
chr5	138467454	138467457	P18146	0	+	138467454	138467457	102,0,51	1	3	0	.	Interaction with DNA. Pubmed:25258363
chr5	138467487	138467490	P18146	0	+	138467487	138467490	102,0,51	1	3	0	.	Interaction with DNA.
chr5	138467499	138467502	P18146	0	+	138467499	138467502	102,0,51	1	3	0	.	Interaction with DNA.
chr5	138467517	138467520	P18146	0	+	138467517	138467520	102,0,51	1	3	0	.	Interaction with DNA. Pubmed:25258363
chr5	138467571	138467574	P18146	0	+	138467571	138467574	102,0,51	1	3	0	.	Interaction with DNA.
chr5	138467583	138467586	P18146	0	+	138467583	138467586	102,0,51	1	3	0	.	Interaction with DNA. Pubmed:25258363
chr5	138467655	138467658	P18146	0	+	138467655	138467658	102,0,51	1	3	0	.	Interaction with DNA. Pubmed:25999311
chr5	138467667	138467670	P18146	0	+	138467667	138467670	102,0,51	1	3	0	.	Interaction with DNA. Pubmed:25258363
chr5	138467685	138467688	P18146	0	+	138467685	138467688	102,0,51	1	3	0	.	Interaction with DNA. Pubmed:25999311, Pubmed:25258363
chr5	140336002	140336005	Q99075	0	-	140336002	140336005	102,0,51	1	3	0	.	Plays a critical role in diphtheria toxin binding and toxin sensitivity.
chr5	147828083	147828089	P00995	0	-	147828083	147828089	102,0,51	1	6	0	.	Necessary for sperm binding.
chr5	147828089	147828095	P00995	0	-	147828089	147828095	102,0,51	1	6	0	.	Reactive bond for trypsin.
chr5	148070376	148070382	Q9NQ38	0	+	148070376	148070382	102,0,51	1	6	0	.	Reactive bond.
chr5	148174296	148174302	Q6IE38	0	+	148174296	148174302	102,0,51	1	6	0	.	Reactive bond.
chr5	148213951	148213957	Q6UWN8	0	+	148213951	148213957	102,0,51	1	6	0	.	Reactive bond.
chr5	148282157	148282163	Q1W4C9	0	+	148282157	148282163	102,0,51	1	6	0	.	Reactive bond.
chr5	148314150	148314156	P58062	0	+	148314150	148314156	102,0,51	1	6	0	.	Reactive bond.
chr5	148338531	148338537	Q5DT21	0	+	148338531	148338537	102,0,51	1	6	0	.	Reactive bond.
chr5	150125574	150126522	P09619	0	-	150125574	150126522	102,0,51	1	948	0	.	Breakpoint for translocation to form the CEP85L-PDGFRB fusion protein.
chr5	150126609	150126615	P09619	0	-	150126609	150126615	102,0,51	1	6	0	.	Breakpoint for insertion to form PDE4DIP-PDGFRB fusion protein.
chr5	150126609	150126615	P09619	0	-	150126609	150126615	102,0,51	1	6	0	.	Breakpoint for translocation to form TRIP11-PDGFRB.
chr5	150403310	150404683	P04233	0	-	150403310	150404683	102,0,51	1	1373	0	.	Breakpoint for translocation to form a CD74-ROS1 fusion protein.
chr5	150795494	150795500	Q9BZL3	0	+	150795494	150795500	102,0,51	1	6	0	.	Cleavage.
chr5	151851434	151851437	P23415	0	-	151851434	151851437	102,0,51	1	3	0	.	Important for obstruction of the ion pore in the closed conformation. Pubmed:25730860
chr5	154911841	154911844	Q8TEQ6	0	-	154911841	154911844	102,0,51	1	3	0	.	Interaction with U4 snRNA and with the 7-methylguanosine cap of RNA molecules. Pubmed:27834343, Pubmed:27881600, Pubmed:27881601
chr5	154912913	154912916	Q8TEQ6	0	-	154912913	154912916	102,0,51	1	3	0	.	Interaction with U4 snRNA and with the 7-methylguanosine cap of RNA molecules. Pubmed:27834343, Pubmed:27881601
chr5	154912970	154912973	Q8TEQ6	0	-	154912970	154912973	102,0,51	1	3	0	.	Interaction with U4 snRNA and with the 7-methylguanosine cap of RNA molecules. Pubmed:27834343, Pubmed:27881601
chr5	154917115	154917118	Q8TEQ6	0	-	154917115	154917118	102,0,51	1	3	0	.	Interaction with U4 snRNA. Pubmed:27881601
chr5	154917935	154917938	Q8TEQ6	0	-	154917935	154917938	102,0,51	1	3	0	.	Interaction with U4 snRNA. Pubmed:27881601
chr5	154921382	154921385	Q8TEQ6	0	-	154921382	154921385	102,0,51	1	3	0	.	Interaction with U4 snRNA and with the 7-methylguanosine cap of RNA molecules. Pubmed:27834343, Pubmed:27881601
chr5	154921394	154921397	Q8TEQ6	0	-	154921394	154921397	102,0,51	1	3	0	.	Interaction with U4 snRNA. Pubmed:27881601
chr5	154925876	154925879	Q8TEQ6	0	-	154925876	154925879	102,0,51	1	3	0	.	Interaction with U4 snRNA. Pubmed:27881601
chr5	154925888	154925891	Q8TEQ6	0	-	154925888	154925891	102,0,51	1	3	0	.	Interaction with U4 snRNA. Pubmed:27834343, Pubmed:27881601
chr5	154926011	154926014	Q8TEQ6	0	-	154926011	154926014	102,0,51	1	3	0	.	Interaction with U4 snRNA. Pubmed:27834343, Pubmed:27881600, Pubmed:27881601
chr5	154927387	154927390	Q8TEQ6	0	-	154927387	154927390	102,0,51	1	3	0	.	Interaction with U4 snRNA. Pubmed:27834343, Pubmed:27881600, Pubmed:27881601
chr5	154927459	154927462	Q8TEQ6	0	-	154927459	154927462	102,0,51	1	3	0	.	Interaction with U4 snRNA. Pubmed:27834343, Pubmed:27881601
chr5	154928588	154928591	Q8TEQ6	0	-	154928588	154928591	102,0,51	1	3	0	.	Interaction with U4 snRNA. Pubmed:27834343, Pubmed:27881601
chr5	154938034	154938037	Q8TEQ6	0	-	154938034	154938037	102,0,51	1	3	0	.	Interaction with U4 snRNA. Pubmed:27834343, Pubmed:27881600, Pubmed:27881601
chr5	159073433	159073436	Q9UH73	0	-	159073433	159073436	102,0,51	1	3	0	.	Interaction with DNA.
chr5	159073460	159073463	Q9UH73	0	-	159073460	159073463	102,0,51	1	3	0	.	Interaction with DNA.
chr5	168090639	168090645	Q9NT68	0	+	168090639	168090645	102,0,51	1	6	0	.	Cleavage.
chr5	171391328	171391331	P06748	0	+	171391328	171391331	102,0,51	1	3	0	.	Interaction between pentamers.
chr5	171391403	171391406	P06748	0	+	171391403	171391406	102,0,51	1	3	0	.	Interaction between pentamers.
chr5	171392976	171400156	P06748	0	+	171392976	171400156	102,0,51	1	7180	0	.	Breakpoint for translocation to form NPM1-MLF1. Pubmed:8570204
chr5	173945100	173945103	Q17RY0	0	+	173945100	173945103	102,0,51	1	3	0	.	RNA-binding.
chr5	173951838	173951841	Q17RY0	0	+	173951838	173951841	102,0,51	1	3	0	.	Important for the positionning of RRM1 relative to RRM2. Pubmed:24990967
chr5	175683524	175683527	P25021	0	+	175683524	175683527	102,0,51	1	3	0	.	Essential for histamine binding.
chr5	175683788	175683791	P25021	0	+	175683788	175683791	102,0,51	1	3	0	.	Essential for tiotidine binding and implicated in H2 selectivity.
chr5	175683800	175683803	P25021	0	+	175683800	175683803	102,0,51	1	3	0	.	Implicated in histamine binding.
chr5	176874098	176874104	Q6ZN44	0	+	176874098	176874104	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr5	179878308	179878311	Q66K14	0	-	179878308	179878311	102,0,51	1	3	0	.	Glutamine finger.
chr5	179878425	179878428	Q66K14	0	-	179878425	179878428	102,0,51	1	3	0	.	Arginine finger.
chr6	2833712	2833718	P30740	0	-	2833712	2833718	102,0,51	1	6	0	.	Reactive bond 2.
chr6	2833715	2833721	P30740	0	-	2833715	2833721	102,0,51	1	6	0	.	Reactive bond 1.
chr6	2890270	2890276	P50453	0	-	2890270	2890276	102,0,51	1	6	0	.	Reactive bond.
chr6	2948402	2948408	P35237	0	-	2948402	2948408	102,0,51	1	6	0	.	Reactive bond.
chr6	3104278	3104284	Q13546	0	+	3104278	3104284	102,0,51	1	6	0	.	Cleavage; by caspase-8.
chr6	3129083	3129086	Q86WA6	0	+	3129083	3129086	102,0,51	1	3	0	.	Binding of alpha-amino group of substrate.
chr6	4119230	4119233	O75521	0	-	4119230	4119233	102,0,51	1	3	0	.	Important for catalytic activity.
chr6	11104257	11104263	P60508	0	-	11104257	11104263	102,0,51	1	6	0	.	Cleavage.
chr6	12292492	12292498	P05305	0	+	12292492	12292498	102,0,51	1	6	0	.	Cleavage; by KEL. Pubmed:10438732
chr6	24504871	24504874	P51649	0	+	24504871	24504874	102,0,51	1	3	0	.	Transition state stabilizer.
chr6	26107925	26107928	P22492	0	-	26107925	26107928	102,0,51	1	3	0	.	Important for nucleosome binding properties.
chr6	28904652	28907228	P14373	0	-	28904652	28907228	102,0,51	1	2576	0	.	Breakpoint for translocation to form the TRIM27/RET oncogene.
chr6	28904654	28907230	P14373	0	-	28904654	28907230	102,0,51	1	2576	0	.	Breakpoint for translocation to form the TRIM27/RET oncogene.
chr6	28904663	28907239	P14373	0	-	28904663	28907239	102,0,51	1	2576	0	.	Breakpoint for translocation to form the TRIM27/RET oncogene.
chr6	28905477	28908053	P14373	0	-	28905477	28908053	102,0,51	1	2576	0	.	Breakpoint for translocation to form the TRIM27/RET oncogene.
chr6	28905530	28908106	P14373	0	-	28905530	28908106	102,0,51	1	2576	0	.	Breakpoint for translocation to form the TRIM27/RET oncogene.
chr6	29555832	29555838	O15205	0	-	29555832	29555838	102,0,51	1	6	0	.	Activation by thioester intermediate formation with UBA6.
chr6	29555882	29555888	O15205	0	-	29555882	29555888	102,0,51	1	6	0	.	Activation by thioester intermediate formation with UBA6.
chr6	29669895	29669898	Q9NU63	0	-	29669895	29669898	102,0,51	1	3	0	.	Crucial for 5-methylcytosine recognition.
chr6	29672824	29672827	Q9NU63	0	-	29672824	29672827	102,0,51	1	3	0	.	Crucial for 5-methylcytosine recognition.
chr6	29673084	29673087	Q9NU63	0	-	29673084	29673087	102,0,51	1	3	0	.	Crucial for 5-methylcytosine recognition.
chr6	29673211	29673214	Q9NU63	0	-	29673211	29673214	102,0,51	1	3	0	.	Crucial for 5-methylcytosine recognition.
chr6	29673256	29673259	Q9NU63	0	-	29673256	29673259	102,0,51	1	3	0	.	Crucial for 5-methylcytosine recognition.
chr6	29673303	29673306	Q9NU63	0	-	29673303	29673306	102,0,51	1	3	0	.	Crucial for 5-methylcytosine recognition.
chr6	29673800	29673803	Q9NU63	0	-	29673800	29673803	102,0,51	1	3	0	.	Crucial for 5-methylcytosine recognition.
chr6	30617133	30617136	Q5SQI0	0	+	30617133	30617136	102,0,51	1	3	0	.	Crucial for catalytic activity. Pubmed:23071318
chr6	30617481	30617484	Q5SQI0	0	+	30617481	30617484	102,0,51	1	3	0	.	Crucial for catalytic activity. Pubmed:23071318
chr6	30617875	30617878	Q5SQI0	0	+	30617875	30617878	102,0,51	1	3	0	.	Crucial for catalytic activity. Pubmed:23071318
chr6	30619861	30619864	Q5SQI0	0	+	30619861	30619864	102,0,51	1	3	0	.	Crucial for catalytic activity. Pubmed:23071318
chr6	30627638	30627641	Q5SQI0	0	+	30627638	30627641	102,0,51	1	3	0	.	Crucial for catalytic activity. Pubmed:23071318
chr6	30672274	30672277	Q5SQI0	0	+	30672274	30672277	102,0,51	1	3	0	.	Crucial for catalytic activity. Pubmed:23071318
chr6	30706093	30706096	Q5SQI0	0	+	30706093	30706096	102,0,51	1	3	0	.	Crucial for catalytic activity. Pubmed:23071318
chr6	30987678	30988002	Q5SSG8	0	+	30987678	30988002	102,0,51	1	324	0	.	Cleavage.
chr6	31557983	31557989	P01375	0	+	31557983	31557989	102,0,51	1	6	0	.	Cleavage; by SPPL2A or SPPL2B.
chr6	31557995	31558001	P01375	0	+	31557995	31558001	102,0,51	1	6	0	.	Cleavage; by SPPL2A or SPPL2B.
chr6	31558025	31558031	P01375	0	+	31558025	31558031	102,0,51	1	6	0	.	Cleavage; by SPPL2A or SPPL2B.
chr6	31558031	31558037	P01375	0	+	31558031	31558037	102,0,51	1	6	0	.	Cleavage; by SPPL2A or SPPL2B.
chr6	31558712	31558718	P01375	0	+	31558712	31558718	102,0,51	1	6	0	.	Cleavage; by ADAM17.
chr6	31563249	31563255	P01375	0	+	31563249	31563255	102,0,51	1	6	0	.	Cleavage; by SPPL2A or SPPL2B.
chr6	31563261	31563267	P01375	0	+	31563261	31563267	102,0,51	1	6	0	.	Cleavage; by SPPL2A or SPPL2B.
chr6	31563291	31563297	P01375	0	+	31563291	31563297	102,0,51	1	6	0	.	Cleavage; by SPPL2A or SPPL2B.
chr6	31563297	31563303	P01375	0	+	31563297	31563303	102,0,51	1	6	0	.	Cleavage; by SPPL2A or SPPL2B.
chr6	31563978	31563984	P01375	0	+	31563978	31563984	102,0,51	1	6	0	.	Cleavage; by ADAM17.
chr6	31566069	31566075	P01375	0	+	31566069	31566075	102,0,51	1	6	0	.	Cleavage; by SPPL2A or SPPL2B.
chr6	31566081	31566087	P01375	0	+	31566081	31566087	102,0,51	1	6	0	.	Cleavage; by SPPL2A or SPPL2B.
chr6	31566111	31566117	P01375	0	+	31566111	31566117	102,0,51	1	6	0	.	Cleavage; by SPPL2A or SPPL2B.
chr6	31566117	31566123	P01375	0	+	31566117	31566123	102,0,51	1	6	0	.	Cleavage; by SPPL2A or SPPL2B.
chr6	31566588	31566594	P01375	0	+	31566588	31566594	102,0,51	1	6	0	.	Cleavage; by SPPL2A or SPPL2B.
chr6	31566600	31566606	P01375	0	+	31566600	31566606	102,0,51	1	6	0	.	Cleavage; by SPPL2A or SPPL2B.
chr6	31566630	31566636	P01375	0	+	31566630	31566636	102,0,51	1	6	0	.	Cleavage; by SPPL2A or SPPL2B.
chr6	31566636	31566642	P01375	0	+	31566636	31566642	102,0,51	1	6	0	.	Cleavage; by SPPL2A or SPPL2B.
chr6	31566800	31566806	P01375	0	+	31566800	31566806	102,0,51	1	6	0	.	Cleavage; by ADAM17.
chr6	31567317	31567323	P01375	0	+	31567317	31567323	102,0,51	1	6	0	.	Cleavage; by ADAM17.
chr6	31575843	31575849	P01375	0	+	31575843	31575849	102,0,51	1	6	0	.	Cleavage; by SPPL2A or SPPL2B.
chr6	31575855	31575861	P01375	0	+	31575855	31575861	102,0,51	1	6	0	.	Cleavage; by SPPL2A or SPPL2B.
chr6	31575885	31575891	P01375	0	+	31575885	31575891	102,0,51	1	6	0	.	Cleavage; by SPPL2A or SPPL2B.
chr6	31575891	31575897	P01375	0	+	31575891	31575897	102,0,51	1	6	0	.	Cleavage; by SPPL2A or SPPL2B.
chr6	31576572	31576578	P01375	0	+	31576572	31576578	102,0,51	1	6	0	.	Cleavage; by ADAM17.
chr6	31615291	31615297	P01375	0	+	31615291	31615297	102,0,51	1	6	0	.	Cleavage; by SPPL2A or SPPL2B.
chr6	31615303	31615309	P01375	0	+	31615303	31615309	102,0,51	1	6	0	.	Cleavage; by SPPL2A or SPPL2B.
chr6	31615333	31615339	P01375	0	+	31615333	31615339	102,0,51	1	6	0	.	Cleavage; by SPPL2A or SPPL2B.
chr6	31615339	31615345	P01375	0	+	31615339	31615345	102,0,51	1	6	0	.	Cleavage; by SPPL2A or SPPL2B.
chr6	31616020	31616026	P01375	0	+	31616020	31616026	102,0,51	1	6	0	.	Cleavage; by ADAM17.
chr6	31627832	31627838	P46379	0	-	31627832	31627838	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr6	31630651	31630657	P46379	0	-	31630651	31630657	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr6	31631172	31631178	P46379	0	-	31631172	31631178	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr6	31640426	31640432	P46379	0	-	31640426	31640432	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr6	31652148	31652154	P01375	0	+	31652148	31652154	102,0,51	1	6	0	.	Cleavage; by SPPL2A or SPPL2B.
chr6	31652160	31652166	P01375	0	+	31652160	31652166	102,0,51	1	6	0	.	Cleavage; by SPPL2A or SPPL2B.
chr6	31652190	31652196	P01375	0	+	31652190	31652196	102,0,51	1	6	0	.	Cleavage; by SPPL2A or SPPL2B.
chr6	31652196	31652202	P01375	0	+	31652196	31652202	102,0,51	1	6	0	.	Cleavage; by SPPL2A or SPPL2B.
chr6	31652877	31652883	P01375	0	+	31652877	31652883	102,0,51	1	6	0	.	Cleavage; by ADAM17.
chr6	31853005	31853008	Q53GD3	0	-	31853005	31853008	102,0,51	1	3	0	.	Breakpoint for translocation with NEU1.
chr6	31858368	31858371	Q53GD3	0	-	31858368	31858371	102,0,51	1	3	0	.	Breakpoint for translocation with NEU1.
chr6	31861201	31861204	Q53GD3	0	-	31861201	31861204	102,0,51	1	3	0	.	Breakpoint for translocation with NEU1.
chr6	31870824	31870827	Q53GD3	0	-	31870824	31870827	102,0,51	1	3	0	.	Breakpoint for translocation with NEU1.
chr6	31996096	31996099	P0C0L4	0	+	31996096	31996099	102,0,51	1	3	0	.	Responsible for effective binding to form amide bonds with immune aggregates or protein antigens.
chr6	32066411	32066417	Q99941	0	-	32066411	32066417	102,0,51	1	6	0	.	Cleavage; by PS1.
chr6	32067231	32067234	Q99941	0	-	32067231	32067234	102,0,51	1	3	0	.	Important for cleavage by PS2.
chr6	32067240	32067243	Q99941	0	-	32067240	32067243	102,0,51	1	3	0	.	Important for cleavage by PS2.
chr6	32093732	32093738	Q99941	0	-	32093732	32093738	102,0,51	1	6	0	.	Cleavage; by PS1.
chr6	32094552	32094555	Q99941	0	-	32094552	32094555	102,0,51	1	3	0	.	Important for cleavage by PS2.
chr6	32094561	32094564	Q99941	0	-	32094561	32094564	102,0,51	1	3	0	.	Important for cleavage by PS2.
chr6	32117959	32117965	Q99941	0	-	32117959	32117965	102,0,51	1	6	0	.	Cleavage; by PS1.
chr6	32118779	32118782	Q99941	0	-	32118779	32118782	102,0,51	1	3	0	.	Important for cleavage by PS2.
chr6	32118788	32118791	Q99941	0	-	32118788	32118791	102,0,51	1	3	0	.	Important for cleavage by PS2.
chr6	32194386	32194392	Q99941	0	-	32194386	32194392	102,0,51	1	6	0	.	Cleavage; by PS1.
chr6	32195206	32195209	Q99941	0	-	32195206	32195209	102,0,51	1	3	0	.	Important for cleavage by PS2.
chr6	32195215	32195218	Q99941	0	-	32195215	32195218	102,0,51	1	3	0	.	Important for cleavage by PS2.
chr6	32765335	32765341	P28062	0	-	32765335	32765341	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr6	32771712	32771718	P28062	0	-	32771712	32771718	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr6	32776604	32778458	P28065	0	+	32776604	32778458	102,0,51	1	1854	0	.	Cleavage; by autolysis.
chr6	32782981	32784835	P28065	0	+	32782981	32784835	102,0,51	1	1854	0	.	Cleavage; by autolysis.
chr6	32832263	32834118	P28065	0	+	32832263	32834118	102,0,51	1	1855	0	.	Cleavage; by autolysis.
chr6	32843017	32843023	P28062	0	-	32843017	32843023	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr6	32854286	32856140	P28065	0	+	32854286	32856140	102,0,51	1	1854	0	.	Cleavage; by autolysis.
chr6	32876493	32876499	P28062	0	-	32876493	32876499	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr6	32882289	32882295	P28062	0	-	32882289	32882295	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr6	32933734	32933740	P28062	0	-	32933734	32933740	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr6	32996777	32996783	P28062	0	-	32996777	32996783	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr6	33008046	33009900	P28065	0	+	33008046	33009900	102,0,51	1	1854	0	.	Cleavage; by autolysis.
chr6	33225756	33225759	O15533	0	-	33225756	33225759	102,0,51	1	3	0	.	May be involved in interaction with TAP.
chr6	33232981	33232984	O15533	0	-	33232981	33232984	102,0,51	1	3	0	.	May be involved in interaction with TAP.
chr6	33282077	33282080	O15533	0	-	33282077	33282080	102,0,51	1	3	0	.	May be involved in interaction with TAP.
chr6	43142022	43142028	Q13308	0	+	43142022	43142028	102,0,51	1	6	0	.	Cleavage; by MMP14.
chr6	44419595	44419598	Q99459	0	+	44419595	44419598	102,0,51	1	3	0	.	Breakpoint for translocation.
chr6	46858929	46858935	Q8IZF2	0	-	46858929	46858935	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr6	46881587	46881593	Q8IZF2	0	-	46881587	46881593	102,0,51	1	6	0	.	Cleavage.
chr6	46900029	46900035	Q8IZF2	0	-	46900029	46900035	102,0,51	1	6	0	.	Cleavage; by furin.
chr6	54308694	54308700	Q9UJW2	0	+	54308694	54308700	102,0,51	1	6	0	.	Cleavage; by furin.
chr6	55174716	55174719	O43614	0	+	55174716	55174719	102,0,51	1	3	0	.	Important for responses to orexin. Pubmed:26950369
chr6	70861704	70861707	Q9NPZ5	0	-	70861704	70861707	102,0,51	1	3	0	.	Interaction with galactose moiety of substrate glycoprotein.
chr6	70894209	70894212	Q9NPZ5	0	-	70894209	70894212	102,0,51	1	3	0	.	Interaction with galactose moiety of substrate glycoprotein.
chr6	77462338	77462341	P28222	0	-	77462338	77462341	102,0,51	1	3	0	.	Important for species-specific agonist sensitivity.
chr6	83253635	83253638	P48163	0	-	83253635	83253638	102,0,51	1	3	0	.	Important for activity.
chr6	85467071	85467074	P21589	0	+	85467071	85467074	102,0,51	1	3	0	.	Transition state stabilizer.
chr6	85467080	85467083	P21589	0	+	85467080	85467083	102,0,51	1	3	0	.	Transition state stabilizer.
chr6	109442797	109442800	O60906	0	+	109442797	109442800	102,0,51	1	3	0	.	Important for substrate recognition.
chr6	110888857	110888863	P17707	0	+	110888857	110888863	102,0,51	1	6	0	.	Cleavage (non-hydrolytic); by autolysis. Pubmed:2687270, Pubmed:2460457
chr6	117321392	117324335	P08922	0	-	117321392	117324335	102,0,51	1	2943	0	.	Breakpoint for translocation to form GOPC-ROS1 fusion protein.
chr6	117324413	117326227	P08922	0	-	117324413	117326227	102,0,51	1	1814	0	.	Breakpoint for translocation to form SLC34A2-ROS1 and CD74-ROS1 fusion proteins.
chr6	117563382	117566857	Q9HD26	0	-	117563382	117566857	102,0,51	1	3475	0	.	Breakpoint for translocation to form GOPC-ROS1 fusion protein.
chr6	118469300	118470539	Q5SZL2	0	-	118469300	118470539	102,0,51	1	1239	0	.	Breakpoint for translocation to form the CEP85L-PDGFRB fusion protein.
chr6	122717860	122717863	Q5T0Z6	0	+	122717860	122717863	102,0,51	1	3	0	.	Important for inhibition.
chr6	122717860	122717863	Q9C010	0	+	122717860	122717863	102,0,51	1	3	0	.	Important for inhibition.
chr6	122717869	122717872	Q5T0Z6	0	+	122717869	122717872	102,0,51	1	3	0	.	Important for inhibition.
chr6	122717869	122717872	Q9C010	0	+	122717869	122717872	102,0,51	1	3	0	.	Important for inhibition.
chr6	122717872	122717875	Q5T0Z6	0	+	122717872	122717875	102,0,51	1	3	0	.	Important for inhibition.
chr6	122717872	122717875	Q9C010	0	+	122717872	122717875	102,0,51	1	3	0	.	Important for inhibition.
chr6	124355344	124658188	Q5VXU1	0	+	124355344	124658188	102,0,51	1	302844	0	.	Breakpoint for interstitial deletion to form SUSP1-NKAIN2.
chr6	128067743	128067749	Q15262	0	-	128067743	128067749	102,0,51	1	6	0	.	Cleavage.
chr6	128071879	128071885	Q15262	0	-	128071879	128071885	102,0,51	1	6	0	.	Cleavage.
chr6	131847838	131847844	P22413	0	+	131847838	131847844	102,0,51	1	6	0	.	Cleavage.
chr6	131890475	131890478	P22413	0	+	131890475	131890478	102,0,51	1	3	0	.	Essential for catalytic activity.
chr6	134939392	134939395	Q9H2A2	0	-	134939392	134939395	102,0,51	1	3	0	.	Transition state stabilizer.
chr6	137154959	137154962	Q969J5	0	-	137154959	137154962	102,0,51	1	3	0	.	Critical for IL22-binding.
chr6	137155115	137155118	Q969J5	0	-	137155115	137155118	102,0,51	1	3	0	.	Critical for IL22-binding.
chr6	137878759	137878765	P21580	0	+	137878759	137878765	102,0,51	1	6	0	.	Cleavage; by MALT1.
chr6	138773899	138776081	Q8IWP9	0	+	138773899	138776081	102,0,51	1	2182	0	.	Breakpoint for translocation to form NUP98-CCDC28A.
chr6	142393932	142393938	Q86SQ4	0	+	142393932	142393938	102,0,51	1	6	0	.	Cleavage; by furin like-convertase. Pubmed:15189448
chr6	142411387	142411393	Q86SQ4	0	+	142411387	142411393	102,0,51	1	6	0	.	Cleavage. Pubmed:15189448
chr6	143502435	143502438	Q9BTY2	0	-	143502435	143502438	102,0,51	1	3	0	.	May be important for catalysis.
chr6	145627424	145627427	O95278	0	-	145627424	145627427	102,0,51	1	3	0	.	Required for homodimerization.
chr6	159811759	159811762	Q8NA58	0	+	159811759	159811762	102,0,51	1	3	0	.	Interaction with poly(A).
chr6	160143611	160143614	O15245	0	+	160143611	160143614	102,0,51	1	3	0	.	Involved in affinity and selectivity of cations as well as in translocation.
chr6	160242328	160242331	O15244	0	-	160242328	160242331	102,0,51	1	3	0	.	Involved in recognition of organic cations and participates in structural changes that occur during translocation of organic cations.
chr6	160707745	160707751	P00747	0	+	160707745	160707751	102,0,51	1	6	0	.	Cleavage; by stromelysin-1.
chr6	160731189	160731195	P00747	0	+	160731189	160731195	102,0,51	1	6	0	.	Cleavage; by stromelysin-19.
chr6	160736942	160736948	P00747	0	+	160736942	160736948	102,0,51	1	6	0	.	Cleavage; by plasminogen activator.
chr6	163478782	163478785	Q96PU8	0	+	163478782	163478785	102,0,51	1	3	0	.	Involved in RNA binding. Pubmed:23630077
chr6	163478851	163478854	Q96PU8	0	+	163478851	163478854	102,0,51	1	3	0	.	Involved in RNA binding. Pubmed:23630077
chr6	163478863	163478866	Q96PU8	0	+	163478863	163478866	102,0,51	1	3	0	.	Involved in RNA binding. Pubmed:23630077
chr6	163478881	163478884	Q96PU8	0	+	163478881	163478884	102,0,51	1	3	0	.	Involved in RNA binding. Pubmed:23630077
chr6	163562002	163562005	Q96PU8	0	+	163562002	163562005	102,0,51	1	3	0	.	Involved in RNA binding. Pubmed:23630077
chr6	163562011	163562014	Q96PU8	0	+	163562011	163562014	102,0,51	1	3	0	.	Involved in RNA binding. Pubmed:23630077
chr6	167010890	167013510	O95684	0	+	167010890	167013510	102,0,51	1	2620	0	.	Breakpoint for translocation to form FGFR1OP-FGFR1 or FGFR1-FGFR1OP fusion proteins.
chr6	167827207	167827210	P55196	0	+	167827207	167827210	102,0,51	1	3	0	.	Breakpoint for translocation to form KMT2A/MLL1-AFDN.
chr7	2520116	2520122	Q8NES3	0	+	2520116	2520122	102,0,51	1	6	0	.	Cleavage; by furin-like protease.
chr7	6054582	6054585	Q9BQI3	0	-	6054582	6054585	102,0,51	1	3	0	.	Heme-binding.
chr7	16308522	16308525	A4D126	0	-	16308522	16308525	102,0,51	1	3	0	.	Positions substrate for the nucleophilic attack.
chr7	16376160	16376163	A4D126	0	-	16376160	16376163	102,0,51	1	3	0	.	Positions substrate for the nucleophilic attack.
chr7	16421124	16421127	A4D126	0	-	16421124	16421127	102,0,51	1	3	0	.	Transition state stabilizer.
chr7	16421145	16421148	A4D126	0	-	16421145	16421148	102,0,51	1	3	0	.	Transition state stabilizer.
chr7	24285327	24285333	P01303	0	+	24285327	24285333	102,0,51	1	6	0	.	Cleavage; by FAP. Pubmed:21314817
chr7	27164965	27164971	P31269	0	-	27164965	27164971	102,0,51	1	6	0	.	Breakpoint for translocation to form MSI2/HOXA9 fusion protein.
chr7	27840862	27840868	Q86VZ6	0	-	27840862	27840868	102,0,51	1	6	0	.	Breakpoint for translocation to form JAZF1-SUZ12 oncogene.
chr7	30912074	30912077	P29972	0	+	30912074	30912077	102,0,51	1	3	0	.	Substrate discrimination.
chr7	30922218	30922221	P29972	0	+	30922218	30922221	102,0,51	1	3	0	.	Substrate discrimination.
chr7	30922578	30922581	P29972	0	+	30922578	30922581	102,0,51	1	3	0	.	Hg(2+)-sensitive residue.
chr7	30922596	30922599	P29972	0	+	30922596	30922599	102,0,51	1	3	0	.	Substrate discrimination.
chr7	44060080	44060086	Q9UJU6	0	+	44060080	44060086	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr7	44064868	44064871	P15259	0	-	44064868	44064871	102,0,51	1	3	0	.	Transition state stabilizer.
chr7	44073797	44073800	Q9NP87	0	-	44073797	44073800	102,0,51	1	3	0	.	Responsible for the low discrimination between dNTP and rNTP.
chr7	50382592	50382595	Q13422	0	+	50382592	50382595	102,0,51	1	3	0	.	Required for both pericentromeric heterochromatin localization and complete DNA binding.
chr7	50382601	50382604	Q13422	0	+	50382601	50382604	102,0,51	1	3	0	.	Required for both pericentromeric heterochromatin localization and complete DNA binding.
chr7	50382679	50382682	Q13422	0	+	50382679	50382682	102,0,51	1	3	0	.	Required for both pericentromeric heterochromatin localization and DNA binding.
chr7	55201286	55201289	P00533	0	+	55201286	55201289	102,0,51	1	3	0	.	Important for interaction with PIK3C2B.
chr7	64991610	64991616	Q14264	0	-	64991610	64991616	102,0,51	1	6	0	.	Cleavage.
chr7	65873518	65873521	Q8N0U8	0	+	65873518	65873521	102,0,51	1	3	0	.	Important for the reduction of the redox-active cysteines.
chr7	65873542	65873545	Q8N0U8	0	+	65873542	65873545	102,0,51	1	3	0	.	Important for the reduction of the redox-active cysteines.
chr7	66240899	66240902	O60507	0	+	66240899	66240902	102,0,51	1	3	0	.	Transition state stabilizer.
chr7	66286520	66286523	O60507	0	+	66286520	66286523	102,0,51	1	3	0	.	Transition state stabilizer.
chr7	76329924	76329927	P61981	0	-	76329924	76329927	102,0,51	1	3	0	.	Interaction with phosphoserine on interacting protein.
chr7	76330149	76330152	P61981	0	-	76330149	76330152	102,0,51	1	3	0	.	Interaction with phosphoserine on interacting protein.
chr7	80674114	80674117	P16671	0	+	80674114	80674117	102,0,51	1	3	0	.	Critical for TLR4-TLR6 dimerization and signaling. Pubmed:20037584
chr7	91873743	91873746	Q99551	0	-	91873743	91873746	102,0,51	1	3	0	.	Interaction with DNA.
chr7	91873929	91873932	Q99551	0	-	91873929	91873932	102,0,51	1	3	0	.	Interaction with DNA.
chr7	91874064	91874067	Q99551	0	-	91874064	91874067	102,0,51	1	3	0	.	Interaction with DNA.
chr7	91874187	91874190	Q99551	0	-	91874187	91874190	102,0,51	1	3	0	.	Interaction with DNA.
chr7	91874307	91874310	Q99551	0	-	91874307	91874310	102,0,51	1	3	0	.	Interaction with DNA.
chr7	92469427	92469433	Q9UQF0	0	-	92469427	92469433	102,0,51	1	6	0	.	Cleavage.
chr7	93887384	93887390	P48307	0	-	93887384	93887390	102,0,51	1	6	0	.	Reactive bond.
chr7	93889170	93889176	P48307	0	-	93889170	93889176	102,0,51	1	6	0	.	Reactive bond.
chr7	93890266	93890272	P48307	0	-	93890266	93890272	102,0,51	1	6	0	.	Reactive bond.
chr7	95528090	95528093	Q9Y574	0	+	95528090	95528093	102,0,51	1	3	0	.	Essential for interaction with HIF1AN.
chr7	95585691	95585694	Q16654	0	-	95585691	95585694	102,0,51	1	3	0	.	Interaction with the other subunit in the homodimer.
chr7	95592805	95592808	Q16654	0	-	95592805	95592808	102,0,51	1	3	0	.	Interaction with the other subunit in the homodimer.
chr7	95592817	95592820	Q16654	0	-	95592817	95592820	102,0,51	1	3	0	.	Interaction with the other subunit in the homodimer.
chr7	97733773	97733779	P20366	0	+	97733773	97733779	102,0,51	1	6	0	.	Cleavage; by FAP. Pubmed:21314817
chr7	97855394	97855397	P08243	0	-	97855394	97855397	102,0,51	1	3	0	.	Important for beta-aspartyl-AMP intermediate formation.
chr7	100606548	100606554	Q15113	0	+	100606548	100606554	102,0,51	1	6	0	.	Cleavage. Pubmed:10625689
chr7	100606551	100606557	Q15113	0	+	100606551	100606557	102,0,51	1	6	0	.	Cleavage. Pubmed:10625689
chr7	100606566	100606572	Q15113	0	+	100606566	100606572	102,0,51	1	6	0	.	Cleavage. Pubmed:10625689
chr7	100606584	100606590	Q15113	0	+	100606584	100606590	102,0,51	1	6	0	.	Cleavage. Pubmed:10625689
chr7	100606596	100606602	Q15113	0	+	100606596	100606602	102,0,51	1	6	0	.	Cleavage. Pubmed:10625689
chr7	101012299	101012305	Q9UKN1	0	+	101012299	101012305	102,0,51	1	6	0	.	Cleavage.
chr7	101050487	101050493	Q685J3	0	+	101050487	101050493	102,0,51	1	6	0	.	Cleavage.
chr7	101137017	101137023	P05121	0	+	101137017	101137023	102,0,51	1	6	0	.	Reactive bond.
chr7	101237377	101237380	P56746	0	-	101237377	101237380	102,0,51	1	3	0	.	Important for the formation of tight-junction strand-like structures.
chr7	101237389	101237392	P56746	0	-	101237389	101237392	102,0,51	1	3	0	.	Important for Na(+)-selective paracellular ion transport.
chr7	101237416	101237419	P56746	0	-	101237416	101237419	102,0,51	1	3	0	.	Important for Na(+)-selective paracellular ion transport.
chr7	105142305	105142311	P78362	0	-	105142305	105142311	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr7	105167437	105167443	P78362	0	-	105167437	105167443	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr7	107918028	107918031	P09622	0	+	107918028	107918031	102,0,51	1	3	0	.	Important for interaction with PDHX and activity of multienzyme pyruvate dehydrogenase complex. Pubmed:20385101
chr7	107919051	107919054	P09622	0	+	107919051	107919054	102,0,51	1	3	0	.	Important for interaction with PDHX and activity of multienzyme pyruvate dehydrogenase complex. Pubmed:20385101
chr7	116700002	116700008	P08581	0	+	116700002	116700008	102,0,51	1	6	0	.	Cleavage.
chr7	116771967	116771970	P08581	0	+	116771967	116771970	102,0,51	1	3	0	.	Required for ligand-induced CBL-mediated ubiquitination. Pubmed:12244174
chr7	116771985	116774882	P08581	0	+	116771985	116774882	102,0,51	1	2897	0	.	Breakpoint for translocation to form TPR-MET oncogene.
chr7	122058937	122058940	P23471	0	+	122058937	122058940	102,0,51	1	3	0	.	Ancestral active site.
chr7	124853111	124853114	Q9NUX5	0	-	124853111	124853114	102,0,51	1	3	0	.	DNA binding.
chr7	134451585	134451588	A0A024R7A8	0	-	134451585	134451588	102,0,51	1	3	0	.	Lowers pKa of active site Tyr.
chr7	134451585	134451588	E9PCX2	0	-	134451585	134451588	102,0,51	1	3	0	.	Lowers pKa of active site Tyr.
chr7	134451585	134451588	P15121	0	-	134451585	134451588	102,0,51	1	3	0	.	Lowers pKa of active site Tyr.
chr7	134530807	134530810	O60218	0	+	134530807	134530810	102,0,51	1	3	0	.	Lowers pKa of active site Tyr.
chr7	134661591	134661594	P07738	0	+	134661591	134661594	102,0,51	1	3	0	.	Not glycated. Pubmed:9832630
chr7	134661642	134661645	P07738	0	+	134661642	134661645	102,0,51	1	3	0	.	Not glycated. Pubmed:9832630
chr7	134661933	134661936	P07738	0	+	134661933	134661936	102,0,51	1	3	0	.	Not glycated. Pubmed:9832630
chr7	134662047	134662050	P07738	0	+	134662047	134662050	102,0,51	1	3	0	.	Not glycated. Pubmed:9832630
chr7	134662068	134662071	P07738	0	+	134662068	134662071	102,0,51	1	3	0	.	Transition state stabilizer. Pubmed:17052986
chr7	134678986	134678989	P07738	0	+	134678986	134678989	102,0,51	1	3	0	.	Not glycated. Pubmed:9832630
chr7	134678989	134678992	P07738	0	+	134678989	134678992	102,0,51	1	3	0	.	Not glycated. Pubmed:9832630
chr7	134679007	134679010	P07738	0	+	134679007	134679010	102,0,51	1	3	0	.	Not glycated. Pubmed:9832630
chr7	134679022	134679025	P07738	0	+	134679022	134679025	102,0,51	1	3	0	.	Not glycated. Pubmed:9832630
chr7	134679025	134679028	P07738	0	+	134679025	134679028	102,0,51	1	3	0	.	Not glycated. Pubmed:9832630
chr7	138554861	138554867	O15164	0	+	138554861	138554867	102,0,51	1	6	0	.	Breakpoint for translocation to form TRIM24-RET oncogene.
chr7	138579425	138579428	O15164	0	+	138579425	138579428	102,0,51	1	3	0	.	Interaction with histone H3 that is not methylated at 'Lys-4' (H3K4me0).
chr7	138852266	138861141	Q9HCM3	0	-	138852266	138861141	102,0,51	1	8875	0	.	Breakpoint for translocation to form KIAA1549-BRAF fusion protein.
chr7	138861453	138867977	Q9HCM3	0	-	138861453	138867977	102,0,51	1	6524	0	.	Breakpoint for translocation to form KIAA1549-BRAF fusion protein.
chr7	139583826	139583832	Q9H2X6	0	-	139583826	139583832	102,0,51	1	6	0	.	Cleavage; by CASP6.
chr7	139584009	139584015	Q9H2X6	0	-	139584009	139584015	102,0,51	1	6	0	.	Cleavage; by CASP6.
chr7	140781690	140783023	P15056	0	-	140781690	140783023	102,0,51	1	1333	0	.	Breakpoint for translocation to form KIAA1549-BRAF fusion protein.
chr7	140787581	140794310	P15056	0	-	140787581	140794310	102,0,51	1	6729	0	.	Breakpoint for translocation to form KIAA1549-BRAF fusion protein.
chr7	142752555	142752558	P07477	0	+	142752555	142752558	102,0,51	1	3	0	.	Required for specificity.
chr7	142774043	142774046	P07478	0	+	142774043	142774046	102,0,51	1	3	0	.	Required for specificity.
chr7	142793272	142793275	P07477	0	+	142793272	142793275	102,0,51	1	3	0	.	Required for specificity.
chr7	142835136	142835139	P07478	0	+	142835136	142835139	102,0,51	1	3	0	.	Required for specificity.
chr7	150520280	150520283	Q8NHV1	0	+	150520280	150520283	102,0,51	1	3	0	.	Important for catalytic activity.
chr7	151048960	151048963	Q9UHC3	0	+	151048960	151048963	102,0,51	1	3	0	.	Potassium ion selectivity and permeability.
chr7	155803478	155803481	Q15465	0	-	155803478	155803481	102,0,51	1	3	0	.	Essential for auto-cleavage.
chr7	155803487	155803490	Q15465	0	-	155803487	155803490	102,0,51	1	3	0	.	Involved in auto-cleavage.
chr7	155803559	155803562	Q15465	0	-	155803559	155803562	102,0,51	1	3	0	.	Involved in cholesterol transfer.
chr7	155803694	155803700	Q15465	0	-	155803694	155803700	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr7	158133948	158133954	Q92932	0	-	158133948	158133954	102,0,51	1	6	0	.	Cleavage.
chr8	8797486	8797492	Q9Y4C4	0	-	8797486	8797492	102,0,51	1	6	0	.	Breakpoint for translocation to form chimeric MASL1.
chr8	22025670	22025673	Q86SE8	0	+	22025670	22025673	102,0,51	1	3	0	.	Interaction between pentamers.
chr8	22025751	22025754	Q86SE8	0	+	22025751	22025754	102,0,51	1	3	0	.	Interaction between pentamers.
chr8	25423252	25423255	P01148	0	-	25423252	25423255	102,0,51	1	3	0	.	Appears to be essential for biological activity.
chr8	26033122	26033125	Q9HAK2	0	-	26033122	26033125	102,0,51	1	3	0	.	Interaction with DNA.
chr8	26033149	26033152	Q9HAK2	0	-	26033149	26033152	102,0,51	1	3	0	.	Interaction with DNA.
chr8	30474790	30474793	Q93062	0	+	30474790	30474793	102,0,51	1	3	0	.	Interaction with RNA. Pubmed:26347403
chr8	30477834	30477837	Q93062	0	+	30477834	30477837	102,0,51	1	3	0	.	Interaction with RNA. Pubmed:26347403
chr8	31064991	31064994	Q14191	0	+	31064991	31064994	102,0,51	1	3	0	.	Interaction with DNA.
chr8	31141570	31141573	Q14191	0	+	31141570	31141573	102,0,51	1	3	0	.	Interaction with DNA.
chr8	32595826	32595829	Q02297	0	+	32595826	32595829	102,0,51	1	3	0	.	Breakpoint for translocation to form gamma-heregulin.
chr8	35722337	35722343	Q6UXZ4	0	+	35722337	35722343	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr8	37833016	37833022	Q96PE1	0	+	37833016	37833022	102,0,51	1	6	0	.	Cleavage; by thrombin. Pubmed:22013897
chr8	37833103	37833109	Q96PE1	0	+	37833103	37833109	102,0,51	1	6	0	.	Cleavage; by thrombin. Pubmed:22013897
chr8	38413798	38413801	P11362	0	-	38413798	38413801	102,0,51	1	3	0	.	Mediates interaction with PLCG1 and SHB.
chr8	38418370	38419535	P11362	0	-	38418370	38419535	102,0,51	1	1165	0	.	Breakpoint for translocation to form CNTRL-FGFR1 OR FGFR1-CNTRL fusion proteins. Pubmed:10688839
chr8	38418370	38419535	P11362	0	-	38418370	38419535	102,0,51	1	1165	0	.	Breakpoint for translocation to form FGFR1OP2-FGFR1. Pubmed:15034873, Pubmed:16946300, Pubmed:17389761
chr8	38418370	38419535	P11362	0	-	38418370	38419535	102,0,51	1	1165	0	.	Breakpoint for translocation to form FGFR1OP-FGFR1 or FGFR1-FGFR1OP fusion proteins. Pubmed:9949182
chr8	39007953	39007959	Q13443	0	+	39007953	39007959	102,0,51	1	6	0	.	Cleavage.
chr8	39018858	39018864	Q13443	0	+	39018858	39018864	102,0,51	1	6	0	.	Cleavage; by furin-like protease.
chr8	41933578	41933584	Q92794	0	-	41933578	41933584	102,0,51	1	6	0	.	Breakpoint for translocation to form KAT6A-CREBBP.
chr8	41934865	41937259	Q92794	0	-	41934865	41937259	102,0,51	1	2394	0	.	Breakpoint for translocation to form KAT6A-EP300 and KAT6A-NCOA2.
chr8	41941438	41941444	Q92794	0	-	41941438	41941444	102,0,51	1	6	0	.	Breakpoint for translocation to form KAT6A-ASXL2.
chr8	42176145	42176148	P00750	0	-	42176145	42176148	102,0,51	1	3	0	.	Important for single-chain activity.
chr8	42179034	42179037	P00750	0	-	42179034	42179037	102,0,51	1	3	0	.	Important for single-chain activity.
chr8	42182762	42182765	P00750	0	-	42182762	42182765	102,0,51	1	3	0	.	Not glycosylated.
chr8	42187963	42187966	P00750	0	-	42187963	42187966	102,0,51	1	3	0	.	Important for binding to LRP1.
chr8	47859754	47859760	P78527	0	-	47859754	47859760	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr8	51408743	51408746	A1KZ92	0	-	51408743	51408746	102,0,51	1	3	0	.	Transition state stabilizer.
chr8	60265993	60265996	P35219	0	-	60265993	60265996	102,0,51	1	3	0	.	Ancestral zinc ligand.
chr8	70144843	70144849	Q15596	0	-	70144843	70144849	102,0,51	1	6	0	.	Breakpoint for translocation to form KAT6A-NCOA2. Pubmed:15657427, Pubmed:9558366, Pubmed:12676584
chr8	78598429	78598432	A0A024R7Y9	0	+	78598429	78598432	102,0,51	1	3	0	.	Important for inhibition.
chr8	78598429	78598432	P61925	0	+	78598429	78598432	102,0,51	1	3	0	.	Important for inhibition.
chr8	78598438	78598441	A0A024R7Y9	0	+	78598438	78598441	102,0,51	1	3	0	.	Important for inhibition.
chr8	78598438	78598441	P61925	0	+	78598438	78598441	102,0,51	1	3	0	.	Important for inhibition.
chr8	78598441	78598444	A0A024R7Y9	0	+	78598441	78598444	102,0,51	1	3	0	.	Important for inhibition.
chr8	78598441	78598444	P61925	0	+	78598441	78598444	102,0,51	1	3	0	.	Important for inhibition.
chr8	86461844	86461847	Q9H0M0	0	+	86461844	86461847	102,0,51	1	3	0	.	Required for ubiquitin-thioester formation.
chr8	92017358	92017364	Q06455	0	-	92017358	92017364	102,0,51	1	6	0	.	Breakpoint for translocation to form AML1-MTG8 in AML-M2. Pubmed:8334990
chr8	96608451	96608457	P34741	0	+	96608451	96608457	102,0,51	1	6	0	.	Cleavage of ectodomain.
chr8	98548140	98548146	Q13188	0	-	98548140	98548146	102,0,51	1	6	0	.	Cleavage; by caspase-3.
chr8	100924952	100924955	P63104	0	-	100924952	100924955	102,0,51	1	3	0	.	Interaction with phosphoserine on interacting protein.
chr8	100948721	100948724	P63104	0	-	100948721	100948724	102,0,51	1	3	0	.	Interaction with phosphoserine on interacting protein.
chr8	102839718	102839721	O14977	0	-	102839718	102839721	102,0,51	1	3	0	.	Not modified.
chr8	116852064	116852070	O60216	0	-	116852064	116852070	102,0,51	1	6	0	.	Cleavage; by ESPL1.
chr8	116856262	116856268	O60216	0	-	116856262	116856268	102,0,51	1	6	0	.	Cleavage; by caspase-3 or caspase-7.
chr8	116857435	116857441	O60216	0	-	116857435	116857441	102,0,51	1	6	0	.	Cleavage; by ESPL1.
chr8	118924379	118924382	O00300	0	-	118924379	118924382	102,0,51	1	3	0	.	Involved in dimerization.
chr8	119557553	119557556	Q13822	0	-	119557553	119557556	102,0,51	1	3	0	.	Essential for catalytic activity.
chr8	132871400	132871403	P01266	0	+	132871400	132871403	102,0,51	1	3	0	.	Not glycosylated. Pubmed:8615697
chr8	132886857	132886860	P01266	0	+	132886857	132886860	102,0,51	1	3	0	.	Not glycosylated. Pubmed:8615697
chr8	132966615	132966618	P01266	0	+	132966615	132966618	102,0,51	1	3	0	.	Not glycosylated. Pubmed:8615697
chr8	133012001	133012004	P01266	0	+	133012001	133012004	102,0,51	1	3	0	.	Not glycosylated. Pubmed:8615697
chr8	143315998	143316001	Q969P6	0	-	143315998	143316001	102,0,51	1	3	0	.	Interaction with DNA.
chr8	143316052	143316055	Q969P6	0	-	143316052	143316055	102,0,51	1	3	0	.	Interaction with DNA.
chr8	143317822	143317825	Q969P6	0	-	143317822	143317825	102,0,51	1	3	0	.	Interaction with DNA.
chr8	143321242	143321245	Q969P6	0	-	143321242	143321245	102,0,51	1	3	0	.	Interaction with DNA.
chr8	143321335	143321338	Q969P6	0	-	143321335	143321338	102,0,51	1	3	0	.	Interaction with DNA.
chr8	143324121	143324124	Q969P6	0	-	143324121	143324124	102,0,51	1	3	0	.	Interaction with DNA.
chr8	143324556	143324559	Q969P6	0	-	143324556	143324559	102,0,51	1	3	0	.	Interaction with DNA.
chr8	143325416	143325419	Q969P6	0	-	143325416	143325419	102,0,51	1	3	0	.	Interaction with DNA.
chr8	143326248	143326251	Q969P6	0	-	143326248	143326251	102,0,51	1	3	0	.	Interaction with DNA.
chr8	143561957	143561963	P57764	0	+	143561957	143561963	102,0,51	1	6	0	.	Cleavage; by inflammatory caspases CASP1 and CASP4. Pubmed:26375003
chr8	143614646	143614649	Q13630	0	-	143614646	143614649	102,0,51	1	3	0	.	Lowers pKa of active site Tyr.
chr8	143614828	143614831	Q13630	0	-	143614828	143614831	102,0,51	1	3	0	.	Important for catalytic activity.
chr8	143614834	143614837	Q13630	0	-	143614834	143614837	102,0,51	1	3	0	.	Important for catalytic activity.
chr9	5055785	5064885	O60674	0	+	5055785	5064885	102,0,51	1	9100	0	.	Breakpoint for translocation to form PCM1-JAK2 fusion protein.
chr9	5066786	5069024	O60674	0	+	5066786	5069024	102,0,51	1	2238	0	.	Breakpoint for translocation to form PCM1-JAK2 fusion protein.
chr9	5069042	5069048	O60674	0	+	5069042	5069048	102,0,51	1	6	0	.	Breakpoint for translocation to form PCM1-JAK2 fusion protein.
chr9	5069204	5069926	O60674	0	+	5069204	5069926	102,0,51	1	722	0	.	Breakpoint for translocation to form PCM1-JAK2 fusion protein.
chr9	5078440	5080230	O60674	0	+	5078440	5080230	102,0,51	1	1790	0	.	Breakpoint for translocation to form PCM1-JAK2 fusion protein.
chr9	5812179	5812182	Q7Z2K6	0	-	5812179	5812182	102,0,51	1	3	0	.	Transition state stabilizer.
chr9	6251201	6251207	O95760	0	+	6251201	6251207	102,0,51	1	6	0	.	Cleavage; by CTSG.
chr9	6251213	6251219	O95760	0	+	6251213	6251219	102,0,51	1	6	0	.	Cleavage; by ELANE.
chr9	6251243	6251249	O95760	0	+	6251243	6251249	102,0,51	1	6	0	.	Cleavage; by CTSG.
chr9	8465633	8465639	P23468	0	-	8465633	8465639	102,0,51	1	6	0	.	Cleavage.
chr9	18504870	18504873	Q8N6G6	0	+	18504870	18504873	102,0,51	1	3	0	.	Not glycosylated.
chr9	20354867	20354870	P42568	0	-	20354867	20354870	102,0,51	1	3	0	.	KMT2A/MLL1 fusion point (in acute myeloid leukemia patient F1).
chr9	20413720	20413723	P42568	0	-	20413720	20413723	102,0,51	1	3	0	.	KMT2A/MLL1 fusion point (in acute myeloid leukemia patient CO).
chr9	21854711	21854714	B4DUC8	0	+	21854711	21854714	102,0,51	1	3	0	.	Important for substrate specificity.
chr9	21854711	21854714	J3QSB7	0	+	21854711	21854714	102,0,51	1	3	0	.	Important for substrate specificity.
chr9	21854711	21854714	Q13126	0	+	21854711	21854714	102,0,51	1	3	0	.	Important for substrate specificity.
chr9	21854858	21854861	J3QSB7	0	+	21854858	21854861	102,0,51	1	3	0	.	Important for substrate specificity.
chr9	21859308	21859311	B4DUC8	0	+	21859308	21859311	102,0,51	1	3	0	.	Important for substrate specificity.
chr9	21859308	21859311	Q13126	0	+	21859308	21859311	102,0,51	1	3	0	.	Important for substrate specificity.
chr9	33166935	33166941	P15291	0	-	33166935	33166941	102,0,51	1	6	0	.	Cleavage; to produce soluble form.
chr9	33246654	33246660	O60575	0	+	33246654	33246660	102,0,51	1	6	0	.	Reactive bond.
chr9	33798610	33798613	P35030	0	+	33798610	33798613	102,0,51	1	3	0	.	Required for specificity.
chr9	34635787	34635790	Q99720	0	-	34635787	34635790	102,0,51	1	3	0	.	Important for ligand binding. Pubmed:11476895
chr9	34637063	34637066	Q99720	0	-	34637063	34637066	102,0,51	1	3	0	.	Important for ligand binding. Pubmed:11476895
chr9	36882103	36923358	Q02548	0	-	36882103	36923358	102,0,51	1	41255	0	.	Breakpoint for translocation to form PAX5-ZNF521.
chr9	36923481	36966551	Q02548	0	-	36923481	36966551	102,0,51	1	43070	0	.	Breakpoint for translocation to form PAX5-FOXP1.
chr9	37002774	37006476	Q02548	0	-	37002774	37006476	102,0,51	1	3702	0	.	Breakpoint for translocation to form PAX5-ETV6.
chr9	37432092	37432095	Q9UBQ7	0	+	37432092	37432095	102,0,51	1	3	0	.	Raises pKa of active site His. Pubmed:16756993
chr9	72925606	72925609	P00352	0	-	72925606	72925609	102,0,51	1	3	0	.	Transition state stabilizer.
chr9	75986173	75986179	Q92824	0	+	75986173	75986179	102,0,51	1	6	0	.	Cleavage; by autolysis.
chr9	84867391	84867394	Q16620	0	+	84867391	84867394	102,0,51	1	3	0	.	Interaction with SHC1.
chr9	84955508	84955511	Q16620	0	+	84955508	84955511	102,0,51	1	3	0	.	Interaction with SH2D1A.
chr9	85021416	85021419	Q16620	0	+	85021416	85021419	102,0,51	1	3	0	.	Interaction with PLCG1.
chr9	94593627	94593630	O00757	0	-	94593627	94593630	102,0,51	1	3	0	.	Important for the conversion from active R-state to inactive T-state in the presence of AMP.
chr9	94955270	94955273	Q8N6M6	0	+	94955270	94955273	102,0,51	1	3	0	.	Transition state stabilizer.
chr9	101421811	101421814	P05062	0	-	101421811	101421814	102,0,51	1	3	0	.	Necessary for preference for fructose 1,6-bisphosphate over fructose 1-phosphate.
chr9	110251384	110251387	P10599	0	-	110251384	110251387	102,0,51	1	3	0	.	Contributes to redox potential value.
chr9	110251387	110251390	P10599	0	-	110251387	110251390	102,0,51	1	3	0	.	Contributes to redox potential value.
chr9	110251408	110251411	P10599	0	-	110251408	110251411	102,0,51	1	3	0	.	Deprotonates C-terminal active site Cys.
chr9	111929517	111929520	Q16739	0	+	111929517	111929520	102,0,51	1	3	0	.	May play an important role in binding to the inhibitors DEPC and PDMP.
chr9	114061057	114061063	P02760	0	-	114061057	114061063	102,0,51	1	6	0	.	Inhibitory (P1) (trypsin).
chr9	114061550	114061556	P02760	0	-	114061550	114061556	102,0,51	1	6	0	.	Inhibitory (P1) (chymotrypsin, elastase).
chr9	114790637	114790640	O95150	0	-	114790637	114790640	102,0,51	1	3	0	.	Important for binding TNFRSF6B.
chr9	114790646	114790649	O95150	0	-	114790646	114790649	102,0,51	1	3	0	.	Important for binding TNFRSF6B.
chr9	114793562	114793568	O95150	0	-	114793562	114793568	102,0,51	1	6	0	.	Cleavage.
chr9	120913540	120913546	Q13077	0	-	120913540	120913546	102,0,51	1	6	0	.	Cleavage; by CASP8.
chr9	121171545	121173245	Q7Z7A1	0	+	121171545	121173245	102,0,51	1	1700	0	.	Breakpoint for translocation to form CEP110-FGFR1.
chr9	121757163	121758900	Q5VWQ8	0	+	121757163	121758900	102,0,51	1	1737	0	.	Breakpoint for translocation to form KMT2A/MLL1-DAB2IP.
chr9	122392328	122392331	P23219	0	+	122392328	122392331	102,0,51	1	3	0	.	Aspirin-acetylated serine.
chr9	123065374	123065377	Q9Y3P9	0	+	123065374	123065377	102,0,51	1	3	0	.	Arginine finger.
chr9	123070385	123070388	Q9Y3P9	0	+	123070385	123070388	102,0,51	1	3	0	.	Glutamine finger.
chr9	124321485	124321488	Q9HC98	0	+	124321485	124321488	102,0,51	1	3	0	.	Autoinhibitory.
chr9	124801623	124801629	Q68BL7	0	+	124801623	124801629	102,0,51	1	6	0	.	Cleavage.
chr9	128127453	128127459	Q9H7Z7	0	-	128127453	128127459	102,0,51	1	6	0	.	Cleavage.
chr9	128598968	128598974	Q13813	0	+	128598968	128598974	102,0,51	1	6	0	.	Cleavage; by mu-calpain.
chr9	128694039	128694643	Q01105	0	+	128694039	128694643	102,0,51	1	604	0	.	Breakpoint for translocation to form SET-CAN oncogene.
chr9	129957374	129957377	Q96RU3	0	-	129957374	129957377	102,0,51	1	3	0	.	Mediates end-to-end attachment of dimers.
chr9	130835521	130854065	P00519	0	+	130835521	130854065	102,0,51	1	18544	0	.	Breakpoint for translocation to form BCR-ABL oncogene.
chr9	130904153	130904156	Q8N539	0	-	130904153	130904156	102,0,51	1	3	0	.	Implicated in ligand binding.
chr9	130904156	130904159	Q8N539	0	-	130904156	130904159	102,0,51	1	3	0	.	Implicated in ligand binding.
chr9	130904204	130904207	Q8N539	0	-	130904204	130904207	102,0,51	1	3	0	.	Implicated in ligand binding.
chr9	130904234	130904237	Q8N539	0	-	130904234	130904237	102,0,51	1	3	0	.	Implicated in ligand binding.
chr9	131151891	131159385	P35658	0	+	131151891	131159385	102,0,51	1	7494	0	.	Breakpoint.
chr9	133636485	133636491	P09172	0	+	133636485	133636491	102,0,51	1	6	0	.	Cleavage.
chr9	134034821	134034827	Q15059	0	-	134034821	134034827	102,0,51	1	6	0	.	Breakpoint for translocation to form BDR3-NUT fusion protein.
chr9	134142002	134142005	P61964	0	+	134142002	134142005	102,0,51	1	3	0	.	Important for interaction with histone H3.
chr9	134142374	134142377	P61964	0	+	134142374	134142377	102,0,51	1	3	0	.	Important for interaction with histone H3.
chr9	134155737	134155740	P61964	0	+	134155737	134155740	102,0,51	1	3	0	.	Important for interaction with histone H3.
chr9	134157951	134157954	P61964	0	+	134157951	134157954	102,0,51	1	3	0	.	Important for interaction with histone H3.
chr9	134909842	134909845	O00602	0	-	134909842	134909845	102,0,51	1	3	0	.	Mediates specificity for sialic acids. Pubmed:17897951
chr9	134909878	134909881	O00602	0	-	134909878	134909881	102,0,51	1	3	0	.	Mediates specificity for sialic acids. Pubmed:20032467, Pubmed:17897951
chr9	136503185	136503191	P46531	0	-	136503185	136503191	102,0,51	1	6	0	.	Cleavage; by ADAM17.
chr9	136503215	136503221	P46531	0	-	136503215	136503221	102,0,51	1	6	0	.	Cleavage; by ADAM17.
chr9	136504695	136504701	P46531	0	-	136504695	136504701	102,0,51	1	6	0	.	Cleavage; by furin-like protease.
chr9	136517785	136517788	P46531	0	-	136517785	136517788	102,0,51	1	3	0	.	Interaction with DLL4.
chr9	137917404	137917407	Q00975	0	+	137917404	137917407	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chr9	138006778	138006781	Q00975	0	+	138006778	138006781	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chr9	138057855	138057858	Q00975	0	+	138057855	138057858	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chr9	138078126	138078129	Q00975	0	+	138078126	138078129	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chrX	7305083	7305086	P08842	0	+	7305083	7305086	102,0,51	1	3	0	.	Not glycosylated.
chrX	7334103	7334106	P08842	0	+	7334103	7334106	102,0,51	1	3	0	.	Not glycosylated.
chrX	10206471	10206474	P51793	0	+	10206471	10206474	102,0,51	1	3	0	.	Mediates proton transfer from the outer aqueous phase to the interior of the protein; involved in linking H(+) and Cl(-) transport.
chrX	10206773	10206776	P51793	0	+	10206773	10206776	102,0,51	1	3	0	.	Mediates proton transfer from the protein to the inner aqueous phase.
chrX	14609157	14609160	P23416	0	+	14609157	14609160	102,0,51	1	3	0	.	Important for obstruction of the ion pore in the closed conformation.
chrX	15252365	15252368	Q96DX5	0	-	15252365	15252368	102,0,51	1	3	0	.	Essential for binding to CKB.
chrX	15252377	15252380	Q96DX5	0	-	15252377	15252380	102,0,51	1	3	0	.	Essential for binding to CKB.
chrX	24714594	24714600	P09884	0	+	24714594	24714600	102,0,51	1	6	0	.	Cleavage.
chrX	43732745	43732748	P21397	0	+	43732745	43732748	102,0,51	1	3	0	.	Important for substrate specificity.
chrX	43740693	43740696	P21397	0	+	43740693	43740696	102,0,51	1	3	0	.	Important for catalytic activity.
chrX	43775263	43775266	P27338	0	-	43775263	43775266	102,0,51	1	3	0	.	Important for catalytic activity.
chrX	43778723	43778726	P27338	0	-	43778723	43778726	102,0,51	1	3	0	.	Important for catalytic activity.
chrX	43802179	43802182	P27338	0	-	43802179	43802182	102,0,51	1	3	0	.	Important for catalytic activity.
chrX	48258534	48258540	Q16384	0	+	48258534	48258540	102,0,51	1	6	0	.	Breakpoint for translocation to form the SSXT-SSX1 fusion protein (rare). Pubmed:7539744
chrX	48261812	48263784	Q16384	0	+	48261812	48263784	102,0,51	1	1972	0	.	Breakpoint for translocation to form the SSXT-SSX1 fusion protein. Pubmed:7539744
chrX	49034248	49038012	P19532	0	-	49034248	49038012	102,0,51	1	3764	0	.	Breakpoint for translocation to form NONO-TFE3, PSF-TFE3 and ASPSCR1-TFE3 oncogenes.
chrX	49038111	49038199	P19532	0	-	49038111	49038199	102,0,51	1	88	0	.	Breakpoint for translocation to form ASPSCR1-TFE3 oncogene.
chrX	49038439	49039109	P19532	0	-	49038439	49039109	102,0,51	1	670	0	.	Breakpoint for translocation to form PRCC-TFE3 oncogene.
chrX	49211465	49211468	O60840	0	-	49211465	49211468	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chrX	49216392	49216395	O60840	0	-	49216392	49216395	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chrX	49222823	49222826	O60840	0	-	49222823	49222826	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chrX	49228274	49228277	O60840	0	-	49228274	49228277	102,0,51	1	3	0	.	Calcium ion selectivity and permeability.
chrX	49251375	49251381	Q9BZS1	0	-	49251375	49251381	102,0,51	1	6	0	.	Cleavage; by PCSK1 or PCSK2. Pubmed:19117830
chrX	49258349	49258355	Q9BZS1	0	-	49258349	49258355	102,0,51	1	6	0	.	Cleavage. Pubmed:19117830
chrX	50081754	50081757	P51795	0	+	50081754	50081757	102,0,51	1	3	0	.	Mediates proton transfer from the outer aqueous phase to the interior of the protein; involved in linking H(+) and Cl(-) transport.
chrX	50086057	50086060	P51795	0	+	50086057	50086060	102,0,51	1	3	0	.	Mediates proton transfer from the protein to the inner aqueous phase.
chrX	51744271	51744274	Q8IYD1	0	+	51744271	51744274	102,0,51	1	3	0	.	Interacts with GTP/GDP.
chrX	51744673	51744676	Q8IYD1	0	+	51744673	51744676	102,0,51	1	3	0	.	Interacts with GTP/GDP.
chrX	52700575	52702583	Q16385	0	-	52700575	52702583	102,0,51	1	2008	0	.	Breakpoint for translocation to form the SSXT-SSX2 fusion protein.
chrX	52704569	52704575	Q16385	0	-	52704569	52704575	102,0,51	1	6	0	.	Breakpoint for translocation to form the SSXT-SSX2 fusion protein (rare).
chrX	52753854	52753860	Q16385	0	+	52753854	52753860	102,0,51	1	6	0	.	Breakpoint for translocation to form the SSXT-SSX2 fusion protein (rare).
chrX	52755846	52757856	Q16385	0	+	52755846	52757856	102,0,51	1	2010	0	.	Breakpoint for translocation to form the SSXT-SSX2 fusion protein.
chrX	54937643	54937646	P16118	0	-	54937643	54937646	102,0,51	1	3	0	.	Transition state stabilizer.
chrX	55003823	55003826	Q9UBZ4	0	+	55003823	55003826	102,0,51	1	3	0	.	Transition state stabilizer.
chrX	55006706	55006709	Q9UBZ4	0	+	55006706	55006709	102,0,51	1	3	0	.	Important for catalytic activity.
chrX	55006787	55006790	Q9UBZ4	0	+	55006787	55006790	102,0,51	1	3	0	.	Interaction with DNA substrate.
chrX	56729440	56729443	A0A0U1RRE5	0	+	56729440	56729443	102,0,51	1	3	0	.	Required for interaction with EDC4. Pubmed:27918561
chrX	56729452	56729455	A0A0U1RRE5	0	+	56729452	56729455	102,0,51	1	3	0	.	Required for interaction with EDC4. Pubmed:27918561
chrX	56817501	56817504	A0A0U1RRE5	0	+	56817501	56817504	102,0,51	1	3	0	.	Required for interaction with EDC4. Pubmed:27918561
chrX	56817513	56817516	A0A0U1RRE5	0	+	56817513	56817516	102,0,51	1	3	0	.	Required for interaction with EDC4. Pubmed:27918561
chrX	56817519	56817522	A0A0U1RRE5	0	+	56817519	56817522	102,0,51	1	3	0	.	Required for interaction with EDC4. Pubmed:27918561
chrX	56817531	56817534	A0A0U1RRE5	0	+	56817531	56817534	102,0,51	1	3	0	.	Required for interaction with EDC4. Pubmed:27918561
chrX	67711676	67711679	P10275	0	+	67711676	67711679	102,0,51	1	3	0	.	Interaction with coactivator LXXL motif.
chrX	67723769	67723772	P10275	0	+	67723769	67723772	102,0,51	1	3	0	.	Interaction with coactivator FXXLF motif.
chrX	69957104	69957110	Q92838	0	+	69957104	69957110	102,0,51	1	6	0	.	Cleavage; by furin. Pubmed:11416205
chrX	70150213	70150219	P78318	0	+	70150213	70150219	102,0,51	1	6	0	.	Cleavage; by calpain.
chrX	71297935	71298471	Q15233	0	+	71297935	71298471	102,0,51	1	536	0	.	Breakpoint for translocation to form NONO-TFE3.
chrX	77969080	77969083	Q8N0Y7	0	-	77969080	77969083	102,0,51	1	3	0	.	Transition state stabilizer.
chrX	103719101	103719104	Q5JXX5	0	-	103719101	103719104	102,0,51	1	3	0	.	Important for obstruction of the ion pore in the closed conformation.
chrX	106840764	106840767	Q0IIM8	0	+	106840764	106840767	102,0,51	1	3	0	.	Arginine finger.
chrX	106840881	106840884	Q0IIM8	0	+	106840881	106840884	102,0,51	1	3	0	.	Glutamine finger.
chrX	124380925	124380931	Q9UKZ4	0	-	124380925	124380931	102,0,51	1	6	0	.	Cleavage.
chrX	130074749	130081258	Q99607	0	-	130074749	130081258	102,0,51	1	6509	0	.	Breakpoint for translocation to form ELF4-ERG oncogene.
chrX	133217839	133217842	Q5H9I0	0	-	133217839	133217842	102,0,51	1	3	0	.	Critical for repression of E2F activity.
chrX	133217866	133217869	Q5H9I0	0	-	133217866	133217869	102,0,51	1	3	0	.	Critical for repression of E2F activity.
chrX	133217869	133217872	Q5H9I0	0	-	133217869	133217872	102,0,51	1	3	0	.	Critical for repression of E2F activity.
chrX	133217896	133217899	Q5H9I0	0	-	133217896	133217899	102,0,51	1	3	0	.	Critical for repression of E2F activity.
chrX	136654417	136654423	P29965	0	+	136654417	136654423	102,0,51	1	6	0	.	Cleavage.
chrX	139551111	139551117	P00740	0	+	139551111	139551117	102,0,51	1	6	0	.	Cleavage; by factor XIa.
chrX	139551216	139551222	P00740	0	+	139551216	139551222	102,0,51	1	6	0	.	Cleavage; by factor XIa.
chrX	153700960	153700966	P51572	0	-	153700960	153700966	102,0,51	1	6	0	.	Cleavage; by caspase-8.
chrX	153703040	153703046	P51572	0	-	153703040	153703046	102,0,51	1	6	0	.	Cleavage; by caspase-8.
chrX	153787474	153787477	P51553	0	-	153787474	153787477	102,0,51	1	3	0	.	Critical for catalysis.
chrX	153787840	153787843	P51553	0	-	153787840	153787843	102,0,51	1	3	0	.	Critical for catalysis.
chrX	153954126	153954132	P51610	0	-	153954126	153954132	102,0,51	1	6	0	.	Cleavage; by autolysis.
chrX	153954426	153954432	P51610	0	-	153954426	153954432	102,0,51	1	6	0	.	Cleavage; by autolysis.
chrX	153954510	153954516	P51610	0	-	153954510	153954516	102,0,51	1	6	0	.	Cleavage; by autolysis.
chrX	153955065	153955071	P51610	0	-	153955065	153955071	102,0,51	1	6	0	.	Cleavage; by autolysis.
chrX	153955152	153955158	P51610	0	-	153955152	153955158	102,0,51	1	6	0	.	Cleavage; by autolysis.
chrX	153955338	153955344	P51610	0	-	153955338	153955344	102,0,51	1	6	0	.	Cleavage; by autolysis.
chrX	154305304	154305307	P51854	0	+	154305304	154305307	102,0,51	1	3	0	.	Important for catalytic activity.
chrX	154312602	154312605	P51854	0	+	154312602	154312605	102,0,51	1	3	0	.	Important for catalytic activity.
chrX	154354642	154354648	P21333	0	-	154354642	154354648	102,0,51	1	6	0	.	Cleavage; by calpain.
chrX	154928662	154928668	P00451	0	-	154928662	154928668	102,0,51	1	6	0	.	Cleavage; by thrombin.
chrX	154928785	154928791	P00451	0	-	154928785	154928791	102,0,51	1	6	0	.	Cleavage (activation).
chrX	154929790	154929796	P00451	0	-	154929790	154929796	102,0,51	1	6	0	.	Cleavage (activation).
chrX	154931509	154931515	P00451	0	-	154931509	154931515	102,0,51	1	6	0	.	Cleavage; by thrombin.
chrX	154966520	154966526	P00451	0	-	154966520	154966526	102,0,51	1	6	0	.	Cleavage; by thrombin.
